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ABSTRACT 
Polybrominated diphenyl ethers (PBDEs) are a class of flame retardant chemicals that 
have been added to consumer products such as foam furniture and electronic equipment 
since the 1970s. Human exposure can occur when PBDEs are released to the 
environment. North Americans are among the most highly exposed populations, with 
median serum concentrations about an order of magnitude higher than European or Asian 
populations. Multiple animal studies have shown PBDEs to be thyroid hormone 
disruptors that may also adversely affect reproductive success. Limited human studies 
exist on the human health effects of PBDEs or their persistence in human tissues. 
We investigated exposure to PBDEs in a longitudinal cohort of 52 healthy adults 
within the Boston metropolitan area, hereafter referred to as the Flame Retardant 
Exposure (FlaRE) cohort. We followed individuals for approximately one year and 
collected serum samples and questionnaire data at three sampling intervals: Winter 2010, 
Summer 2010, and Winter 2011. Serum samples were analyzed for 11 PBDE congeners, 
thyroid function, and reproductive function tests. We used these data to assess the 
stability of PBDEs in serum measures, determine potential temporal trends in PBDE 
serum concentrations over 1 year, and assess the relationship between PBDE exposure 
v 
and thyroid and reproductive function tests over time. 
In the FlaRE cohort, geometric mean sum concentrations of the five most prevalent 
PBDE congeners (BDE 28, 47, 99, 100, 153) were 21.8 ng/g lipid in Winter 2010, 22.8 
ng/g lipid in Summer 2010, and 18.7 ng/g lipid in Winter 2011. We found that a single 
PentaBDE serum measurement is a stable estimate, either continuously or categorically, 
of a participant's blood concentration over the one-year study period. After adjustment of 
important confounders, we found that serum PentaBDE congeners were inversely 
associated with Total T 4, which is consistent with animal experiments and some previous 
epidemiology studies. Among men 40 years or older, increased exposure to PentaBDEs 
was associated with a decrease in inhibin-B, an increase in follicular stimulating 
hormone, and decreases in the inhibin-B/FSH ratio thus indicating PBDE exposure may 
decrease testicular function in men. 
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CHAPTER 1: INTRODUCTION 
Polybrominated diphenyl ethers (PBDEs) are additive flame retardant chemicals 
used since the 1970s in commercial and household consumer products to satisfy fire 
safety standards. At high temperatures, PBDEs release bromine atoms, which bind with 
oxygen atoms, chemically reducing and slowing the development of fire (Darnerud et al. 
2001). There are 209 possible PBDE congeners with a general chemical structure 
composed of two phenyl rings connected by an ether bond with bromine molecules 
attached to the phenyl rings (Figure 1.1) (USEPA 2008). The naming system used to 
identify PBDE congeners was adopted from the nomenclature used for polychlorinated 
biphenyls (Table 1.1). The technical formulation of Pentabromodiphenyl ether 
(PentaBDE) is composed of PBDE congeners containing three to six bromines. 
PentaBDE was typically added to products containing polyurethane foam. 
Octabromodiphenyl ether (OctaBDE) is a mixture of PBDE congeners containing seven 
to eight bromines, but has minor fractions (e.g. 1-8%) of the BDE-153 congener present 
in PentaBDE (La Guardia et al. 2006). The Decabromodiphenyl ether (DecaBDE) 
formulation is predominately composed of the fully brominated congener (e.g. BDE-
209). OctaBDE and DecaBDE were primarily added to electronic equipment and textiles. 
Since the highly brominated congeners were not frequently detected in the serum samples 
of our cohort (e.g. 1-22% ), the PentaBDE congeners are the focus of this dissertation. 
The common congeners (approximate % of mixture) in commercial formulations 
ofPentaBDE are BDE-99 (43%), BDE-47 (28%), BDE-100 (8%), BDE-153 (6%), BDE-
154 (4%), BDE-28 (<1 %) (USEPA 2008). Each congener is chemically distinct, but they 
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share properties such as lipophilicity, toxicity, and persistence m the environment. 
Therefore they are concerning to environmental and human health (Darnerud et al. 2001). 
PBDEs are additive flame retardants, which means the are not chemically bound to their 
source products, and may be gradually released during a products' life-cycle (Sjodin et al. 
2003). Additionally, they are applied to some products at high levels (e.g. 5-30% by 
weight) (Hale et al. 2002). It is likely that the widespread use of PBDEs in durable 
products, the method of application, and their chemical properties have led to pervasive 
contamination of PBDEs in the environment and people (Hites 2004; Sjodin et al. 2003). 
Interest in PBDEs increased following the publication of a study showing 
concentrations of PBDEs in Swedish human breast milk had been doubling 
approximately every five years from 1972 to 1997 (Meironyte et al. 1999). Globally, 95% 
of PentaBDE was used in North America (Morland et al. 2005). Concentrations in North 
American populations are significant! y higher than in European and Asian populations 
(Meironyte et al. 1999; Sjodin et al. 2004). There is ample evidence that PBDEs, 
particularly the lower brominated congeners present in PentaBDE and OctaBDE, are 
endocrine disrupting chemicals (Stoker et al. 2004). Their manufacture was banned in 
Europe and phased out in the U.S. in 2004 (USEPA 2006). PentaBDE and OctaBDE 
were added to the list of persistent organic pollutants in the Stockholm Convention 
(UNEP 2001). The higher brominated DecaBDE is no longer used in Europe and is 
scheduled to be phased out in the US by 2014 (USEPA 2010). Despite the discontinued 
use of lower brominated congeners, there is evidence that highly brominated congeners 
can degrade in the environment or in animals to lower brominated congeners (de Wit 
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2002). 
The 2003-4 National Health and Nutrition Examination Survey (NHANES), a 
representative sample of the US population, reported US serum detection rates and 
geometric means (GM) of serum levels in adults of the following major PentaBDE 
congeners: BDE-47 (97%, 20.5 ng/g lipid), BDE-99 (65%, 5.0 ng/g lipid), BDE-100 
(97%, 3.9 ng/g lipid), and BDE-153 (93%, 5.7 ng/g lipid) (Sjodin et al. 2008). BDE-47 is 
the dominant congener in serum of most US residents followed by BDE-153 (Sjodin et 
al. 2008). 
It is unclear how serum concentrations of the PentaBDE congeners have changed 
since the 2004 US phase-out. This is further complicated by the fact that the various 
congeners appear to have different half-lives in humans. A longitudinal study of 
Americans in the Great Lakes region reported no significant decreases in the combined 
total of BDE-28, 47, 49, 99, 100, 138, and 153, or the individual PentaBDE congeners. 
However, the percent contribution of BDE-153 to 2: PBDE increased while percent 
contribution of BDE-47 decreased from 2001-03 to 2004-05 (Turyk et al. 2010). A recent 
study comparing two demographically similar study populations found BDE-47, -99 and 
-100 decreased more than BDE-153 in samples collected in 2008-09 and 2011-12 (Zota 
et al. 2013). Outside of the US, a retrospective Swedish study comparing pooled breast 
milk samples reported decreasing concentration of BDE-47 beginning in the late 1990s 
while BDE-153 did not change (Fangstrom et al. 2005; Meironyte et al. 1999). The half-
lives of PentaBDEs in humans have not been directly measured. They have not yet been 
directly measured for PentaBDEs because a suitable study population has not been 
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identified: one that changes from high to zero or much lower exposure. Failure to take 
into account background exposure biases half-lives (Bartell 2012). Estimates derived 
from human and animal studies suggest that the lower brominated congeners have half-
lives on the order of years while more heavily brominated congeners are on the order of 
weeks to months (Thuresson et al. 2006; Trudel et al. 2011). 
In the US, dust from the indoor environment and consumption of contaminated 
food are both important pathways for human exposure to PentaBDEs. Concentrations of 
the lower brominated congeners (BDE-47, BDE-99, and BDE-100) in residential dust are 
correlated with concentrations in serum or breast milk samples (Johnson et al. 2010; 
Watkins et al. 2012; Wu et al. 2007). Exposures to PentaBDE also occur in office 
environments (Watkins et al. 2011). Indoor exposure has been linked to PBDE residues 
on hands, likely due to hand-to-mouth activity (Buttke et al. 2013; Stapleton et al. 2012; 
Watkins et al. 2011). Diet is also a source of PentaBDE body burdens. Meat and other 
high fat animal food products (e.g. dairy products) have been found to be contaminated 
with PBDEs (Lorber 2008). Fraser et al. reported that PentaBDEs are lower in 
vegetarians than omnivores in the US (Fraser et al. 2009). Additionally, body burdens of 
BDE-153 are more strongly associated with red meat intake and total daily fat intake than 
the other PentaBDE congeners (Fraser et al. 2009). PBDEs have also been found in air, 
water, and soil; however inhalation and dermal absorption are expected to be minor 
routes of human exposure (Frederiksen 2009). 
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PEDEs and Thyroid Function 
In humans, thyroid hormones (THs) are essential for proper growth and 
development in utero and during infancy, as well as maintenance of many organ systems 
and metabolism throughout life. In early development, THs stimulate secretion of 
extracellular matrix proteins and act in combination with human growth hormone, 
insulin-like growth factor, and other factors that promote bone formation (Widmaier et al. 
2008). THs are involved in the formation of nerve terminals, myelin, and growth of 
dendritic synapses (Schroeder and Privalsky 2014). Insufficient levels of THs result in 
in-eversible developmental delay called cretinism. In adulthood, THs maintain basal 
metabolic rates (e.g. carbohydrate and lipid metabolism) and promote optimal central 
nervous system functioning (Widmaier et al. 2008). Thyroxine (T4) and triiodothyronine 
(T 3) are the two iodine-containing molecules produced in the thyroid gland. Production of 
THs is tightly regulated by the hypothalamus and anterior pituitary, which produce 
thyroid releasing hormone (TRH) and thyroid stimulating hormone (TSH) respectively. 
T4 is the major hormone measured in blood. It is tightly bound to the plasma proteins, 
thyroxine binding globulin (TBG), transthyretin (TTR), and albumin, but also exists as 
free T4 (fT4) (Braverman and Cooper 2013). Total T4 (TT4) refers to the sum of the free 
and bound hormones. The bioactive hormone is triiodothyronine (T3), which is either 
directly produced by the thyroid or converted from T4 to T3 by enzymatic de-iodination 
after transport into the target cell. Inside the cell, T 3 binds to nuclear receptors and alters 
DNA transcription rates. The following are the three main TH receptors (TR) with their 
associated tissue: TR-alpha (cardiac and skeletal muscles), TR-betal (brain, liver and 
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kidney), TR-beta2 (hypothalamus and pituitary) (Widmaier et al. 2008). 
Many animal studies have investigated adverse effects of PBDEs exposure in 
rodent models. Thyroid hormone disruption was recognized early as a possible toxic 
endpoint because the PentaBDEs and hydroxylated PentaBDEs are structurally similar to 
the thyroid hormones thyroxine (T4) and triiodothyronine (T3) (Meerts et al. 2000; Sjodin 
et al. 1998). Multiple toxicological studies have shown that exposure to PentaBDE 
formulations or individual congeners results in a decrease in total T4. (Blanco et al. 2013; 
Bondy et al. 2013; Ellis-Hutchings et al. 2006; Ernest et al. 2012; Fowles et al. 1994; He 
et al. 2011; Stoker et al. 2004; Szabo et al. 2009; Van der Ven et al. 2008a; Zhou et al. 
2001; Zhou et al. 2002). However, one animal study reported an increase in T4 after 
exposure to DE-71 (Blake et al. 2011). Table 2 presents the results from well-designed 
animal experiments that have explored PentaBDE exposure and subsequent effects on TH 
homeostasis and other relevant physiological endpoints. 
The results regarding the effect of Pen taB DEs on TSH and TT 3 have not been 
consistent. Some experiments have shown an increase in TSH that would be indicative of 
PBDEs having an effect on the HPT axis (Stoker et al. 2004; Zoller 2010). Others have 
shown a decrease in TT 4 without an increase in TSH (Ernest et al. 20 12; He et al. 2011; 
Zhou et al. 2001). Similarly, some experiments report a decrease in TT3, while others 
have shown no relationship between PentaBDE exposure and TT3 of ff3 measures. 
Results from these studies may be inconsistent due to differing exposure levels, exposure 
routes, duration of exposure, timing of exposure, and other relevant experimental 
characteristics. 
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A decrease of peripheral THs (TT 4 or TT 3) in animals has prompted investigations 
of the possible underlying mechanisms for this phenomenon. The following are a few of 
the proposed mechanisms by which PBDEs affect TH levels in animals: reduction of 
serum TH binding proteins (Szabo et al. 2009), binding of PentaBDE metabolites to TTR 
(Hallgren and Darnerud 2002), decreased thyroid hormone deiodinase activity (Butt et al. 
2011), competitive binding to the TH receptor (lbhazehiebo et al. 2011), increased liver 
enzymatic activity (Fowles et al. 1994; Hallgren and Darnerud 2002; Hallgren et al. 
2001; Stoker et al. 2004; Zhou et al. 2001) The mechanisms underlying TH disruption by 
PBDEs in animals has not been completely elucidated and is likely multifactorial. 
Nevertheless, toxicological studies to date have consistently shown that exposure leads to 
a decrease in serum TT 4 concentrations. 
There have been multiple studies that have explored the relationship between 
PBDE exposure and possible thyroid hormone (TH) disruption in human populations. 
Table 3 demonstrates the results from large, well-designed, human studies that have 
explored PentaBDE exposure and subsequent effects on TH homeostasis and other 
relevant endpoints. Conclusions from epidemiological studies have been mixed, with 
PentaBDE exposure associated with increases, decreases, or no association with thyroid 
hormone levels. Two studies found that PentaBDE exposure was associated with a 
decrease in TSH (Chevrier et al. 2010; Turyk et al. 2008). One study found that 
PentaBDE exposure was associated with an increase in TSH (Zota et al. 2011) and many 
other studies found no relationship between PentaBDEs and TSH. Similarly, two studies 
found PentaBDE exposure to be positively linked with TT4 or IT4 (Stapleton et al. 2011; 
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Turyk et al. 2008). Two studies found exposure associated with decreases in TT4 or IT4 
(Abdelouahab et al. 2013; Herbstman et al. 2008), two found increases and many other 
studies found no relationship. The inconsistent direction of these and other reported 
associations was discussed by Chevrier, who offered the following possible explanations: 
reverse causation (e.g. thyroid hormone levels are affecting PBDE levels in serum), 
determination of iodine status, type of measurement of free hormone concentrations (e.g. 
equilibrium dialysis vs. immunoassays), effect of hydroxylated PBDE metabolites, 
method of adjustment of serum lipids in regression analysis, co-exposure to other 
environmental chemicals; non-linear dose-response curves, differences between 
populations (e.g., pregnant vs. non-pregnant) (Chevrier 2013). 
It is difficult to compare toxicological experiments and epidemiological studies 
due to the inherent differences in study design, e.g., doses, mixtures of compounds. In 
addition, there are differences between TH physiology in rodents and humans. The major 
binding protein for T 4 is TTR in rodents and TBG in humans (Braverman and Cooper 
2013). Additionally, in rodents the thyroid gland directly produces approximately 25% of 
T3 whereas in humans the thyroid gland directly produces less than 1% of T3, thus 
making de-iodination a more important mechanism in humans than in rodents (Zoeller 
2004). 
PEDEs and Reproductive Function in men 
Recent epidemiological studies indicate there are possible increases in the 
incidence of several pathologies of the male reproductive tract and/or increases in male 
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infertility. There have been reports of increases in testicular cancer in North America and 
Europe (dos Santos Silva et al. 1999; McGlynn et al. 2003; Olesen et al. 2007; Power et 
al. 2001; Richiardi et al. 2004; Zheng et al. 1996). There have been reported increases in 
male developmental reproductive pathologies (e.g. hypospadias, cryptorchidism) (Acerini 
et al. 2009; Skakk:ebaek et al. 2001; Toppari et al. 2010). There have also been reports of 
decreases in semen quality or quantity (Carlsen et al. 2005; Jorgensen et al. 2001; Swan 
et al. 2003), but in certain cases results have been conflicting and/or specific to 
geographic regions (Richiardi et al. 2004). While the causes of these pathologies are 
likely multifactorial, it is hypothesized that exposure to xenobiotic compounds in the 
environment have contributed to adverse effects on male reproductive function 
(Giwercman and Giwercman 2011). 
Proper male reproductive function requires appropriately developed, healthy 
reproductive organs (e.g. testes, vas deferens, prostate, penis) as well as appropriate 
hormonal control. Testosterone is the primary male hormone and is required for 
initiation/maintenance of spermatogenesis, negative feedback of gonadotropin-releasing 
hormone (GnRH) and luteinizing hormone (LH), differentiation of reproductive organs, 
and induction of secondary sexual characteristics (Widmaier et al. 2008). LH acts on the 
Leydig cells of the testis, which stimulates testosterone secretion. Testosterone and LH 
are kept in appropriate concentrations via negative feedback at the anterior pituitary and 
Leydig cells. Follicular stimulating hormone (FSH) acts on the Sertoli cells of the testis, 
which stimulates secretion of paracrine agents, that aid spermatogenesis. Inhibin-B is 
secreted by the Sertoli cells and is the feedback signal that acts on the anterior pituitary 
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inhibiting FSH secretions. The total amount of FSH, inhibin, LH, testosterone, and sperm 
counts remain relatively constant on a daily basis in an adult male (Widmaier et al. 2008). 
This is entirely different in females, which have daily and monthly cyclical variations in 
reproductive hormone measurements (For this and other reasons, potential effects of 
PentaBDEs on female reproductive hormones are beyond the scope of this dissertation). 
Animal studies have indicated that PentaBDE exposure may lead to adverse 
effects on the male reproductive system. Table 4 summarizes well-designed toxicological 
studies that have investigated PentaBDE exposure and reproductive function in male 
rodents. PentaBDE exposure in animal models has resulted in a decrease in male 
reproductive organ weights (e.g. testis, seminal vesicle, prostate) (Ellis-Hutchings et al. 
2006; Kuriyama et al. 2005; Talsness et al. 2008; van der Ven et al. 2008b), whereas 
other studies have reported no change (Ernest et al. 2012; He et al. 2011). Some studies 
have shown changes in reproductive hormone levels (Stoker et al. 2005; Talsness et al. 
2008). A few studies report adverse effects on sperm production and morphology 
(Kuriyama et al. 2005; van der Ven et al. 2008b). Similar to the PentaBDE/thyroid 
hormone toxicology, results may be inconsistent due to differing exposure levels, 
exposure routes, duration of exposure, timing of exposure, and other relevant 
experimental characteristics. For example, fetal exposure during the critical gonadal sex 
determination period can lead to altered gene expression resulting in adult onset diseases 
such as spermatogenic cell apoptosis and male infertility (Baldi and Muratori 2014). 
There have been few human studies examining the association between 
PentaBDEs and reproductive hormone levels in males. Table 5 presents the results from 
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well-designed epidemiological studies exploring PentaBDE exposure and reproductive 
function in men with an emphasis on large studies and/or studies conducted in North 
America. In adult men, PBDE exposure has been associated with increases (Johnson et al. 
2013; Turyk et al. 2008) or decreases (Meeker et al. 2009; Toft et al. 2014) in total or free 
testosterone. There have also been reported associations with other reproductive function 
tests in males (follicular stimulating hormone, luteinizing hormone, sex hormone binding 
globulin, inhibin-B), but the results have been inconsistent. Similar to the inconsistent 
direction of results in the PentaBDE/TH epidemiology studies, outcomes could diverge 
because of the following reasons: different exposure timing (e.g. prenatal, early postnatal, 
adults), different measures of exposure (e.g. serum, dust, breast-milk), various data 
analysis techniques used to account for confounding variables (e.g. age, BMI, serum 
lipids), reverse causation, co-exposure to other compounds and hydroxyl metabolites of 
PBDEs. 
Research Objectives 
Overall the current health effects of PBDEs on endocrine function are unclear. 
However, toxicological studies in rodents (Tables 1.2 and 1.4) and epidemiologic studies 
in humans (Tables 1.3 and 1.5), suggest that PBDEs may adversely affect hormone 
homeostasis in humans. Thus conducting human studies specifically designed to address 
the relationship between PBDE exposure and hormone homeostasis is an outstanding 
research need. 
The aim of this research is to investigate the stability and time trends of PBDEs in 
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serum over a one-year period and to assess the association between PBDE exposure and 
disruption of thyroid and male reproductive hormones. We recruited a cohort of 52 
healthy adults within the Boston metropolitan area, hereafter referred to as the Flame 
Retardant Exposure (FlaRE) cohort. We collected blood and urine samples at three 
sampling intervals (Winter 2010, Summer 2010, and Winter 2011). Biologic samples 
were measured for PBDEs, thyroid hormones, reproductive hormones, and other 
potentially important compounds (e.g., perchlorate, iodine). We developed and 
administered a questionnaire designed to collect information on demographic variables, 
potential confounders and effect measure modifiers. The rest of this dissertation is 
structured as follows. 
The primary aim of Chapter 2 was to summarize serum measurements of 
PentaBDEs in our cohort and investigate temporal trends during the one-year study 
period. Additionally we used our repeated serum data to determine how reliably a single 
serum sample could classify exposure (either continuously or categorically) over a one-
year period. 
The primary aim of Chapter 3 was to use repeated measures in serum to assess 
the association between PentaBDE exposure and thyroid function in the FlaRE cohort. 
Additionally, because multiple thyroid hormone measurements are typically needed to 
assess an individuals thyroid function (Andersen et al. 2003) we used our repeated serum 
data to assess within- and between-subject variability of thyroid hormones. We used 
these data to examine possible explanations for the inconsistencies in the current 
epidemiologic literature (e.g. the possibility of reverse causation, determination of iodine 
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status, method of lipid adjustment from non-fasting serum samples). We also examined 
the effect of potential confounding variables and effect modifiers (i.e. age, sex, BMI, 
iodine and some other environmental contaminants) in the relationship between 
PentaBDEs and thyroid function tests. 
The primary aim of Chapter 4 was to use repeated measures in serum to assess 
the association between PBDE exposure and reproductive function in men of the FlaRE 
cohort. We used our repeated serum measures to assess within- and between- subject 
variability on reproductive function tests (total testosterone, free testosterone, follicular 
stimulating hormone, luteinizing hormone, inhibin-B, prolactin, sex hormone binding 
globulin) in our cohort. We also examined the effect of potential confounding variables 
and effect measure modifiers (i.e. lipids, age, and BMI) in the relationship between 
PentaBDEs and reproductive function tests. 
The findings of Chapters 2-4 are summarized m Chapter 5. Limitations and 
suggestions for future research are discussed. 
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Figure 1.1 General Chemical Structure of PBDEsA 
0 
A (USEP A, 2008) 
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Table 1.1 List of IUPACA numbers for common PBDEB congeners. 
IUPAC Number PBDE congener name 
BDE-28 2,4,4'- tribromodiphenyl ether 
BDE-47 2,2' ,4,4'- tetrabromodiphenyl ether 
BDE-99 2,2' ,4,4' ,5-pentabromodiphenyl ether 
BDE-100 2,2' ,4,4' ,6-pentabromodiphenyl ether 
BDE-153 2,2' ,4,4' ,5,5' -hexabromodiphenyl ether 
BDE-209 Decabromodiphenyl ether 
A International Umon of Pure and Applied Chermstry 
B Polybrominated diphenyl ethers 
Table 1.2 Summary of major published animal experiments investigating PentaBDE exposure and thyroid function in 
rodents. A 
First Author Animal Exposure Timing TSH Total T4 Total T3 Other Physiological Proposed Mechanism 
(year) Model Free T4 Free T3 Endpoints 
Fowles Mice DE-71 Adult NM ~TT4 NMTT3 1-o P450 (EROD) Thyroid gland dysfunction 
(1994) ~ fT4 NM fT3 -to corticosteroid Activate or antagonize TH 
receptor 
Zhou Rats DE-71 PND 28 ~TT4 ~TT3 1-o P450 1-o T 4 metabolism + 
(2001) 
-
NM fT4 NM fT3 (EROD/PROD) excretion 
1-o UDPGT 
Zhou Rats DE-71 Perinatal (GD ~TT4 - TT3 1-o P450 1-o T 4 metabolism + 
(2002) 6- PND 20) 
-
NM fT4 NM fT3 (EROD/PROD) excretion 
1-o UDPGT 
Stoker Rats DE-71 PND 22/23 1-o TSH ~TT4 ~TT3 1-o P450 Thyroid gland pathology 
(2004) NM fT4 NM fT3 (EROD/PROD) 
1-o UDPGT 
Ellis- Rats DE-71 Perinatal (GD 1-o TSH ~TT4 - TT3 1-o TT3jTT4 OH-PBDEs interactw/ BPs 
Hutchings 6- PND 18) NMfT4 NM fT3 -TTR 1-o T 4 metabolism 
I c2oo6) 
van der Ven Rats DE-71 PND 56 NM ~TT4 -TT3 1-o CYP (1A1) (2B) 1-o T 4 metabolism 
(2008) NM fT4 NM fT3 (3A) 
Hepatocellular injury 
Blake Rats DE-71 GD 1 to PND NM 1-o T4 1-o T3 1-o TG weight -to Release or reduced 
(2011) 21 NM fT4 NM fT3 clearance of THs in F1 
offspring 
Szabo Rats DE-71 GD 6 to PND NM ~TT4 - TT3 1-o UGT-T4 Phase II excretion 
(2009) 21 NM fT4 NM fT3 1-o CYP (1A1) (2B) Displacement on TTR 
~ DI activity ~ DI-1 activity 
1-o SUL TlB 1-o Hepatic transpor ter III 
elimination 
-0\ 
Table 1.2 (continued) Summary of major published animal experiments investigating PentaBDE exposure and thyroid 
function in rodents. A 
First Author Animal Exposure Timing TSH Total T4 Total T3 Other Physiological Proposed Mechanism 
(year) Model FreeT4 Free T3 Endpoints 
Blake Rats DE-71 GD 1 to PND NM 1-' T4 1-' T3 1-' TG weight 1-' Release or reduced 
(2011) 21 NM ff4 NM ff3 clearance of THs in F1 
offspring 
He Rats BDE-47, PCB- PND 10 
-
~TT4 -TT3 ~ TGweight Thyroid gland pathology 
(2011) 153 NM ff4 NM ff3 
Ernest Rats DE-71, DE-79, Adult 
-
~TT4 NMTT3 1-' P450 (E/P /M/B- Thyroid gland pathology 
(2012) BDE-209, NM ff4 NM ff3 ROD) 
HBCD 
Blanco Rats BDE-99 GD 6 to PND NM ~TT4 ~TT3 Down-regulation of 1-' T 4 excretion 
(2013) 21 ~ ff4 NM ff3 TH-mediated gene 
Bondy Rats DE-71 FO to PND 42 NM ~TT4 ~TT3 1-' Liver/body weight 1-' T 4 metabolism + 
(2013) NM ff4 NM ff3 excretion 
A An upward facing arrow ( -t-) indicates PBDE exposure was associated with an increase in the outcome parameter. A downward 
facing arrow (~) indicates PBDE exposure was associated with a decrease in the outcome parameter. A horizontal bar (-) 
indicates no relationship between PentaBDE exposure and outcome parameter. (NM) indicates the outcome parameter was not measured. 
........ 
-.) 
Table 1.3 Summary of key human studies examining PentaBDE exposure and thyroid hormone homeostasis. A 
First Author (Year) Study Location, No of Median PBDE TSH TT4 TT3 Other TFTsjfindings 
Study type Subjects Level fT4 fT3 
I (unit, media) 
Bloom, M. USA, 36 BDE-47 (7.9) - TSH - TT4 - TT3 
(2008) Adult, Cross- BDE-99 (1.8) - ff4 NMIT3 
sectional BDE-153 (1.8) 
(ngfg serum lipid) 
Herbstman, J USA, 297 BDE-47 (6.1), BDE- - TSH ~ TT4 NMTT3 EMM by delivery 
(2008) Birth cohort 99 (2.1), BDE-100 ~ ff4 NMIT3 mode 
(0.8), BDE-153 
13.5) (ng/g lipid)_ 
Turyk, M, USA, 308 BDE-47 (0.11), ~TSH 1" TT4 ~ TT3 ~TBG 
(2008) Adult, Cross- BDE-99 (0.03), 1" IT 4 ~ TBG bound T 4 
sectional BDE-100 (0.01), 1" rT3 
BDE-153 (0.03) 
ngfg serum 
Chevrier, J USA, 270 BDE-47 (15) BDE- ~TSH - TT4 NMTT3 1" odds of subclinical 
(2010) Birth cohort 99 ( 4.0) BD E- -IT4 NMIT3 hyperthyroidism 
100(2.4) 
BDE-153 (2.1) 
Lngfg lipid, serum) 
Lin, Shu-Ming Taiwan, 54 BDE-47 (0.67), - TSH - TT4 ~TT3 
(2011) Birth cohort BDE-99 (0.72), NMIT4 ~ fT3 
BDE-100 (0.17), 
BDE-153 (0.92) 
(ng/g lipid cord-
L_ 
blood) 
........ 
00 
Table 1.3 (continued). Summary of human studies examining PentaBDE exposure and thyroid hormone homeostasis. 
First Author Study No of Median PBDE Level TSH TT4 TT3 OtherTFTs 
(Year) Location, Subjects (unit, media) fT4 fT3 
Study Type 
Stapleton, H USA, 140 BDE-47 (19) -TSH ~TT4 ~ TT3 None 
(2011) Birth cohort BDE-99 (5.5) ~ IT4 NRIT3 
BDE-100 (4.6) (ng/g 
lipid, serum) 
Zota, A USA, 25 BDE-47 (42), ~TSH NRTT4 NMTT3 None 
(2011) Birth cohort BDE-99 (9.8), BDE- NRIT4 NMIT3 
100 (9.0), BDE-153 
I (17) (ng/g lipid) 
Abdelouahab, N. (2013) Canada, 380 BDE-47 (20.5) BDE- - TSH ~ TT4 ~ TT3 None 
Birth Cohort 99 (2.3) ~ ff4 ~ IT3 
BDE-100 (2.4) BDE-
153 (2.1) (ng/g lipid, 
serum) 
Makey, CM. (2014) USA, 52 BDE-47 (8.9), BDE- - TSH ~ TT4 NR TT3 None 
This Dissertation Adult Cohort 99 (1.8), BDE-100 NRIT4 NMIT3 
(1.8), BDE-153 (6.4) 
ng/g lipid, serum 
--
A An upward facing arrow ( 1') indicates PBDE exposure was associated with an increase in the outcome parameter. A downward facing 
arrow (~) indicates PBDE exposure was associated with a decrease in the outcome parameter. A horizontal bar (-) indicates no 
relationship between PentaBDE exposure and outcome parameter. (NM) indicates the outcome parameter was not measured. 
....... 
\0 
Table 1.4 Summary of major animal experiments investigating PentaBDE exposure and reproductive endpoint in male rodents 
First Author Animal Exposure Timing T Other Reproductive Sperm quality Other endpoints 
(year) Model FreeT RFT organ weights 
Stoker Rats DE-71 PND 22/23 ~ TTNS ~ LH ~ seminal vesicle NM Delayed puberty 
I r2oos1 ~prostate (male) 
Kuriyama Rats BDE-99 GD 6 -TT - LH ~testis ~ Sperm Counts 
(2005) NM IT ~ epididymis ~ Daily Sperm 
Production 
Ellis- Rats DE-71 Perinatal (GD NM NM ~testis NM 
Hutchings 6- PND 18) 
[2006) 
van derVen Rats DE-71 PND 56 NM NM ~ epididymis ~ deformed sperm 
(2008) ~ seminal vesicle 
~prostate 
Blake Rats DE-71 GD 1 to PND NM NM -testes ~ expression DE-71 activated 
(2011) 21 -ovary gonadal osteopontin osteopontin gene 
mRNA promoter 
construct 
He Rats BDE-47, PCB- PND 10 NM NM -testis NM Induced liver 
(2011) 153 - epididymis detoxification 
response 
Ernest Rats DE-71, DE-79, Adult -TT NM -testis -sperm DNA 
(2012) BDE-209, integrity 
HBCD 
-- - - --
An upward facing arrow ( lfl) indicates PBDE exposure was associated with an increase in the outcome parameter. A downward facing 
arrow (~) indicates PBDE exposure was associated with a decrease in the outcome parameter. A horizontal bar (-) indicates no 
relationship between PentaBDE exposure and outcome parameter. (NM) indicates the outcome parameter was not measured. 
I 
N 
0 
Table 1.5 S fkev h d" p B d d 
--- - - - - - --- - - -----o - - - -- --- - -- - - r -- --- ----- -· - -r -- ~-- --- - - -- - - ------------- - - -
First Author Study No of Median PBDE Level T, free T FSH LH Other Repo. Endpoints 
(Year) Location Subjects (unit, matrix) Inhibin-B, Prolactin 
SHBG 
Main, K.M. Denmark 130 BDE-47 (1.27) 8DE-99 (0.42) -T - FSH 1'- LH 1'-cryptorchidism in 
(2007) Finland BDE-100 (0.29) BDE-153 -.:rr - Inhibin-B NM Prolactin newborns 
'(0.85) (ng/g, breast milk fat) - SH8G 
Turyk, M, USA 308 BDE-47 (0.11), 8DE-99 (0.03), 1'-T NM - SH8G ~ SH8G-bound T 
(2008) 8DE-100 (0.01), BDE-153 
(0.03) ng/g serum 
Meeker, JD USA 24 8DE-47 (500) 8DE-99 (838) ~T ~FSH ~LH ~FA! 
(2009) BDE-100(180) (ng/g, dust) 1'- Inhibin-B ~Prolactin 1'- estradiol 
1'- SHGB 
Abdelouahab, Canada 52 BDE-47 (0.186) 8DE-99 NM NM NM ~ semen mobility 
N. (2011) (0.053) 8DE-100 (0.030) BDE-
153 (0.004) (ng/ml, serum) 
Johnson, Pl. USA 38 Penta8DE (47, 99, 100) 1049 1'-T ~FSH ~LH 1'- estradiol 
(2013) (ngjg, dust) 1'- lnhibin-8 1'- Prolactin ~FA! 
1'- SHBG 
Toft, G. (2014) Greenland 299 BDE-47 (0.2- 2.0), BDE-153 ~T ~ inhibin-B - SHBG ~estradiol 
Poland (2,7 to 0.3). (ng/g serum - FSH - LH ~FA! 
Ukraine lipid) ~ semen quality 
Makey, CM. USA 27 BDE-47 (9.4), BDE-99 (1.9), -T ~ inhibin-B - LH ~ Inhibin-8/FSH ratio 
(2014) BDE-100 (1.8), 8DE-153 (8.6) -IT 1'- FSH -Prolactin ~FA! 
This ngjg serum lipid -SHBG 
Dissertation 
-
An upward facing arrow ( 1-) indicates PBDE exposure was associated with an increase in the outcome parameter. A downward facing 
arrow (~) indicates PBDE exposure was associated with a decrease in the outcome parameter. A horizontal bar (-) indicates no 
relationship between PentaBDE exposure and outcome parameter. (NM) indicates the outcome parameter was not measured. 
N 
....... 
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ABSTRACT. 
PentaBDEs are flame retardant chemicals manufactured for use in consumer products in 
the US until 2004. They are currently common contaminants in human serum and 
associated with adverse health effects. We collected three repeated measurements at six-
month intervals from 52 office workers from the greater Boston (USA) area from 2010 to 
2011. The intraclass correlation coefficient for BDEs 28, 47, 99, 100 and 153 ranged 
from 0.87 to 0.99, indicating that a single serum measurement can reliably estimate 
exposure over a one-year period. This was true for both lipid adjusted and non-lipid 
adjusted concentrations. The kappa statistics, quantifying the level of agreement of 
categorical exposure classification, based on medians, tertiles, or quartiles ranged from 
0.67 to 0.90. Some PentaBDE congeners had significant temporal declines from sampling 
Round 2 to Round 3. This study highlights the high reliability of a single PentaBDE 
serum measurement for use in human epidemiologic studies and suggests downward 
trends of serum concentrations of some congeners. 
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Introduction 
Polybrominated diphenyl ethers (PBDEs) are additive flame retardant chemicals 
used since the 1970s in commercial and household products. The technical formulation 
PentaBDE is composed of PBDE congeners containing three to six bromines. It was 
primarily used in furniture containing polyurethane foam to meet fire standards such as 
California Technical Bulletin TB117. Of the worldwide production, 95% of the 
PentaBDE produced was consumed in North America (Birnbaum and Staskal 2004), 
where concentrations in the environment and people are approximately an order of 
magnitude higher than those reported in Europe or Asia (Hites 2004; Meironyte et al. 
1999; Sjodin et al. 2004; Sjodin et al. 2008). 
Due to their persistence, ability to bioaccumulate, and concerns regarding adverse 
effects on human health, PentaBDE and OctaBDE were banned in the European Union 
(EU) and added to the list of persistent organic pollutants (POPs) in the Stockholm 
Convention (UNEP 2001). In the US, the main chemical manufacturers voluntarily 
withdrew PentaBDE from use in 2004 (USEPA 2004). Despite the current restrictions, 
human exposure is still occurring due to the release of PentaBDEs from existing products 
and through foods containing PBDEs (Betts 2008; Schecter et al. 2006). Unlike the 
highly brominated BDE-183 and BDE-209 that have half-lives on the order of weeks to 
months, the half-lives of the PentaBDE congeners in humans are estimated to be on the 
order of years but have not been directly measured (Sjodin et al. 2004; Trudel el al. 2011 ; 
Thuresson et al. 2006). 
It is unclear how serum PentaBDE levels have changed since the 2004 phase-out 
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in the US. Two serial, cross-sectional, non-representative studies conducted in the US 
before the phase-out have shown that PBDE levels increased from 1973 to 2003 
(Schecter et al. 2005), and from 1985 to 2002 (Sjodin et al. 2004). A small study of 
pregnant San Francisco women found decreased PentaBDE serum levels between 
participants recruited in 2008-9 (n=25) and 2011-12 (n=36) (Zota et al. 2013). In the only 
US longitudinal study, reported concentrations of :2:PBDEs (sum of BDE-28, 47, 49, 99, 
100, 138, and 153) and individual BDE congeners did not differ between 2001-03 and 
2004-05 (Turyk et al. 2010). In a subset of this same cohort, repeated serum PBDE 
congener concentrations sampled in 2004-05 and 2008 did not change significantly over 
time and were highly correlated within individuals (p<0.0001) (lmm et al. 2009). 
Toxicological studies have demonstrated that PBDEs, particularly of the 
PentaBDE formulations, adversely affect endocrine homeostasis (Stoker et al. 2004), 
neurodevelopment (Erikkson et al. 2001), and have reproductive effects (van der Ven et 
al. 2008). Recently epidemiological studies conducted in the US have linked PBDE 
exposure to adverse effects on neurodevelopment (Herbstman et al. 2010, Eskenazi et al. 
2013, Hoffman et al. 2012) and altered thyroid and reproductive hormone levels (Turyk 
et al. 2008; Meeker et al. 2009; Stapleton et al. 2011; Johnson et al. 2013). Even though 
the half-lives of PentaBDEs are estimated to be on the order of years, it is still unclear 
how reliable a single PBDE serum measure is for assigning exposure in epidemiological 
studies. 
This study therefore analyzed three repeated serum measurements of PBDEs 
collected over approximately a one-year study period in a well-defined adult US cohort. 
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Our primary objectives were to characterize PBDE body burdens, explore possible 
temporal trends over a one-year period, and assess the between- and within-subject 
variability of PBDE congeners in semm. We also examined demographic characteristics 
and semm lipid concentrations as predictors of PentaBDE body burden. 
Experimental 
Study Design and Population. We recmited a convenience sample of 52 adults 
living and working in the greater Boston (USA) metropolitan area from winter 2010 to 
summer 2011 to participate in the Flame Retardant Exposure Study (FlaRE Study). 
Eligible subjects had to be healthy, non-smoking adults over the age of 18, working in an 
office environment at least 20 hours a week, and planning to reside in the greater Boston 
metropolitan area for the study duration. Participants were excluded for having a prior 
diagnosis of thyroid or male reproductive disease or if they were pregnant. 
We conducted three sampling rounds: Round 1 (1113110 - 4115/10), Round 2 
(6/3110- 9115/10), and Round 3 (1131111- 4/27111). Semm samples were provided by 49 
of 51 (96%) participants in Round 1, 50 of 52 (96%) participants in Round 2, and 42 of 
52 (81 %) participants in Round 3. One participant was added in Round 2. The missing 
blood samples were due to the following reasons: phlebotomist was unable to conduct 
venipuncture, participant declined, participant moved out of study area, or participant 
could no longer be contacted. All blood samples were non-fasting. 
During each sampling visit, trained study personnel administered a questionnaire 
designed to collect basic demographic and health information. We obtained age, sex, 
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race, education, height, and weight from self-reported data collected during the 
participants' initial sampling round. The Boston University Medical Center Institutional 
Review Board approved the study protocol and all subjects gave written informed 
consent prior to participation. The involvement of the Centers for Disease Control and 
Prevention (CDC) laboratory was determined not to constitute engagement in human 
subjects research. 
Blood Samples. A trained phlebotomist collected 30 mL of blood from each 
participant during each sampling round. Blood samples were processed on the day of 
collection and serum samples were stored at -80°C in amber glass vials until analysis. To 
eliminate potential issues with inter-assay variability, serum samples collected from all 
three rounds were analyzed at one time following Round 3. Serum samples were 
analyzed for lipids (total triglycerides, total cholesterol) and 11 PBDE congeners (BDE-
17, BDE-28, BDE-47, BDE-66, BDE-85, BDE-99, BDE-100, BDE-153, BDE-154, BDE-
183, BDE-209) at the CDC using established methods (Sjodin et al. 2004). Final analytic 
determination of the PBDE congeners was performed by gas chromatography isotope 
dilution high-resolution mass spectrometry using a MAT95XP (ThermoFinnigan MAT, 
Bremen, Germany) instrument. Samples were randomized and analyzed with quality 
control (QC) (n=3) and blank samples (n=3) in each batch of 24 unknowns. The 
coefficient of variation of included QC samples was less than 10%. All concentration 
data were reported as background subtracted, where correction was made based on the 
median amount present in blank samples. Limits of detection (LOD) were calculated as 
the highest of two methods (i) 3 times the standard deviation of the method blank 
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samples and (ii) as the lowest point in the calibration curve having a signal to noise ratio 
greater than 3 (primarily for analytes with low to no detectable method blank 
concentration). 
Statistical Analysis. For measurements below the LOD, we substituted Yz LOD. 
PBDE congeners were log-normally distributed, as identified by histograms and Shapiro-
Wilks tests, and thus log-transformed. We calculated round-specific geometric means 
(GM) and geometric standard deviation (GSD) for congeners detected in >50% of the 
samples. ~PBDEs is the sum of BDE-28, BDE-47, BDE-99, BDE-100, and BDE-153. 
For repeated measures, ni is an individual, nij is an individual at a defined point in time, 
and n is the overall number of samples. All statistical analyses were conducted using SAS 
version 9.3 (SAS Institute, Cary, NC, USA). Statistical significance is reported at the 
0.05 level. 
We calculated kappa statistics to assess the amount of agreement between 
exposure classification in Round 1 and Round 3, the two winter time points. This analysis 
was restricted to participants that provided a blood sample in both sampling rounds 
(ni=40). Contingency tables were constructed to display the level of agreement between 
each subject's initial exposure classification, and their classification based on their third 
exposure classification. We report the weighted kappa, instead of the simple kappa, when 
there was more than one category because the weighted kappa assigns less weight to 
agreement as categories are further apart (Viera and Garrett 2005). 
We used the following general linear model with a random intercept to estimate 
the between- and within-subject variance components associated with PBDE levels over 
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the study time: 
Yij = /Jo + bi + E:ij (1) 
where Y iJ represents the natural logarithm of the PBDE level of the ith participant on the 
jth day, /Jo is the fixed effect intercept, b i is the random intercept of the ith individual, and 
E:ij is the random error. To determine how serum lipids affect the variance components of 
the intercept only model, we added a predictor variable, LIPIDiJ. the lipid level of the ith 
participant on the jth day: 
(2) 
We estimated the intraclass correlation coefficient (ICC) to assess reliability of serum 
PBDE concentrations using the formula: 
ICC= rls I (rls + rlw) (3) 
where r/8 is the between-subject variance and rlw is the within-subject variance. 
We used a general linear model with a random intercept to determine whether 
biomarker levels (a) increased or decreased over the study period or (b) were associated 
with independent predictor variables derived from questionnaires. We did not have 
completely balanced data; however we considered the reasons for missing serum data not 
related to PBDE level and thus classified these data as missing completely at random 
(MCAR). As general linear models are robust to MCAR and missing at random (MAR) 
patterns of missing data, inferences reported from our regression models are likely 
unbiased (Fitzmaurice and Laird 1997). Rather than standardizing PBDE measurements 
to lipids, we adjusted for lipid as a covariate in regression models (Schisterman et al. 
2005) allowing us to estimate the effect of this variable. To evaluate the fixed effects of 
30 
time and covariates, we used the following model: 
Yij =Po + /JJTIME2 + fJ2TIME3 + jJ3AGEi + /)4SEXi + fJsBM!i + /36LIPIDij+ bi + C:ij (4) 
where Yij, /30 , bi and C:ij are defined as earlier. TIME2 and TIME3 are indicator variable: f31 
is the average difference of the log(PBDE) measurement from Round 1 to Round 2; f32 is 
the average difference of the log(PBDE) measurement from Round 1 to Round 3. AGE is 
the age of the ith participant at the initial sampling round (categorized as ~ 37 or < 37 
years old); SEX is the gender of the ith participant; BMI is the body mass index of the ith 
participant at the initial sampling round (categorized as ~25 mglki or <25 mglkg\ We 
exponentiated the beta estimates to estimate a percent change in PentaBDE per unit 
change in predictor variable. 
Results 
The study population consisted of 27 males and 25 females. The median age was 
37 years old, 88% were white, 98% had a college degree, and 64% had BMI < 25 kg/m2 
(Table 2.1 ). Baseline self-reported health status ranged from good to excellent (not 
shown). Forty-one participants provided a serum sample in all three sampling rounds, 
nine provided a sample in two rounds, and two provided a single serum sample. One 
serum sample was contaminated during field collection and removed from analysis. We 
had 142 valid serum PBDE measurements .from 52 participants. 
Table 2.2 presents the round-specific geometri<;: means (GM), geometric standard 
deviations (GSD), and ranges for PBDE congeners that were detected at >50%: BDE-28, 
BDE-47, BDE-99, BDE-100, BDE-153. Both lipid-standardized and wet weight serum 
concentrations are shown. Detection rates for BDE-17, BDE-66, BDE-85, BDE-154, 
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BDE-183, and BDE-209 ranged from 1% to 22% and were not further analyzed (Table 
2.5). See figure 2.1 for a graph of individual data for BDE-47. 
Table 2.3 presents the estimated ICCs for the serum PBDE measurements 
calculated using equations 1 (unadjusted), 2 (adjusted for lipid) or 4 (adjusted for lipid 
and other covariates). Variance components are shown in Table 2.6. The ICC expresses 
the proportion of variance attributable to differences between subjects compared to 
variability within subjects over the study period (Fleiss 1996). For a valid, reproducible, 
and reliable exposure classification, an ICC close to 1 is optimal (de Vet et al. 2006). The 
ICC estimates were very high, particularly for .LPBDEs, BDE-47, and BDE-153, ranging 
from 0.96 to 0.99. These results signify that a single PentaBDE serum measurement is a 
reliable, reproducible biomarker for estimating exposure. As a sensitivity analysis for 
missing data, we calculated ICCs using equation (1) on a subset of individuals that 
contributed three serum measurements (n=40) and the results were similar (not shown). 
See Figure 2.2 for a simple correlation analysis for BDE-47. 
The ICC is very useful for analyzing continuous measures. Epidemiologists often 
categorize exposure data as well. Table 2.3 also presents the agreement statistics (kappa) 
quantifying the extent to which a single serum PBDE measurement corresponds with a 
participant's exposure classification approximately twelve months later. The kappa 
statistics for BDE-47, based on categorization by median, tertile, or quartile, were 0.80, 
0.67, and 0.84, respectively. Supplemental figure 3 presents the contingency tables 
associated with the kappa statistics for BDE-47 . .LPBDEs, a commonly used aggregate 
exposure metric, had kappa statistics that ranged from 0.80 to 0.83, indicating exposure 
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categorization is reproducible over a one-year time period. 
Table 2.4 presents parameter estimates and p-values for regression models 
(equation 4) predicting PBDE levels as a function of time, serum lipids, age, sex, and 
BMI. Exponentiating the beta coefficients, we find that BDE-47 and BDE-100 levels 
significantly decreased by 7.9% (p=0.029), and 13.9% (p=0.024) respectively, from 
Round 2 to Round 3. While there were no other significant temporal trends, all congeners 
except BDE-99 had negative slopes from Round 2 to Round 3 and positive trends from 
Round 1 to Round 2. We also ran regression analysis using PentaBDE standardized to 
lipids and our results were similar to the presented model with lipid as a covariate (not 
shown). Using Akaike Information Criterion (AIC) as a guide, we found that evaluating 
time as a categorical variable (instead of continuous in months) provided the better fit, 
though results were similar in both models (not shown). We also analyzed these data 
using a model with continuous time (in months) and covariate for season (summer vs. 
winter), and did not find any significant trends (not shown). 
Serum lipids were highly significant predictors of all the PentaBDEs. PentaBDEs 
increased between 0.15% to 0.21% per unit of total lipids, while controlling for age, sex, 
time and BMI. Since PentaBDEs are lipophilic, we would expect that as lipid levels 
increase we would see an increase in PBDE levels, which our results confirm (Gaskins 
and Schisterman 2009). For example, if total serum lipids increase one standard deviation 
above the mean in Round 1 (18%), our model predicts that LPBDEs should increase by 
about 19%. Additionally, we calculated ICCs for the lipid measurements using equation 1 
and 2 with the dependent variable Yij representing the lipid level of the ith participant on 
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the jth day. The ICCs were 0.80, 0.86, and 0.65 for total lipids, total cholesterol, and 
triglycerides, respectively (data not shown). 
Although not statistically significant, sex and age were suggestive predictors for 
BDE-153 (Such associations have been previously observed) (Sjodin et al. 2008; Toms at 
al. 2009; Gari and Grimault 2013). On average men had 84% (p=0.06) higher BDE-153 
levels than women, after controlling for other covariates. Levels of BDE-153 were 41% 
lower (p=0.09) in the older participants than the younger participants. Interestingly, for 
all other congeners, this trend was reversed where PentaBDE levels were non-
significantly higher on average in the older than the younger participants. BMI was not a 
significant predictor of any congener. We ran univariate models analyzing each fixed 
effect independently and found that the univariate and multivariate results were similar. 
Discussion 
The PentaBDE serum levels in our study were lower for BDE-28, BDE-47, BDE-
99, and BDE-100 than in the National Health and Nutrition Examination Survey 
(NHANES) 2003-2004, the most recent published US nationally representative data. 
Sjodin et al. reported geometric means and 95% Cis for BDE-28, BDE-47, BDE-99, and 
BDE-100, as 1.2 (1.0- 1.4) ng/g lipid, 20.5 (17.6- 23.9) ng/g lipid, 5.0 (4.4-5.6) ng/g 
lipid, 3.9 (3.4-4.5) ng/g lipid, respectively (Sjodin et al. 2008). All of our GM 
concentrations (Table 2.2) are lower than these NHANES values. Comparisons between 
our study and NHANES are limited: NHANES 2003-2004 was a representative sample of 
the USA while our population is a convenience sampling of Boston, USA office workers 
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at a later time point. There are geographic differences within the USA: Californians have 
higher PentaBDE serum levels (Zota at al. 2008). In a pilot study to this investigation, 
Watkins et al. reported GM serum concentrations of BDE-28, BDE-47, BDE-99, and 
BDE-100 that were approximately 1.5 to 2 times greater than our Round 1 values 
collected one year later (p<0.001) (Watkins et al. 2011). For example, Watkins et al. 
reported GM (GSD) serum levels of BDE-47 of 14.2 (3.0) ng/g lipid which are different 
from our Round 1 serum levels of 9.6 (2.8) ng/g lipid (t=7.02, p<0.001). This population 
was demographically and geographically similar to our study, and utilized the same 
analytical laboratory. On the other hand, the levels of BDE-153 in our study were similar 
to those reported for NHANES 2003-2004, 5.7 ng/g lipid (CI = 5.1-6.3), and for the 
Boston office workers, 5.0 ng/g lipid (Sjodin et al. 2008; Watkins et al. 2011) 
We found a significant decreasing trend over time for BDE-47 and BDE-100, 
over a six-month time interval. BDE-47, the predominant congener in human serum, and 
BDE-100 decreased on average 7.9% and 13.9%, respectively, from Round 2 to Round 3, 
after controlling for age, sex, lipid and BMI. Time trends for other congeners were not 
significant. The only previous longitudinal study of Americans reported no significant 
decreases in LPBDE or the individual PentaBDE congeners; however percent 
contribution of BDE-153 to LPBDE increased while percent contribution of BDE-47 to 
LPBDE decreased significantly from 2001-03 to 2004-05 (Turyk et al. 2010). A recent 
study comparing two demographically similar study populations found BDE-47, -99 and 
-100 decreased more than BDE-153 in samples collected in 2008-09 and 2011-12 (Zota 
et al. 2013) Outside of the US, a retrospective Swedish study comparing pooled breast 
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milk samples reported decreasing concentration of BDE-47 beginning in the late 1990s, 
while BDE-153 appeared to level off (Fangstrom et al. 2005; Meironyte et al. 1999). 
We observed a non-significant increase in all PentaBDE congener concentrations 
from Round 1 (winter) to Round 2 (summer) This trend was present in the fully adjusted 
model (Table 2.3) as well as the wet weight and lipid standardized PBDE concentrations 
(Table 2.2). While there is typically a seasonal increase in mean serum cholesterol over 
the winter months compared to the summer (Fyfe at al. 1968; Rastam et al. 1992), 
average serum lipid concentrations in our population did not differ by Round (Table 2.2). 
Since we only have one summer season we were unable to determine if serum 
concentration changes can be attributed to seasonal variation (e.g., activity patterns, diet). 
However, the non-significant increases in PentaBDE serum concentrations observed in 
Round 2 were not the result of a change in blood lipid levels. 
A possible decreasing trend of some congeners is consistent with the hypothesis 
that exposure may be declining since the discontinuation of PentaBDE manufacturing in 
the mid-2000s. There are a few possible explanations for congener specific temporal 
patterns. This trend may be partly explained by a difference in the elimination rates of 
these congeners. The median half-life of BDE-153 is indirectly estimated to be 7.4 years 
compared to 1.4 years for BDE-47 (Trudel et al. 2011). However, the estimated half-life 
of BDE-99 is 0.8 years, but there were no temporal trends for this congener in our study. 
Unfortunately, we were unable to reliably estimate half-lives for PentaBDEs with our 
data (Bartell 2012). 
The different temporal trends for congeners may also be partly due to differences 
36 
in exposure sources. In the US, both dust from the indoor environment and consumption 
of food were shown to be important pathways for adult exposure to PBDEs (Johnson et 
al. 2010; Wu et al. 2007). Exposure routes may vary by congener however. Johnson et al. 
reported strong correlations between paired household dust and adult serum samples for 
BDEs 47, 99, and 100, but not for BDE-153 (Johnson et al. 2010). In a study of young 
children, Stapleton et al. reported association between serum concentrations, hand-wipes 
and dust for BDEs 47, 99, 100 and 153; only BDE-153 serum concentrations were 
strongly associated with duration of breastfeeding (Stapleton et al. 2010). In a study using 
NHANES data, BDE-153 serum concentrations had stronger associations with red meat 
and total daily fat intake than the other PentaBDE congeners (Fraser et al. 2009). 
A major strength of our study is the use of three serum samples from a 
longitudinal study of a relatively homogeneous population. With similar working 
conditions and demographic characteristics, the study population is likely to be similar 
with respect to unknown confounders. A limitation of our study is that our serum 
collection was not completely balanced; participants contributed one, two, or three serum 
samples. However, as we had a high retention rate (>80% ), and study dropout was 
classified as MCAR, this limitation was unlikely to have biased our results. Our study 
sample size (n;=52, n=142) limited the amount of variables we could evaluate 
simultaneously in regression models and likely reduced our power to detect statistically 
significant associations. We used a convenience sample of office workers in the Boston 
area, that were mostly white, not overweight, and highly educated and we cannot be 
certain our results can be generalized to the general US population. 
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Our study demonstrates that a single PentaBDE serum measurement reliably 
estimates, either continuously or categorically, a participant's blood concentration over a 
one-year period. This result held for both lipid adjusted and non-lipid adjusted serum 
concentrations. Our analysis thus supports PentaBDE epidemiology studies that use 
single serum samples. We also observed decreases of serum concentrations of some 
PentaBDE congeners over one year that were not explained by changes in serum lipid. 
Future studies should be conducted to investigate changes in serum levels of PBDEs in 
the US population, PentaBDE half-lives, and the possible implications of sampling 
season on PBDE serum concentrations. 
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Table 2.1 Baseline characteristics of 52 
adults from the FlaRE cohort. 
Characteristic n (%) 
Age 
20-39 years 29 (56) 
40-59 years 19 (36) 
~ 60 years 4 (8) 
Sex 
female 25 (48) 
male 27 (52) 
Race/ethnicity 
white 46 (88) 
other 6 (12) 
Education 
College graduate 51 (98) 
< college graduate 1 (2) 
BMI (mg/kg 2) 
<25 33 (63) 
25-29.9 17 (33) 
~30 2 (4) 
Table 2.2 Selected polybrominated diphenyl ethers, lipids, and their geometric mean (GM), geometric standard deviation 
(GSD), and range by samrling round (ni=52, n=142). 
Round 1 (n=49) Round 2 (n=50) Round 3 (n=43) 
Analyte GM (GSD) Range GM (GSD) Range GM (GSD) Range 
Serum (ng/g lipid) 
I:PBDE 23 (2.2) 2.3-290 24 (2.5) 2.7- 294 20 (2.3) 2.4- 211 
BDE- 28 0.58 (2.3) 0.15-4.2 0.62 (2.2) 0.15-5.1 0.52 (2.2) 0.15- 3.6 
BDE- 47 9.6 (2.8) 0.6- 151 9.9 (2.7) 1.3- 149.0 7.9 (2.6) 0.9-98.9 
BDE- 99 1.8 (2.9) 0.2-43.5 1.9 (3.0) 0.2- 34.1 1.7 (2.5) 0.2-20.1 
BDE- 100 1.8 (3.4) 0.2- 42.4 1.9 (3.3) 0.2- 44.1 1.4 (3.0) 0.15- 35.2 
BDE- 153 6.4 (3.2) 0.6-96.7 6.7 (3.1) 0.7- 94.7 5.4 (3.1) 0.25- 55.2 
Serum (pg/g wet weight) 
BDE- 28 3.5 (2.4) 1.3- 29.1 3.7 (2.4) 1.3-30.4 3.1 (2.3) 1.3- 24.5 
BDE- 47 57 (2.9) 3.9-986 59 (2.8) 7.3- 1000 48 (2.7) 5.5 -707 lJ.) 
BDE- 99 11 (3.0) 1.3- 285 11 (3.2) 1.3- 229 10 (2.6) 1.3- 144 \0 
BDE- 100 11 (3.5) 1.3- 278 11 (3.4) 1.3- 297 8 (3.1) 1.3- 252 
BDE- 153 38 (3.2) 3.9- 695 40 (3.1) 4.5- 584 36 (2.7) 5.3- 395 
Serum lipids (mg/dL) 
Cholesterol* 190 (33) 120- 290 190 (33) 110- 360 190 (45) 92- 330 
Triglycerides * 130 (70) 50- 340 130 (71) 42- 340 140 (65) 45-290 
Total Lipids* 620 (110) 450- 860 620 (150) 370- 1100 640 (140) 330- 1000 
* Means and standard deviation presented. 
Selected congeners were detected in serum no less than 65% of the samples 
Additional congeners that were analyzed but detected infrequently (BDE-17, BDE-66, BDE-85, 
BDE-154, BDE-183, BDE-209) are presented in Supplemental table 1. 
Table 2.3 Intraclass Correlation Coefficients (ICCs) and kappa statistics for repeated serum markers for 
selected PBDEs (ni=52, n=142). 
Parameter 
A ICC NULL 
B ICCuPID 
c ICC FULL 
Median Classification 
IPBDE 
Estimate (95% Cl) 
0.96 (0.95 to 0.98) 
0.97 (0.95 to 0.98) 
0.97 (0.95 to 0.98) 
BDE- 28 
Estimate (95 % CI) 
0.87 (0.80 to 0.91) 
0.89 (0.82 to 0.93) 
0.89 (0.82 to 0.93) 
BDE- 47 
Estimate (95% CI) 
0.96 (0.95 to 0.98) 
0.97 (0.95 to 0.98) 
0.97 (0.95 to 0.98) 
K 0.80 (0.61 to 0.99) 0.80 (0.62 to 0.99) 0.80 (0.61 to 0.99) 
Tertile Classification 
Kweighted 0.83 (0.71 to 0.96) 0.75 (0.60 to 0.90) 0.67 (0.50 to 0.84) 
Quartile Classification 
Kweighted 0.82 (0.71 to 0.93) 0.78 (0.66 to 0.90) 0.84 (0.73 to 0.95) 
A Equation (1) Yij = fJo + bi + c:ij 
8 Equation (2) Yij = ;J 0 + ;J JLIPID + bi + E ij 
c Equation (4) Yu = ;J o + ;J 1TIME2 + ;J 2TIME3 + ;J 3AGEi + fJ4SEXi + fJSBM/i + fJ6L/P/Dij+ bi + 
c:ij 
.j::. 
0 
Table 2.3 (continued) Intraclass Correlation Coefficients (ICCs) and kappa statistics for repeated serum markers for 
selected PBDEs (ni=52, n= 142). 
Parameters BDE- 99 BDE- 100 BDE- 153 
Estimate (95% Cl) Estimate (95% Cl) Estimate (95% Cl) 
ICC NULL A 0.91 (0.86 to 0.94) 0.92 (0.88 to 0.95) 0.98 (0.97 to 0.99) 
ICCupm B 0.91 (0.86 to 0.94) 0.93 (0.88 to 0.95) 0.99 (0.98 to 0.99) 
ICC FULL c 0.91 (0.86 to 0.94) 0.93 (0.88 to 0.96) 0.98 (0.97 to 0.99) 
Median Classification 
K 0.80 (0.61 to 0.99) 0.85 (0.69 to 1.0) 0.90 (0.77 to 1.0) 
Tertile Classification 
Kweighted 0.72 (0.57 to 0.88) 0.78 (0.64 to 0.92) 0.81 (0.66- 0.96) 
Quartile Classification 
Kweighted 0.76 (0.64 to 0.88) 0.82 (0.71 to 0.93) 0.90 (0.81 to 0.98) 
A Equation (1) Yij = fJo + bi + eij 
8 Equation (2) Yu = /J o + /J 1LIPID + bi + E iJ 
c Equation (4) Yu = /l o + /l 1TIME2 + /l 2TIME3 + jJ3AGEi + fJ4SEXi + fJ5BMii + fJ6LIPIDij+ bi + eij 
~ 
...... 
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Table 2.4. General linear models for repeated measures assessing PentaBDE serum 
measurements from 2010-11 by demographic characteristic (ni=52, n=142). 
Parameters IPBDE (ln(pg/g)) BDE-28 (ln(pg/g)) 
fJ (SE) p-values fJ (SE) p-values 
Fixed Effects 
Time (overall) 0.22 0.33 
Time 1 ref ref 
Time2 0.029 (0.032) 0.37 0.048 (0.053) 0.37 
Time3 -0.030 (0.034) 0.39 -0.034 (0.057) 0.55 
Time 2 vs. 3 -0.059 (0.034) 0.084 -0.082 (0.056) 0.15 
Lipid 0.0016 (0.00027) <0.0001 0.0016 (0.00042) 0.0002 
Sex 
Female ref ref 
Male 0.13 (0.27) 0.62 -0.16 (0.21) 0.45 
Age A 
< 37 yo ref ref 
~ 37 yo -0.069 (0.26) 0.79 0.39 (0.21) 0.073 
BMI8 
Normal ref ref 
Overweight/Obese 0.26 (0.28) 0.35 0.29 (0.22) 0.21 
~ coefficients are regression coefficients for log-transformed outcome data. ExpW) 
yields the multiplicative increase in PBDE per unit change in predictor (e.g., exp(-
0.082) = 0.921 = 7.9% decrease) 
A Age was dichotomized at 37 years old because that was the median age at enrollment 
in the cohort. 
8 Normal BMI ( <25 kg/m2), Overweight/Obese (~25 kg/m2) 
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Table 2.4 (continued). General linear models for repeated measures assessing PentaBDE 
serum measurements from 2010-11 by demographic characteristic (ni=52, n=142). 
Parameters BDE-47 (ln(pg/g)) BDE-99 (ln(pg/g)) 
fJ (SE) p-values fJ (SE) p-values 
Fixed Effects 
Time (overall) 0.077 0.88 
Time 1 ref ref 
Time2 0.017 (0.035) 0.61 0.020 (0.063) 0.75 
Time 3 -0.064 (0.037) 0.089 0.034 (0.068) 0.61 
Time 2 vs. 3 -0.082 (0.037) 0.029 0.014 (0.067) 0.83 
Lipid 0.0015 (0.00029) <0.0001 0.0014 (0.00051) 0.0049 
Sex 
Female ref ref 
Male -0.12 (0.27) 0.68 -0.07 (0.29) 0.81 
Age A 
< 37 yo ref ref 
~ 37 yo 0.25 (0.28) 0.37 0.34 (0.29) 0.23 
BMIB 
Normal ref ref 
Overweight/Obese 0.44 (0.29) 0.14 0.32 (0.30) 0.30 
~ coefficients are regression coefficients for log-transformed outcome data. Exp(~) 
yields the multiplicative increase in PBDE per unit change in predictor (e.g., exp(-
0.082) = 0.921 = 7.9% decrease) 
A Age was dichotomized at 37 years old because that was the median age at enrollment 
in the cohort. 
B Normal BMI ( <25 kg/m2), Overweight/Obese (~25 kg/m2) 
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Table 2.4 (continued). General linear models for repeated measures assessing PentaBDE 
serum measurements from 2010-11 by demographic characteristic (ni=52, n=142). 
Parameters BDE-100 (ln(pg/g)) BDE-153 (ln(pg/g)) 
fJ (SE) ,e-values fJ (SE) p-values 
Fixed Effects 
Time (overall) 0.077 0.31 
Time 1 ref ref 
Time2 0.076 (0.063) 0.23 0.044 (0.029) 0.13 
Time3 -0.077 (0.067) 0.26 0.028 (0.31) 0.37 
Time 2 vs. 3 -0.15 (0.067) 0.024 -0.017 (0.030) 0.59 
Lipid 0.0021 (0.00051) <0.0001 0.0017 (0.00025) <0.0001 
Sex 
Female ref ref 
Male 0.0089 (0.34) 0.98 0.61 (0.32) 0.061 
Age A 
< 37 yo ref ref 
~ 37 yo 0.15 (0.33) 0.65 -0.53 (0.31) 0.091 
BMI8 
Normal ref ref 
Overweight/Obese 0.41 (0.35) 0.25 -0.081 (0.33) 0.81 
B coefficients are regression coefficients for log-transformed outcome data. Exp(B) 
yields the multiplicative increase in PBDE per unit change in predictor (e.g., exp(-
0.082) = 0.921 = 7.9% decrease) 
A Age was dichotomized at 37 years old because that was the median age at enrollment 
in the cohort. 
8 Normal BMI ( <25 kg/m2), Overweight/Obese (~25 kg/m2) 
Table 2.5 Polybrominated diphenyl ethers measured from 2010-11 in 52 participants over three sampling rounds. 
Total number of valid measurements above the limit of detection (LOD) and range of measurements. 
LOD 
Serum ng/g % 
Analyte Abbr. Subject Samples lipid Detect Range 
Polybrominated Diphenyl Ethers (PBDEs) 
2,2',4-tribromodiphenyl ether BDE-17 52 142 0.2 - 0.8 1 <LOD- 0.8 
2,4,4'-tribromodiphenyl ether BDE-28 52 142 0.2-0.8 68 <LOD- 5.1 
2,2'4,4'-hexabromodiphenyl ether BDE-47 52 142 0.2-0.8 100 0.6- 151 
2,3',4,4'-tetrabromodiphenyl ether BDE-66 52 142 0.2-0.8 1 <LOD- 0.7 
2,2',3,4,4'-pentabromodiphenyl ether BDE-85 52 142 0.2-0.8 22 <LOD- 4.0 
2,2',4,4,5-pentabromodiphenyl ether BDE-99 52 142 0.2-0.8 92 < LOD- 43 .5 
2,2' ,4,4' ,6-pentabromodiphenyl ether BDE-100 52 142 0.2-0.8 89 < LOD- 44.1 
2,2',4,4',5,5'-hexabromodiphenyl ether BDE-153 52 142 0.2-0.8 100 0.06-96.7 
2,2',4,4',5,6'-hexabromodiphenyl ether BDE-154 52 142 0.2-0.8 19 <LOD- 4.5 
2,2',3,4,4',5',6-heptabromodiphenyl ether BDE-183 52 142 0.2-0.8 12 < LOD- 3.3 
2,2',3,3',4,4',5,5',6,6'-decabromodiphenyl 
ether BDE-209 52 142 2.3-7.9 16 < LOD- 18.3 
ni is the number of subjects. 
n is the total number of serum samples. 
~ 
VI 
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Table 2.6 Estimated ICCs and variance components for selected PBDEs (52 subjects, 
142 serum samples). 
Parameters 
ICCNULLA 
2 A 
0 W Null 
2 A 
(J B Null 
ICCuprn8 
2 B 
(J w Lipid 
2 B 
(J B Lipid 
ICCruLLc 
2 c 
(J W Full 
IpentaBDE BDE-28 
Estimate (95% CI) Estimate (95% Cl) 
0.96 0.90 
0.033 (0.03 to 0.05) 0.076 (0.06 to 0.1) 
0.86 (0.5 to 1) 0.66 (0.4 to 0.9) 
0.97 0.89 
0.025 (0.02 to 0.03) 0.069 (0.05 to 0.1) 
0.83 (0.5 to 1) 0.56 (0.3 to 0.8) 
0.97 0.89 
0.025 (0.02 to 0.03) 0.069 (0.05 to 0.1) 
o28 Fullc 0.85 (0.5 to 1) 0.53 (0.3 to 0.8) 
A Equation (1) Yij =flo + bi + cij 
B Equation (2) Yij = ,8 0 + ,8 1LIPID + bi + E ij 
c Equation (4) Yij = /Jo + /J1TIME2 + /hTIME3 + jJ3AGEi + f34SEXi + f35BM!i + 
f36LIPIDij+ bi + cij 
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Table 2.6 (continued) Estimated ICCs and variance components for selected PBDEs (52 
subjects, 142 serum samples). 
Parameters BDE -47 BDE- 99 
Estimate (95% CI) Estimate (95% CI) 
ICC NULLA 0.96 0.91 
2 A 
(j W Null 0.037 (0.03 to 0.05) 0.10 (0.08 to 0.15) 
2 A 
(j B Null 1.0 (0.6 to 1.4) 1.0 (0.6 to 1.4) 
ICCuprn8 0.97 0.91 
2 B 
cr W Lipid 0.030 (0.02 to 0.04) 0.096 (0.07 to 0.13) 
2 B 
(j B Lipid 0.95 (0.6 to 1.3) 0.96 (0.6 to 1.4) 
ICCFULLC 0.97 0.91 
2 c 
cr WFull 0.029 (0.02 to 0.04) 0.098 (0.07 to 0.14) 
cr2 8 Fullc 0.94 (0.6 to 1.3) 0.97 (0.6 to 1.4) 
A Equation (1) Yij = fJo +hi + eij 
8 Equation (2) Y ij = /3 0 + /3 1LIPID + hi + E iJ 
c Equation ( 4) Yu = /3 o + /31 TIME2 + /3 2TIMEJ + /3 3AGEi + f34SEXi + f35BMii + 
f36LIPIDij+ hi+ eij 
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Table 2.6 (continued) Estimated ICCs and variance components for selected PBDEs (52 
subjects, 142 serum samples) . 
Parameters 
ICCNULLA 
2 A 
0 W Null 
2 A 
0 B Null 
ICCurm8 
2 B 
0 W Lipid 
2 B 
0 B Lipid 
ICCFULLC 
2 c 
0 WFull 
BDE -100 BDE- 153 
Estimate (95% Cl) Estimate (95% Cl) 
0.92 0.98 
0.12 (0.09 to 0.14) 0.030 (0.02 to 0.04) 
1.4 (0.8 to 2) 1.2 (0.7 to 1.7) 
0.93 0.99 
0.10 (0.08 to 0.14) 0.020 (0.02 to 0.03) 
1.3 (0.8 to 1.8) 1.3 (0.08 to 1.8) 
0.93 0.98 
0.097 (0.07 to 0.13) 0.02 (0.02 to 0.03) 
cr\ Fullc 1.3 (0.8 to 1.9) 1.2 (0.7 to 1.7) 
A Equation ( 1) Yij = fJo + bi + c:ij 
8 Equation (2) Yu = /] o + /] 1LIPID + b; + E u 
c Equation (4) Yu = !lo + lliTIME2 + 1l2TIMEJ + /]3AGE; + f34SEXi + f35BM!i + 
f36LIPIDij+ bi + c:ij 
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Figure 2.1 Serum concentrations ofBDE-47 (ng/g lipid) from repeated samples collected 
from 52 adult men and women over approximately a one-year period. 
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Figure 2.2 Correlation of BDE-47 (ng/g lipid) in serum for individuals in round 1 and 
round 3. 
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Figure 2.3. Contingency tables of BDE-47 by type 
of exposure classification ( 40 participants). 
Dichotomize 
Round 3 Total 
Round 1 Low High 
Low 18 2 20 
High 2 18 20 
Total 20 20 40 
Tertiles 
Round 3 Total 
Round 1 Low Medium High 
Low 10 3 0 13 
Medium 3 8 3 14 
High 0 3 10 13 
Total 13 14 13 40 
Quartiles 
Round 3 
Round 1 Low Medium High Very High 
Low 9 1 0 0 
Medium 1 7 2 0 
High 0 2 7 1 
Very High 0 0 1 9 
Total 10 10 10 10 
Total 
10 
10 
10 
10 
40 
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ABSTRACT. 
BACKGROUND: Polybrominated diphenyl ethers (PBDEs) are a class of flame 
retardant chemicals that were added to many consumer products. Multiple animal studies 
have shown PBDEs to be thyroid hormone (TH) disruptors, leading to hypothyroidism. 
Epidemiologic evidence of PBDE exposure associated with TH disruption has been 
inconclusive. 
OBJECTIVES: Our study is the first to use repeated measures in serum to assess the 
association between PBDE exposure and TH function in a North American adult cohort. 
METHODS: From 2010-11, we collected three repeated serum samples from 52 
participants in the greater Boston metropolitan area. Samples were collected at 
approximately 6-month intervals and analyzed for PBDE congeners and thyroid function 
tests. 
RESULTS: Geometric mean sum concentrations of the five most prevalent PBDE 
congeners (BDE 28, 47, 99, 100, 153) were 21.8 ng/g lipid in Winter 2010, 22.8 ng/g 
lipid in Summer 2010, and 18.7 ng/g lipid in Winter 2011. In multivariate mixed 
regression models, we found that for every unit increase in BDE-100 (ng/g serum) there 
was a 7.4 ng/mL (95% Cl=-14 to -1.1) decrease in total T4 (p =0.01). Total T4 was also 
observed to be inversely associated with each PBDE congener, but the inverse 
relationship was only statistically significant for LPBDE, BDE-47 and BDE-100. Serum 
concentrations of PBDEs were not associated with total T3, free T4, or TSH. 
CONCLUSION: These results are consistent with the animal studies showing exposure 
to PBDEs is associated with a decrease in T4. The most likely mechanism of action based 
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on toxicological studies is a decrease in serum T 4 binding, leading to decreases in total 
T4. Since the free T4 and TSH concentrations were unchanged, it is unlikely that BDE 
exposure affected the pituitary/thyroid axis in this study. 
KEYWORDS: endocrine disruption, environmental health, flame retardants, persistent 
organic pollutants, polybrominated diphenyl ethers (PBDEs), thyroid hormones. 
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Introduction 
Polybrominated diphenyl ethers (PBDEs) have been used since the 1970's as 
additive flame retardants. The technical formulation Pentabromodiphenyl ether 
(PentaBDE) is composed of PBDE congeners containing three to six bromines and was 
added primarily to products containing polyurethane foam (USEPA 2008). Of the 
worldwide production, 95% of the PentaBDE produced was used in North America 
(Birnbaum and Staskal 2004), where concentrations in people have been reported to be 
approximately an order of magnitude higher than general populations in Europe or Asia 
(Hites 2004; Meironyte et al. 1999; Sjodin et al. 2004a; Sjodin et al. 2008). Due to their 
persistence in the environment, ability to bioaccumulate, and potential adverse health 
effects, PentaBDE and OctaBDE were banned in the European Union (EU) and added to 
the list of persistent organic pollutants (POPs) in the Stockholm Convention (UNEP 
2001). US manufacturers of PentaBDE and OctaBDE voluntarily halted production in 
2004 (US EPA 2008). Nevertheless, PentaBDEs are still commonly found in food 
products (Schecter et al. 2010) and indoor microenvironments (e.g. homes, offices, and 
vehicles) (Watkins et al. 2012). Therefore, it is likely that people in the US are continuing 
to be exposed to PBDEs through exposures to indoor dust and diet (Fraser et al. 2009; 
Harrad et al. 2010; Watkins et al. 2012). 
Animal studies have established that the PentaBDEs are endocrine disrupting 
chemicals, which modify thyroid hormone (TH) levels. The PentaBDEs and their CYP 
450-mediated metabolites, hydroxylated PentaBDEs (OH-PBDEs), are structurally 
similar to thyroxine (T4) and triiodothyronine (T3) (Meerts et al. 2000; Sjodin et al. 
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1998). Multiple experimental studies in rodents have shown that exposure to PentaBDEs 
leads to hypothyroxinemia, characterized by a decrease in serum T4 concentrations 
(Blanco et al. 2013; Ellis-Hutchings et al. 2006; Fowles et al. 1994; Hallgren et al. 2001; 
Stoker et al. 2004; Zhou et al. 2002). Proposed mechanisms by which PBDEs affect TH 
levels in animals include a reduction in serum TH binding proteins (Szabo et al. 2009), a 
decrease in thyroid hormone deiodinase activity (Butt et al. 2011), competitive binding 
for the TH receptor (lbhazehiebo et al. 2011), or an increase in liver enzymatic activity, 
which increases the clearance of THs (Fowles et al. 1994; Hallgren and Darnerud 2002; 
Hallgren et al. 2001; Stoker et al. 2004; Zhou et al. 2001). 
In humans, THs are essential for proper growth and development in utero and 
infancy, as well as maintenance of many organ systems and metabolism throughout life. 
Production of THs is tightly regulated by negative feedback via thyroid stimulating 
hormone (TSH). T4 is the major hormone measured in blood (TT4), which is tightly 
bound to the plasma proteins, thyroxine binding globulin (TBG), transthyretin (TTR), and 
albumin, but also exists as free hormone, free T4 (IT4) (Braverman and Cooper 2013). 
The bioactive hormone is triiodothyronine (T3), which is either directly produced by the 
thyroid or converted from T4 to T3 by enzymatic deiodination, after transport into the 
target cell (Braverman and Cooper 2013). Thyroid disorders in humans are diagnosed 
using clinical symptoms and serum levels of TSH, IT4, TT4, and T3, which are classified 
as follows: overt hypothyroidism (elevated TSH, low IT4), subclinical hypothyroidism 
(high TSH, normal IT4), overt hyperthyroidism (low TSH, high IT4 or T3), or subclinical 
hyperthyroidism (low TSH, normal IT4 and T3) (Garber et al. 2012). Based on the 
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National Health and Nutrition Examination Survey ill (NHANES Ill) study, 4.6% (0.3 % 
clinical and 4.3% subclinical) and 1.3% (0.5% clinical, 0.7% subclinical) of the general 
US non-institutionalized population have hypothyroidism and hyperthyroidism, 
respectively (Hollowell et al. 2002). Thyroid disease is more common in women and, 
based on estimates available for 2008, approximately 13 million adult US women 
received treatment for thyroid disease at an approximate cost of 4.3 billon dollars (Soni 
2011). 
While toxicological evidence of PBDEs causing thyroid disruption is robust, the 
epidemiologic evidence has been inconsistent, with PBDE exposure associated with 
increases, decreases, or no effect on THs (Abdelouahab et al. 2013; Bloom et al. 2008; 
Chevrier et al. 2011; Stapleton et al. 2011; Turyk et al. 2008; Zota et al. 2011). The 
inconsistent direction of reported associations may be due to differing susceptibility in 
study populations (adult men, pregnant women, infants), non-linear dose response curves 
(e.g. assuming high dose effects are the same as low-dose effects (Myers et al. 2009)), 
reverse causation, measurements of PBDEs and hormones in various biologic media 
(serum, umbilical cord blood, spot blood, urine), possible confounders and effect 
modifiers (iodine status, sex, other environmental contaminants, thyroid peroxidase 
antibodies) and the method of adjustment for serum lipids in regression analysis 
(Chevrier 2013). 
Our study uses repeated serum measures to assess the association between PBDE 
exposure and thyroid function in a longitudinal prospective cohort of healthy adults. Our 
primary aim is to use these robust monitoring data to examine the association between the 
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PentaBDEs and thyroid function tests (TT4, IT4, T3, and TSH). Our secondary aims are to 
assess the stability of thyroid function tests (TFTs) over a one-year period and the effects 
of possible confounders and effect modifiers in our cohort: sex, age, BMI, serum lipids, 
thyroid peroxidase antibody (TPO Ab ), urinary iodine concentration (UIC), urinary 
perchlorate, urinary thiocyanate, and use of oral contraceptives. 
Methods 
Study Design and Population. We recruited 52 male and female adults living in the 
Boston Metropolitan area and collected serum samples at approximately six-month 
intervals from January 2010 to May 2011 (total of 143 serum samples). Characteristics 
and descriptions of the FlaRE (Flame Retardant Exposure Study) population have been 
presented elsewhere (Makey et al. 2014). Participation rate by sampling round was: 96% 
in round 1 (Winter 2010), 96% in round 2 (Summer 2011), and 81 % in round 3 (Winter 
2011). Briefly, participants had to be healthy, non-smoking adults over the age of 18, 
work in an office environment at least 20 hours a week, and plan to reside in the greater 
Boston metropolitan area for the study duration. Participants were excluded for having a 
prior diagnosis of thyroid or male reproductive disease, or if they were pregnant. After 
recruitment and participation, we excluded 6 serum samples from participants who were 
on a thyroid-affecting medication (n=3), became pregnant during the study (n=l), had an 
inadequate serum amount (n=l), or field contamination of specimens (n=l). The present 
study thus utilized 137 PBDE and hormone measures in serum collected from 51 
participants. We obtained informed consent prior to participation and the Boston 
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University Medical Center Institutional Review Board approved the study protocol. 
Blood Samples. A trained phlebotomist collected 30 mL of blood from non-fasting 
participants during each sampling round. Serum samples were stored at -80°C in amber 
glass vials until analysis. To eliminate potential issues with inter-assay variability, we 
collected a blood sample at each round, but analyzed all samples at one time following 
round 3. A technical assistance agreement was established between the Division of 
Laboratory Sciences at the National Center for Environmental Health, Centers for 
Disease Control and Prevention (CDC), and Boston University. Serum samples were 
analyzed for lipids (total triglycerides, total cholesterol) and 11 PBDE congeners (BDE-
17, BDE-28, BDE-47, BDE-66, BDE-85, BDE-99, BDE-100, BDE-153, BDE-154, BDE-
183, BDE-209) at the Centers for Disease Control and Prevention (CDC) using 
established methods (Sjodin et al. 2004b ). Samples were randomized and analyzed with 
quality control (n=3) and blank samples (n=3) in each batch of 24 unknowns. The CV of 
included QC samples was less than 10%. 
Serum thyroid function tests were measured at the Boston University School of 
Medicine, Section of Endocrinology, Diabetes, and Nutrition. Enzyme-linked 
imrnunosorbent assays (ELISA) were used to measure serum thyroid stimulating 
hormone (TSH) (normal range: 0.4-4.2 miU/L), free thyroxine (ff4) (normal range: 0.8-
2.0 ng/dL), T3 (normal range 0.52-1.85 ng/mL), and TT4 (normal range 4.4-10.8 ~-tg/dL in 
men and 4.8-11.6 ~-tg/dL in women) (Imrnuno-Biological Laboratories, Inc., Minneapolis, 
MN). TPO Abs were measured by imrnunometric enzyme immunoassay (Orgentec 
Diagnostika, Germany) with reference range: normal <50 IU/mL; borderline 50-75 
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IU/rnL, and elevated >75 IU/rnL. 
Urine Samples. At each sampling round, we collected approximately 90 rnL of urine 
from each participant. After collection, specific gravity was measured using a 
refractometer and samples were aliquoted and stored at -20°C until chemical analysis. 
We measured levels of urinary iodide, perchlorate, and thiocyanate by ion 
chromatography-mass spectrometry using established methods (Valentin-Blasini et al. 
2005). The limit of detection and coefficient of variation was 0.05 1-1g/L (CV = 2.2% to 
5.9%) and lOug/L (CV < 5%), for perchlorate and thiocyanate, respectively. 
Statistical Analysis. For PBDE measurements below the LOD (level of detection), we 
substituted Y2 LOD. ~PBDE was defined as the sum of the five most prevalent PentaBDE 
congeners: BDE-28, -4 7, -99, -100, and -153. Summary statistics were calculated for 
individual PBDE congeners detected in >50% of samples, ~PBDE, thyroid function tests, 
urinary iodine, total cholesterol, triglycerides, and total lipids. We assessed normality of 
PBDEs, thyroid function tests, and covariates using histograms and Shapiro-Wilks tests. 
TSH, fT4, and T3 were log-normally distributed and log-transformed for regression 
analysis. TT4 was normally distributed. Regression makes no assumptions about the 
distribution of independent (predictor) variables. Influential points were identified by 
scatterplot. All statistical analyses were conducted using SAS statistical software version 
9.3 (SAS Institute, Cary, NC, USA) and statistical significance is reported at the 0.05 
level. 
We used a general linear model with a random intercept to assess the association 
between PBDEs and thyroid function tests, which in its simplest form is: 
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(1) 
where Yu represents the thyroid hormone level of the ith participant on the jth day. f3a is 
the fixed effect intercept, /31 is the effect on the TFT of a one-unit change in PBDE level, 
PBDE is the PBDE level of the ith participant on the jth day, bi is the random intercept of 
the ith individual, and Cij is the random error of the ith participant on the jth day. We refer 
to ni as the number of individuals, nii as the number of samples at time j and n as the total 
number of samples. The following covariates were added to equation (1): Time -
categorical (round 1, 2, or 3) or time - continuous (days), total lipids (mg/dL), urinary 
iodine concentration (UIC) ()..lg/L), age (years), sex (male/female), BMI (mglkg2), TPO 
antibody (yes/no), birth control pill (yes/no), perchlorate (f,.lg/L), and thiocyanate (f,.lg/L). 
For equations with a log-transformed dependent variable, we estimated the percent 
change of thyroid hormone per unit of predictor by exponentiating the PBDE beta 
estimate, subtracting 1 and multiplying by 100. We selected potential confounding 
variables based on a priori expectation that they could be associated with the exposure 
and outcome but not on the causal pathway. We assessed confounding using a change of 
10% or greater in the PBDE beta coefficient as a guide. We ran regression models on 
datasets excluding women on birth control pills (7 women) and participants who were 
TPO Ab positive (3 participants) to assess their potential to affect regression estimates. 
We assessed effect measure modification by stratification on the following variables: sex, 
and urinary iodine (UI) ( <100 f,!g/L vs. ~ 100 f,!g/L). For the continuous covariates, we 
assessed possible effect modification by including a cross product of PBDE level and 
covariate (total lipids, iodine, age, BMI). 
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We estimated intraclass correlation coefficients (ICCs) for repeated measures to 
assess stability of serum thyroid function tests and UIC using an intercept-only general 
linear model with a random intercept. The ICCs were estimated by dividing the between-
subject variance by the total variance (between- plus within- subject variance). An ICC 
close to 1 means that most of the overall variance is attributable to variability between 
subjects rather than variability within subjects, suggesting that the biomarker is stable and 
reproducible (Fleiss 1986). Agreement was classified as "poor" (ICC=O to 0.39), 
"moderate" (ICC=0.4 to 0.59), "good" (ICC= 0.6 to 0.79), or "excellent" (ICC~0.80). 
Forty-one participants provided a serum sample in all three sampling rounds, nine 
provided a sample in two rounds, and two provided a single serum sample. We therefore 
did not have complete data over time. However, it is unlikely that the reasons for missing 
serum data are related to TH levels and thus we considered these data to be missing 
completely at random (MCAR). As general linear models are robust to MCAR, 
inferences reported from our regression models are likely unbiased (Fitzmaurice and 
Laird 1997). 
For the primary models described above (Model A, B, C, D) we included PBDEs 
on a wet weight basis (ng/g serum), treating lipids as a covariate in our regression 
models, which allows us to assess the independent effects of PBDEs and serum lipids. 
Standardizing PBDE measurements (ng/g lipids) or adding lipids as a covariate in 
regression models may cause bias in some causal frameworks (Schisterman et al. 2005). 
Since the correct causal model is unclear, we also ran regression models standardizing 
PBDEs to lipids (Model E), e.g., I:PBDE ng/g lipid (Chevrier 2013). 
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Results 
The final study population for the thyroid analysis consisted of 26 males and 25 
females. The median age was 37 years old, 88% were white, 98% had a college degree, 
and 63% had BMI < 25 (Table 3.1). 
Table 3.2 presents the round-specific geometric means (GM), geometric standard 
deviations (GSD), and range for PBDE congeners that were detected in serum at >50%: 
BDE-28, BDE-47, BDE-99, BDE-100, BDE-153. BDE-47 and BDE-153 were detected 
in 100% of serum samples (Table 3.2). Detection rates for BDE-17, BDE-66, BDE-85, 
BDE-154, BDE-183, and BDE-209 ranged from 1% to 22% and were not further 
analyzed (Makey et al. 2014). GM concentrations of LPBDE by sampling round were 
21.8 ng/g lipid, 22.8 ng/g lipid, and 18.7 ng/g lipid, respectively. BDE-47 was the PBDE 
congener present at the highest serum concentration followed by BDE-153, BDE-99, 
BDE-100, and BDE-28. Since BDE-28 is a minor congener in serum and highly 
correlated with BDE-47 in our cohort (rspearman>0.90, p<0.001), regression analysis is not 
presented for BDE-28. The mean total cholesterol, total triglycerides and total lipids were 
very similar in all three rounds. 
Thyroid function tests were predominantly within normal ranges (Table 3.2). The 
GM and range of TSH by round were 0.71 (0.2 to 2.7), 0.75 (0.2 to 2.3), and 0.89 (0.2 to 
4.8) miU/L serum, respectively. Our GM TSH levels are lower than those reported in a 
thyroid disease free reference population [median=1.40, range=(1.37 to 1.44) miU/L] 
from NHANES ill (Hollowell et al. 2002). Three participants had elevated TPO 
antibodies, which are markers for thyroid autoimmunity (McLachlan and Rapoport 
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2007). These participants had TFT values within normal ranges. Sensitivity analysis 
excluding these three participants did not alter results (data not shown). The GM urinary 
iodide concentrations by sampling round were 130 ~-tgiL, 140 ~-tg/L, and 150 11g/L urine, 
respectively, indicative of iodine sufficiency (WHO 2007, 2013). The GMs and GSDs for 
thiocyanate by round were 450 (470), 570 (360), 480 (450) ~-tgiL, respectively. The GM 
and GSDs for perchlorate by round were 3.8 (4.3), 2.9 (18), and 5.2 (11), respectively. 
We found significant, inverse associations between :LPBDE and the individual 
congeners and serum TT4 (Table 3.3). Adjusting for sampling round, blood lipid level, 
age, sex, UIC, specific gravity, and BMI (Model C), we found that for every one unit 
increase in BDE-47 there was a 2.5 llg/dL (95% Cl= -4.7 to -0.23) decrease in TT4. 
Additionally, we found that for every unit increase in BDE-100 there was a 7.4 ng/mL 
(95% Cl=-14 to -1.1) decrease in total T4 (p =0.01). The inverse relationship between 
PBDEs and TT4 persists in the crude (Model A), lipid-adjusted (Model B), and models 
adjusted for other thyroid-affecting environmental contaminants: perchlorate and 
thiocyanate (Model D). In almost all cases, adjusting for serum lipid affected the beta 
coefficients (greater than 10% change). On the other hand, adjusting for age, sex, or BMI 
did not affect our results as strongly. Our results were not confounded by urinary iodide: 
while UIC was significantly, negatively associated with TT4 and T3, it was not associated 
with any of the PBDE congeners, TSH, or IT4 (data not shown). 
We also analyzed the associations with TT4 cross-sectionally by sampling round, 
and the inverse relationships were persistent (Figure 3.1 and Figure 3.2). Using 
scatterplots, we identified a possible influential point in the relationship between PBDEs 
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and TI4 (Figure 3.1 and Figure 3.2). When the point was omitted, the inverse 
relationships between PBDEs and TI4 was strengthened (Figure 3.1, Figure 3.2, Table 
3.6). 
Tables 3.3 and 3.4 show the associations between thyroid function tests and 
PBDEs. While associations of PBDEs with TSH were positive in crude and adjusted 
models, the effects were small, imprecise, and not statistically significant. BDE-153 
showed a small, inverse trend with T 3, but the relationships between the lower 
brominated PBDE congeners and T3 were imprecise. We found a positive, significant 
trend between BDE-153 and ff4, however there were no consistent trends between the 
lower brominated PBDEs and ff4. 
As the best method for taking serum lipids into account is unclear, we also 
examined the relationship with THs using lipid-standardized PBDEs (Model E). When 
the covariates age, sex, BMI, UI, and specific gravity were added to the model with a 
lipid standardized PBDE exposure predictor, results were not appreciably changed (data 
not shown). These models produced inverse trends between PBDEs and TI4, but only 
reached statistical significance for the relationship between BDE-1 00 and TT 4· 
When we stratified our cohort by sex, and ran regression models on datasets 
which excluded women taking oral contraceptives or those participants that were TPO 
positive, our effect estimates were not altered (data not shown), but we did lose power to 
detect statistically significant associations. We did not find statistically significant 
interaction for PBDE level with age, sex, BMI, or total lipids. Inverse relationships 
between PBDEs and TI4 were persistent and similar in groups dichotomized by iodide 
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status at round one: UIC <100 f,tg/L vs. UIC ~ 100 f,tg/L) (data not shown). 
Our previous research on the FlaRE cohort indicated that serum PentaBDEs had 
high ICCs, i.e., a single serum PentaBDE measurement provided a stable estimate of an 
individual's exposure level (Mak:ey et al. 2014). These results are consistent with half-
lives of these congeners estimated to be on the order of years. Serum TSH varies within 
an individual as a result of both pulsatile and diurnal stimuli with mean maximum levels 
at night and minimum levels in the afternoon (Andersen et al. 2003). Additionally, the 
pituitary gland is sensitive to minor changes in serum T3 and T4, where small variations 
in concentrations of circulating hormone produce large changes in TSH (Carr et al. 
1988). Having repeated measures on our participants allowed us to calculate ICCs to 
assess the stability of the TFTs in our population (Table 3.5). TSH, and IT4 were 
classified as having good stability with ICCs of 0.72 and 0.71, respectively. TT4 had 
excellent stability with an ICC of 0.80. T3 had moderate stability with an ICC of 0.56. As 
expected, UIC varied substantially within individuals and had poor stability with an ICC 
of0.38. 
Discussion 
Our study population of 51 adults living in the Greater Boston Metropolitan area 
was iodine sufficient and did not have overt thyroid dysfunction. Using repeated serum 
measures in our prospective cohort, we found an inverse association between the 
PentaBDE congeners and TT4. The inverse association between PBDEs and TT4 was 
persistent regardless of method of lipid-adjustment, inclusion of potential confounders or 
several thyroid affecting substances. Our result is consistent with animal studies showing 
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exposure to PentaBDEs causes a decrease in T 4, and may be related to the displacement of 
T4 from thyroid hormone transport proteins by PBDEs and/or affecting serum binding 
protein concentrations. As TSH concentrations were not changed, PBDEs did not affect 
the hypothalamic-pituitary-thyroid axis (HPT axis) or cause clinically significant thyroid 
dysfunction in this study. 
PBDEs and their hydroxylated metabolites (OH-PBDEs) are structurally similar 
to the thyroid hormones: T4 and T3. Therefore PBDEs have been extensively researched 
as possible TH disruptors in animal studies. Many toxicological studies have reported a 
reduction in TT4 following exposures to commercial PentaBDE (e.g. DE-71) or 
individual congeners (Blanco et al. 2013; Ernest et al. 2012; Fowles et al. 1994; He et al. 
2011; Kodavanti et al. 2010; Stoker et al. 2004; van der Yen et al. 2008b; Zhou et al. 
2001; Zhou et al. 2002), except for one study showing an increase in TT4 (Blake et al. 
2011). The two toxicological studies that measured fT4 reported a decrease in fT4 
following exposure (Blanco et al. 2013, Fowles et al. 1994). This decrease in TT4 has 
been observed in rodents using multiple exposure protocols (acute, sub-acute, chronic) 
and at various developmental time points (prenatal, perinatal, postnatal, adolescent, 
adult). While most animal exposure experiments have shown decreases in TT3 (Bondy et 
al. 2011; Stoker et al. 2004; Zhou et al. 2001), TT3 was not always measured or the 
decrease in TT3 was not significant (He et al. 2011; Zhou et al. 2002). Results regarding 
the effect of PBDEs on TSH have been less consistent. Some experiments have shown an 
increase in TSH, which would be indicative of PBDEs having an effect on the HPT axis 
(Stoker et al. 2004; Zoller 2010), while others have shown a decrease in TT4 without an 
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increase in TSH (Ernest et al. 2012; He et al. 2011; Zhou et al. 2001). 
A decrease of peripheral THs (TT 4, IT 4, or T 3) in animals has prompted 
investigations on the possible underlying mechanisms for this phenomenon. In vitro 
experiments have shown that some hydroxylated PBDEs interact with TIR, possibly 
displacing T4 from TTR (Marchesini et al. 2008; Meerts et al. 2000). Additionally, BDE-
47 may alter T4 transport by affecting hepatic TTR mRNA expression, decreasing the 
amount of binding protein available (Richardson et al. 2008). In vivo experiments 
demonstrate that exposure leads to an induction of uridinediphosphate-
glucuronosyltransferase (UDPGT), which may increase T4-glucuronidation and deplete 
circulating T4, leading to decreased TT4 levels (Capen 1997; Stoker et al. 2004; Zhou et 
al. 2001; Zhou et al. 2002). Some hydroxylated metabolites of PBDEs, but not the parent 
compounds, have been shown to bind to the human TH receptor in vitro (Ibhazehiebo et 
al. 2011; Suvorov et al. 2011). In vitro experiments have shown that PBDEs may 
compete with T4 for deiodinase activity, which would alter the deiodination of T4 in 
peripheral tissues into the biologically active T3 or inactive reverse T3 (Butt et al. 2011; 
Kohrle 1999), affecting the free TH levels and possibly the HPT axis. The mechanism(s) 
underlying TH disruption by PBDEs in animals has not been completely elucidated and is 
likely multifactorial. Nevertheless, toxicological studies to date have consistently shown 
that exposure leads to a decrease in serum TT4 concentrations. It should be emphasized 
that comparisons of inhibition of T 4 binding to plasma proteins in rodents and humans 
may be hazardous since the major binding protein in rodents is TIR and in humans TBG. 
T4 exists in two forms: approximately 99.97% of circulating T 4 is bound to 
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plasma proteins (TBG, TTR, and albumin), with the remaining T4 (ff4) being unbound 
and available for deiodination in the outer phenolic ring to generate the active hormone, 
T3. In humans, measurements of ff4 have mostly replaced TT4 (which is predominately 
bound hormone) as a measure of thyroid status in clinical practice, because abnormally 
high or low total TT4 is affected by factors involving TH serum transport proteins, and is 
not necessarily indicative of thyroid dysfunction (Garber et al. 2012). Typically TT4 is 
decreased if substances that can displace TH from protein binding sites are present (De 
Groot et al. 2012; Stockigt and Lim 2009) or if there is a decrease in the TH transport 
proteins, mainly TBG. While mechanistic explanations are difficult to elucidate using a 
single epidemiology study, we report that increasing PBDE exposure is associated with a 
decrease in serum TT4, which is consistent with animal studies and the hypothesis that 
PBDEs are displacing the THs from their transport proteins or decreasing the amount of 
plasma binding proteins. 
Many epidemiological studies have reported associations between PBDEs and 
thyroid function tests, but the results have been inconsistent. While our results showing a 
decrease in TT4 are consistent with those typically observed in animal experiments and 
some human studies (Abdelouahab et al. 2011; Abdelouahab et al. 2013; Herbstman et al. 
2008; Lin et al. 2011), they differ from other studies that have found an increase in TT4. 
Turyk et al., found PBDEs were positively associated with TT4 and urinary T4, but also 
found PBDEs were related to the percentage of TBG bound to T 4, and an increase in the 
percentage of TT4 bound to albumin, indicating PBDEs may affect serum binding 
patterns (Turyk et al. 2008). Additionally, they report I:PBDEs (BDE-28, -47, -49, -85, -
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99, -100, -138, and -133) and BDE-47 were associated with an increase in ff4, where we 
found BDE-153 was positively associated with ff4. A few studies in pregnant women 
have shown PBDE exposure results in a decrease in TSH (Chevrier et al. 2010; Zota et al. 
2011) or increase in TT4 or ff4 (Stapleton et al. 2011). It is difficult to compare the 
results in pregnant women to those in our study because total TT4 is increased by up to 
50% starting in the first trimester because of estrogen-induced elevations of serum TBG 
(Stagnaro-Green et al. 2011) and the timing of the exposure during pregnancy differs 
between studies (Abdelouahab et al. 2013). There have also been a few human studies 
that have shown no association between PBDEs and THs (Bloom et al. 2008; Chevrier et 
al. 2011; Eggesbo et al. 2011; Zhang et al. 2010)) 
Our study addresses possible measurement error, which has historically been 
associated with inconsistencies in epidemiological studies. We previously reported that 
one non-fasting serum PBDE measurement is a stable serum biomarker that can assess an 
individual's exposure level, whether as a continuous or categorical measure (Makey et al. 
2014). In the present study, TT4, TSH, and ff4 were found to have "good" to "excellent" 
stability when used as a continuous measure. T3 had moderate reliability; however serum 
T3 measures are primarily used to diagnose hyperthyroidism, and not typically used to 
detect hypothyroidism. 
Iodide (1), an essential component of the THs, has been reported to be an effect 
modifier in epidemiologic studies, where groups with less iodine intake are more 
vulnerable to xenobiotic effects on TH levels than iodine-sufficient populations (Blount 
et al. 2006). No effect measure modification was found when our cohort was 
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dichotomized by baseline iodide sufficiency. However, iodide has a short half-life and 
urinary measurements are inconsistent in estimating an individual's overall iodine status 
(Swanson et al. 2012). Because of this variability, population median urinary iodide 
concentrations are typically used to determine iodine sufficiency (WHO 2013). In our 
study, all GMs were above the WHO recommended threshold of 100 ~g/L for non-
pregnant adults. We were able to calculate the stability of our UIC measurements to 
determine how well a single urine measurement can classify the individual's iodide 
status. As expected, we found that a single UIC is not a stable biomarker with an ICC of 
0.38 (Supplemental Table 1). 
There is current debate regarding how (or whether) to adjust for serum lipids-
lipids as a covariate, lipid-standardization-when studying the health effects of lipophilic 
chemicals (Schisterman et al. 2005). As expected, serum PBDE concentrations are 
positively associated with serum lipid concentrations in our population (Makey et al. 
2014). Additionally, thyroid hormones maintain lipid homeostasis by affecting gene 
expression in adipose tissue and the liver, affecting lipolysis and clearance (Pearce 2012; 
Zhu and Cheng 2010), making serum lipids dependent on the thyroid hormones. The 
causal structure between PBDEs, serum lipids, and TH is currently unclear. Therefore as 
recommended elsewhere, we compared multiple methods for lipid adjustment (Chevrier 
2013; Schisterman et al. 2005). We found that the results obtained from our crude and 
lipid-adjusted models were generally consistent in the direction of the association but the 
magnitude of the ~-coefficients were altered by more than 10%. The inverse direction of 
associations between PBDEs and TT4 remained between the lipid-adjusted and lipid-
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standardized models. Comparison between these models is difficult to make as the 
denominator for the /f-coefficients are different, however the lipid-standardized model 
was generally less precise. 
It has also been suggested that since thyroid hormones regulate lipid metabolism 
(Pearce 2012), which affect the activity of enzymes (CYP3A) (Takahashi et al. 2010) that 
possibly bio-transform PBDEs (Van der Yen et al. 2008a), THs may be affecting 
concentrations of PBDEs in humans (Chevrier 2013). If reverse causation was occurring 
through lipids, the association between PBDEs and TH would theoretically disappear 
after adjustment for lipids. We found attenuation in the PBDEfiT4 relationship after 
adjustment of serum lipids, but the inverse relationship was still present. Additionally, the 
apparent long half-life's of PentaBDEs and the longitudinal nature of the study reduces, 
but does not eliminate, the possibility that we are observing an association due to reverse 
causation, which is much more likely in cross-sectional studies. While we cannot 
conclusively establish the time ordering of PBDE exposure and thyroid hormone status, 
we did find a consistency in the relationships between BDE-47 and TT4 when using 
cross-sectional (Figure 1) and longitudinal (Table 3) data analysis techniques. 
A major strength of our study is the use of three serum samples from a 
longitudinal study of a relatively homogenous population. Our cohort was free of overt 
thyroid dysfunction and we collected appropriate demographic and medical information 
to assess confounding and effect measure modification. We did not measure the OH-
PBDE metabolites, which have been shown to have binding affinities to TBG and TTR 
(Marchesini et al. 2008). However, most parent PBDE levels and their metabolites are 
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correlated (Stapleton et al. 2011). Our study sample size (51 adults, 137 serum samples) 
was small, and likely decreased our ability to detect associations. We used a convenience 
sample of office workers in the Boston area, that were 85% white and highly educated 
and we cannot be certain our results can be generalized to the general US population. 
However, having a fairly homogenous population in which to study health effects can 
arguably be associated with increased internal study validity (Rothman 2008). With 
similar working conditions and demographic characteristics, the study population is 
likely to be similar with respect to unknown confounders. 
In conclusion, our results from this prospective cohort study suggest that 
environmental exposure to PBDEs was associated with a decrease in total IT 4, a finding 
that is consistent with the toxicological literature and some human studies. Our 
conclusions were robust to potential confounders and various methods of data analysis. 
Future prospective studies are needed to further understand how PBDEs and their 
metabolites may affect TH homeostasis in healthy adults. 
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Table 3.1 Baseline Characteristics from the 
FlaRE Cohort, collected in 2010-11 (51 adults) 
Characteristic n (%) 
Age 
20-39 years 
40-59 years 
~ 60 years 
Sex 
female 
male 
Race/ethnicity 
white 
other 
Education 
College graduate 
< college graduate 
BMI (mglkg2) 
<25 
25- 29.9 
~ 30 
29 (57) 
18 (35) 
4 (8) 
25 (49) 
26 (51) 
45 (88) 
6 (12) 
50 (98) 
1 (2) 
33 (63) 
16 (33) 
2 (4) 
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Table 3.2. Descriptive statistics of analytes by sampling round. (51 participants, 137 
serum samEles) 
Analytes Round 1 (n=47) Mean (SD) %Detect 
2:PBDE (ng/g lipid)A 21.8 (2.5) 100 
BDE - 28 (ng/g lipid)A 0.6 (2.2) 68 
BDE- 47 (ng/g lipid)A 8.95 (2.9) 100 
BDE - 99 (ng/g lipid)A 1.8 (3) 94 
BDE- 100 (ng/g lipid)A 1.8 (3.5) 87 
BDE- 153 (ng/g lipidt 6.4 (3.2) 100 
Thiocyanate (!-!g!L)A 450 (470) 100 
Perchlorate (!-!g!L)A 3.8 (4.3) 100 
Total T4 (!--Lg/dl)8 7.3 (1.3) 100 
Free T4 (ng/dl)A 1.2 (1.2) 100 
TSH (!-!IU/rnl)A 0.71 (1.8) 100 
Total T3 (ng/rnl)A 1.1 (1.2) 100 
Urinary Iodide (!-!g!L)A 130 (170) 100 
Urinary Specific Gravitl 1.02 (0.007) 100 
TPO (IU/mL)c 3 n/a 6.5 
Cholesterol (mg/dL)8 190 (34) 100 
Trigl ycerides8 130 (70) 100 
Total Lipids8 620 (110) 100 
A Geometric mean and geometric standard deviation presented. 
B Means and standard deviation presented. 
Range 
2.3-290 
0.2-2.8 
0.6-151 
0.2-44 
0.2-42 
0.6-97 
72 -2300 
0.4 to 19 
3.2-9.6 
0.9- 2.1 
0.2- 2.7 
0.8- 1.5 
27-890 
1.004- 1.03 
< 5- 810 
120-290 
50-340 
450- 860 
c The number of participants that tested positive for TPO in each round are presented. 
0 (n=l) specific gravity measurement was missing in round 2. 
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Table 3.2 (continued) Descriptive statistics of analytes by sampling round. (51 
participants, 137 serum samples) 
Analytes Round 2 (n=49) Mean (SD) %Detect Range 
L.PBDE (ng/g lipidl 22.8 (2.0) 100 2.7- 294 
BDE - 28 (ng/g lipid)A 0.6 (2.2) 73 0.2-5.1 
BDE- 47 (ng/g lipid)A 9.36 (2.7) 100 1.3- 149 
BDE - 99 (ng/g lipid)A 1.9 (3.0) 90 0.2-34 
BDE- 100 (ng/g lipid)A 1.9 (3 .3) 90 0.2-44 
BDE- 153 (ng/g lipid)A 6.7 (3.1) 100 0.7-95 
Thiocyanate (f.lg/L)A 570 (360) 100 61- 1500 
Perchlorate (!!giLl 2.9 (18) 100 0.4- 130 
Total T4 (f.lg/dl)B 7.3 (1.4) 100 3.9- 10 
Free T4 (ng/dl)A 1.2 (1.2) 100 1.0- 2.2 
TSH (f!IU/mll 0.75 (1.8) 100 0.2-2.3 
Total T3 (ng/ml)A 1.2 (1.2) 100 0.8- 1.4 
Urinary Iodide (f.lg/Ll 140 (104) 100 11 - 550 
Urinary Specific Gravity8 1.02D (0.009) 100 1.003- 1.04 
TPO (IU/mL)c 3 n/a 100 < 5-680 
Cholesterol (mg/dL)B 190 (46) 100 110- 360 
TriglyceridesB 130 (71) 100 42- 340 
Total LipidsB 620 (150) 100 370- 1100 
A Geometric mean and geometric standard deviation presented. 
8 Means and standard deviation presented. 
c The number of participants that tested positive for TPO in each round are presented. 
0 (n=l) specific gravity measurement was missing in round 2. 
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Table 3.2 (continued) Descriptive statistics of analytes by sampling round. (51 
participants, 137 serum samples) 
Analytes Round 3 (n=44) Mean (SD) %Detect 
IPBDE (ng/g lipidl 18.7 (2.1) 100 
BDE - 28 (ng/g lipid)A 0.6 (2.1) 68 
BDE- 47 (ng/g lipid)A 7.56 (2.6) 100 
BDE - 99 (ng/g lipid)A 1.7 (2.5) 95 
BDE- 100 (ng/g lipid)A 1.4 (3) 90 
BDE- 153 (ng/g lipidl 5.3 (3 .3) 100 
Thiocyanate (flg/L)A 480 (450) 100 
Perchlorate (flg/L)A 5.2 (11) 100 
Total T4 (flg/dl)B 7.1 (1.3) 100 
Free T4 (ng/dll 1.2 (1.2) 100 
TSH (f!IU/ml)A 0.89 (1.9) 100 
Total T3 (ng/ml)A 1.2 (1.2) 100 
Urinary Iodide (flg!Ll 150 (116) 100 
Urinary Specific Gravitl 1.02 (.007) 100 
TPO (IU/mLf 3 n/a 100 
Cholesterol (mg/dL)B 190 (44) 100 
Trigl yceridesB 140 (66) 100 
Total LipidsB 630 (140) 100 
A Geometric mean and geometric standard deviation presented. 
8 Means and standard deviation presented. 
Range 
2.4- 211 
0.2-3.6 
0.9-99 
0.2-20 
0.2-35 
0.1 -55 
16- 1815 
0.4- 73 
4.7- 9.2 
1.0- 1.6 
0.2-4.8 
0.8- 1.5 
32-660 
1.000- 1.03 
< 5-640 
92- 330 
45-290 
330- 1000 
c The number of participants that tested positive for TPO in each round are presented. 
0 (n=l) specific gravity measurement was missing in round 2. 
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Table 3.3. Crude and adjusted ~-estimates and 95% CI from general linear regression 
models for repeated measures evaluating the association between PBDEs (ng/g) and total 
thyroxine ([!g/dL) and thyroid stimulating hormone ([!IU/mL) (51 adults, 137 serum 
samples). 
l:PBDE BDE-47 
p (95% CI) p-value p (95% CI) p-value 
Total T4 (J.tg/dL) 
Crude A 
-1.4 ( -2.4 to -0.36) 0.01 -2.7 (-4.8 to -0.61) 0.01 
Model B -1.2 (-2.2 to -0.17) 0.02 -2.3 (-4.5 to -0.18) 0.03 
Model C -1.2 (-2.3 to -0.14) 0.03 -2.5 (-4.7 to -0.23) 0.03 
Model D -1.2 (-2.2 to -0.21) 0.02 -2.5 ( -4.6 to 0.32) 0.03 
ModelE -6.7 (-13 to 0.026) 0.05 -13 (-27 to 0.57) 0.06 
TSH (J.tiU/mL) 
Crude A 0.26 (-0.22 to 0.75) 0.28 0.32 (-0.71 to 1.4) 0.54 
ModelB 0.18 (-0.32 to 0.67) 0.48 0.10 (-0.95 to 1.2) 0.85 
Model C 0.19 (-0.32 to 0.70) 0.45 0.18 (-0.91 to 1.3) 0.75 
Model D 0.19 (-0.30 to 0.69) 0.44 0.13 (-0.93 to 1.2) 0.81 
ModelE 1.2 (-2.0 to 4.5) 0.45 0.81 (-6.0 to 7.6) 0.81 
A Yij =Po + P1PBDEij + P2Roundi + bi + G'ij 
B . 
Yii =Po + P1PBDEij + P2Roundi +P3LIPIDii+ bi + G'ij c . 
Yij =Po+ P1PBDEij + P2Round + P3LIPIDij + P4AGEi + PsSEXi + P6BMii + 
P7Iodineii + PsSpecific Gravityii + bi + G'ii 
D Yij =Po+ P1PBDEiJ + P2Roundij + P3LIPIDij + P3Perchlorateij + P4Thiocyanateij + 
P5Specific Gravityij + bi + G'ij 
E Yij =Po+ P1PBDE([!g/gLipid)ij + P2Round + bi + G'ij 
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Table 3.3 (continued). Crude and adjusted ~-estimates and 95% CI from general linear 
regression models for repeated measures evaluating the association between PBDEs 
(ng/g) and total thyroxine (f,tg/dL) and thyroid stimulating hormone (f,!IU/mL) (51 adults, 
137 serum samples). 
Total T4 
(~g/dL) 
Crude A 
Model B 
Model C 
Model D 
ModelE 
TSH 
(~IU/mL) 
Crude A 
ModelB 
Model C 
Model D 
ModelE 
BDE-99 
p (95% Cl) 
-7.3 (-15 to 0.042) 
-6.4 ( -14 to 0.93) 
-7.6 ( -15 to 0.0001) 
-7.0 (-14 to 0.41) 
-34 (-81 to 13) 
1.6 (-2.1 to 5.3) 
1.2 ( -2.6 to 4.9) 
1.5 (-2.4 to 5.4) 
1.2 (-2.5 to 5.0) 
6.1 (-18 to 30) 
p-value 
0.05 
0.09 
0.05 
0.06 
0.16 
0.39 
0.54 
0.45 
0.52 
0.61 
A Yij =flo + fl,PBDEii + flzRoundi + bi + E:ij 
BDE-100 
p (95% CI) 
-8.4 (-14 to -2.5) 
-7.5 (-14 to -1.4) 
-7 .4 ( -14 to -1.1) 
-7.8 (-14 to -1.8) 
-48 ( -90 to -6.7) 
1.3 ( -1.6 to 4.2) 
0.84 ( -2.1 to 3.8) 
0.90 (-2.2 to 4.0) 
0.91 (-2.0 to 4.0) 
7.5 (-12 to 17) 
p-value 
0.01 
0.02 
0.02 
0.01 
0.02 
0.37 
0.58 
0.56 
0.54 
0.46 
B Yii =flo + fl,PBDEii + flzRoundi +fl3LIPIDii+ bi + f:ij c . . . . . 
Yij =flo + fl1PBDEij + flzRound + fl3LIPIDij + fl4AGEi + flsSEXi + fl6BMii + 
fl7Iodineii + fl8Specific GravitYii + bi + E:ii 
0 Yij =flo + fl1PBDEiJ + flzRoundij + fl3LIPIDij + fl3Perchlorateij + fl4Thiocyanateij + 
fl5Specific Gravityij + bi + E:ij 
E Yij =flo+ fl,PBDE(f,tg/gLipid)ij + fl2Round + bi + f:ij 
- - - - - --
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Table 3.3 (continued). Crude and adjusted ~-estimates and 95% CI from general linear 
regression models for repeated measures evaluating the association between PBDEs 
(ng/g) and total thyroxine (f,lg/dL) and thyroid stimulating hormone (f.liU/rnL) (51 adults, 
137 serum samples). 
Total T4 
(f.lg/dL) 
Crude A 
Model B 
Model C 
Model D 
ModelE 
TSH 
(f.liU/mL) 
Crude A 
Model B 
Model C 
Model D 
ModelE 
BDE-153 
p (95% Cl) 
-2.8 ( -5.5 to 0.036) 
-2.4 (-5.2 to 0.43) 
-2.1 (-5 .1 to0.82) 
-2.3 (-5.1 to 0.47) 
-12 (-31 to 6.8) 
0.97 (-0.34 to 2.3) 
0.83 ( -0.49 to 2.2) 
0.80 ( -0.57 to 2.2) 
0.87 ( -0.44 to 2.2) 
5. 6 (-3. 1 to 14) 
p-value 
0.05 
0.10 
0.16 
0.10 
0.21 
0.15 
0.21 
0.25 
0.19 
0.2 
A Yii = f3o + fJ1PBDEij + fJ2Roundi + bi + G'ij 
8 Yii = f3o + fJ1PBDEii + fJ2Roundi +/33LIPIDij+ bi + G'ij c . 
Yij = f3o + fJ1PBDEij + fJ2Round + /33LIPIDij + /34AGEi + fJsSEXi + /36BMii + 
f37Iodineii + f38Specific Gravityii + bi + G'ij 
D Yij = f3o + f3 1PBDEij + fJ2Roundij + /33LIPIDij + /33Perchlorateij + /34Thiocyanateij + 
f35Specific Gravityij + bi + G'ij 
E Yij = f3o + fJIPBDE(f,lg/gLipid)ij + fJ2Round + bi + G'ij 
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Table 3.4. Crude and adjusted ~-estimates and 95% CI from general linear regression 
models for repeated measures evaluating the association between PBDEs (ng/g) and free 
thyroxine (ng/dL) and total triiodothyronine (ng/rnL) (51 adults, 137 serum samples). 
:EPBDE BDE-47 
p (95% Cl) p-value p (95% Cl) p-value 
Free T4 (ng/dL) 
Crude A 0.021 (-0.10 to 0.15) 0.74 -0.13 (-0.39 to 0.1) 0.35 
ModelB 0.034 (-0.09 to 0.16) 0.59 -0.10 (-0.38 to 0.17) 0.46 
Model C 0.011 (-0.11 to 0.14) 0.87 -0.13 (-0.40 to 0.1) 0.33 
Model D 0.038 (-0.09 to 0.17) 0.56 -0.10 ( -0.4 to 0.18) 0.48 
ModelE 0.30 ( -0.54 to 1.1) 0.49 -0.57 ( -2.3 to 1.2) 0.53 
Total T3 (ng/mL) 
Crude A 
-0.05 ( -0.17 to 0.08) 0.46 -0.01 (-0.3 to 0.3) 0.94 
Model B -0.03 (-0.16 to 0.01) 0.62 0.03 ( -0.25 to 0.3) 0.82 
Model C -0.02 (-0.15 to 0.11) 0.78 0.04 ( -0.24 to 0.3) 0.77 
Model D -0.03 (-0.16 to 0.1) 0.63 0.03 ( -0.25 to 0.3) 0.82 
ModelE -0.19 (-1.0 to 0.65) 0.65 0.15 (-1.7 to 1.9) 0.87 
A Yij =Po + P1PBDEij + P2Roundi + bi + cii 
~ Yii =Po + P1PBDEii + P2Roundi +P3LIPIDii+ bi + cjj . 
Yij =Po+ P1PBDEij + P2Round + P3LIPIDij + P4f\GEi + PsSEXi + P6BMii +P7Iodmeij + 
PsSpecific Gravityii + bi + cii D . . . 
Yij =Po + P1PBDEii + P2Roundij + P3LIPIDij + P3Perchlorateij + P4Thiocyanateij + 
P5Specific Gravityij + bi + cij 
E Yij =Po+ PIPBDE(!lg/gLipid)ij + P2Round + bi + cij 
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Table 3.4 (continued). Crude and adjusted ~-estimates and 95% CI from general linear 
regression models for repeated measures evaluating the association between PBDEs 
(ng/g) and free thyroxine (ng/dL) and total triiodothyronine (ng/mL) (51 adults, 137 
serum samples). 
BDE-99 BDE-100 
p (95% Cl) p-value p (95% CI) p-value 
Free T 4 (ng/dL) 
Crude A 
-0.72 (-1.7 to 0.23) 0.14 0.27 ( -0.47 to 1.0) 0.47 
Model B -0.67 ( -1 .6 to 0.30) 0.17 0.35 (-0.41 to 1.1) 0.37 
Model C -0.83 (-1.8 to 0.14) 0.09 0.21 (-0.54 to 0.95) 0.58 
Model D -0.70 (-1.7 to 0.30) 0.17 0.37 (-0.4 to 1.1) 0.34 
ModelE -3.7 (-9.8 to 2.5) 0.24 2.5 (-2.6 to 7.5) 0.33 
Total T3 (nglmL) 
Crude A 0.12 ( -0.91 to 1.1) 0.82 -0.28 (-1.0 to 0.47) 0.46 
Model B 0.23 (-0.81 to 1.3) 0.67 -0.20 (-0.98 to 0.6) 0.61 
Modele 0.21 (-0.84 to 1.3) 0.69 -0.13 (-0.9 to 0.64) 0.73 
Model D 0.17 ( -0.87 to 1.2) 0.74 -0.21 (-0.99 to 0.6) 0.58 
ModelE 1.4 (-5.3 to 8.0) 0.68 -1.3 (-6.4 to 3.8) 0.62 
A Yii = fJ0 + fJ1PBDEii + fJ2Roundi + hi + C:ij 
8 Yij = fJo + f3tPBDEij + fJ2Roundi +fJ3LIPIDij + hi + C:ij 
c Yij = fJo + fJ1 PBDEij + fJ2Round + (J3LIPIDij + f34AGEi + fJsSEXi + fJ6BMii +fJ1Iodineij + 
fJ8Specific GravitYii + hi + C:ii 
0 Yij = fJo + fJ1PBDEu + fJ2Roundij + (J3LIPIDij + (J3Perchlorateij + (J4Thiocyanateij + 
fJ5Specific Gravityij + hi + C:ij 
E Yij = fJo + fJJPBDE(!lg/gLipid)ij + fJ2Round +hi + C:ij 
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Table 3.4 (continued). Crude and adjusted ~-estimates and 95% CI from general linear 
regression models for repeated measures evaluating the association between PBDEs 
(ng/g) and free thyroxine (ng/dL) and total triiodothyronine (ng/mL) (51 adults, 137 
serum samples). 
BDE-153 
p (95% Cl) p-value 
Free T4 (ng!dL) 
Crude A 0.40 (-0.09 to 0.72) 0.01 
Model B 0.42 (0.10 to 0.75) 0.01 
Model C 0.35 (0.03 to 0.67) 0.04 
ModelD 0.44 ( -0.40 to 1.1) 0.34 
ModelE 3.0 (0.87 to 5.0) 0.01 
Total T3 (ng!mL) 
Crude A 
-0.28 ( -0.6 to 0.05) 0.10 
Model B -0.27 ( -0.6 to 0.08) 0.13 
Model C -0.19 (-0.54 to 0.2) 0.28 
Model D -0.26 ( -0.60 to 0.1) 0.14 
ModelE -1.5 (-3.7 to 0.70) 0.18 
A Yii =flo + fl1PBDEii + flzRoundi +hi+ C'ij 
B Yii =flo + fl1PBDEii + flzRoundi +fl3LIPIDii +hi+ C'ij 
c Yij =flo+ fl1PBDEij + flzRound + fl3LIPIDij + fl4AGE, + flsSEXi + fl6BMii +fl1Iodineij + 
fl8Specific GravitYii + bi + C'ij 
0 Yij =flo + fl1PBDEij + flzRoundij + fl3LIP1Dij + fl3Perchlorateij + fl4Thiocyanateij + 
fl5Specific Gravityij + bi + C'ij 
E Yij =flo+ fl1PBDE([Ag/gLipid)ij + fl2Round +hi+ C'ij 
Table 3.5. Estimated intraclass correlation coefficients and variance components for repeated serum 
markers of thyroid function tests. 
ICCA 
a2 w (null model)8 
a2 8 (null model)8 
TSH (~IU/mL) 
Estimate (95% Cl) 
0.72 (0.56 to 0.78) 
0.11 (0.09 to 0.2) 
0.28 (0.2 to 0.4) 
A Intraclass correlation coefficient 
Total T4 (~g/dL) 
Estimate (95% Cl) 
0.80 (0.68 to 0.85) 
0.36 (0.3 to 0.5) 
1.4 (0.8 to 2.0) 
Free T4 (ng/dL) 
Estimate (95% Cl) 
0.69 (0.53 to 0.77) 
0.0075 (0.006 to 0.01) 
0.017 (0.009 to 0.03) 
8 Within-person ( cr2 w) and between-person ( cr2 8 ) estimates from the intercept -ony model. 
Total T3 (ng/mL) 
Estimate (95% Cl) 
0.56 (0.39 to 0.67) 
0.012 (0.009 to 0.02) 
0.015 (0.007 to 0.03) 
Urinary Iodine 
Estimate (95% Cl) 
0.38 (0.19 to 0.50) 
0.38 (0.29 to 0.53) 
0.23 (0.077 to 0.38) 
00 
.j:::.. 
Table 3.6 Crude and adjusted P-estimates, 95% Cis, and p-values from general linear regression models for repeated measures 
evaluating the association between PBDEs and total T4 with outlying participant removed (ni=50, n=134). 
PBDE (ng/g) Crude A p-value Lipid-adjusted8 p-value 
L.PBDE -2.3 (-3.7 to -0.9)* 0.002 -2.0 (-3.5 to -0.54)* 0.008 
BDE- 28 -38 (-94 to 17) 0.120 -16 (-77 to 45) 0.464 
BDE- 47 -6.0 (-9.6 to -2.5)* 0.001 -5.3 (-9.1 to -1.4)* 0.008 
BDE- 99 -17 (-33 to -1.8)* 0.026 -13 (-29 to 2.9) 0.100 
BDE- 100 -13 (-21 to -5.6)* 0.001 -12 (-20 to -4.1)* 0.004 
BDE- 153 -3.2 (-6.2 to -0.14)* 0.041 -2.8 (-5.9 to 0.28) 0.074 
A Yij = ~o + ~ 1PBDEij + ~2Round + bi + eij 
8 Yij = ~o + ~ 1PBDEij + ~2Round + ~3LIPIDij + bi + eij 
c Yij = ~o + ~ 1 PBDEij + ~2Round + ~3LIPIDij + ~~GEi + ~5SEXi + ~6BMii +~7Iodine bi + eij 
0 Yij = ~o + ~ 1 PBDEij + ~2Round + B3LIPIDij + ~4Perchlorateij + ~5Thiocyanateij + bi + eij 
00 
VI 
Table 3.6 (continued) Crude and adjusted ,8-estimates, 95% Cis, and p-values from general linear regression models for 
repeated measures evaluating the association between PEDEs and total T4 with outlying participant removed (ni=50, n=134). 
PBDE ( I ) Lipid-adjusted and 1 Lipid-adjusted and 1 ng g . c p-va ue . n p-va ue 
covanates contammants 
LPBDE -2.0 (-3.6 to -0.50)* 0.008 -2.1 (-3.5 to -0.55)* 0.005 
BDE- 28 -18 (-80 to 43) 0.440 -16 (-76 to -44) 0.462 
BDE- 47 -5.5 (-9.4 to -1.6)* 0.006 -5.4 (-9.2 to -1.6)* 0.005 
BDE- 99 -14 (-30 to 1.6) 0.057 -15 (-31 to 1.2) 0.041 
BDE- 100 -12 (-20 to -3.8)* 0.004 -12 (-20 to -4.2)* 0.002 
BDE- 153 -2.3 (-5.9 to 0.56) 0.105 -2.6 (-5.7 to 0.41) 0.073 
A Yij = Bo + B,PBDEij + B2Round + bi + ~::ij 
6 Yij = Bo + B,PBDEij + B2Round + B3LIPIDij + bi + ~::ij 
c Yij = Bo + B,PBDEij + B2Round + B3LIPIDij + B4AGEi + BsSEXi + B6BMii +B1Iodine hi+ ~::ij 
0 Yij = Bo + B1PBDEij + B2Round + B3LIPIDij + B4Perchlorateij + BsThiocyanateij +hi+ ~::ij 
00 
0\ 
Figure 3.1. Relationship between BDE-47 and Total T4 in Round 1: A) without outlier B) with outlier. 
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Figure 3.2 Relationship between BDE-47 and Total T4 in Round 2: A) without outlier B) with outlier, and Round 3: 
C) without outlier D) with outlier. 
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BACKGROUND: Animal experiments and some human studies indicate that PBDEs 
may adversely affect male reproductive function . 
OBJECTIVES: Our study is the first to use repeated measures in serum to assess the 
association between PBDE exposure and reproductive function tests in a North American 
male adult cohort. 
METHODS: We collected three serum samples from 27 healthy adult men at 6-month 
intervals in the FlaRE study and assessed associations between PBDE exposure and 
reproductive function tests using mixed effects regression models, adjusting for 
confounders. 
RESULTS: Geometric mean concentrations of the five most prevalent PBDE congeners 
(BDE 28, 47, 99, 100, 153) by sampling round (Winter 2010, Summer 2010, Winter 
2011) were 25.5 ng/g lipid, 25.5 ng/g lipid, and 21.1 ng/g lipid, respectively. PentaBDEs 
were significantly and inversely associated with inhibin-B. Among men 40 years or older 
(n=13, age range: 40 to 66 years old), increased exposure to BDE-100 was associated 
with a decrease in inhibin-B (p=0.02), an increase in follicular stimulating hormone 
(FSH) (p=0.008), and decreases in the inhibin-B/FSH ratio (p=0.002) and the free 
androgen index (p=0.065). Although we did not examine sperm counts and testicular 
volume, these outcomes are typically positively correlated with inhibin-B serum levels. 
CONCLUSIONS: These findings suggest that excessive PBDE exposure may decrease 
testicular function in older men. 
91 
KEYWORDS: endocrine disruption, environmental health, flame retardants, male 
reproductive health, persistent organic pollutants, polybrominated diphenyl ethers 
(PBDEs), reproductive hormones. 
Introduction 
Pentabromodiphenyl ether (PentaBDE) contains the congeners (BDE-28, -47, -99, 
-100, and -153) and was used as an additive flame retardant in furniture containing 
polyurethane foam in the US from the 1970s (USEPA 2008). Of the worldwide 
production, 95% of the PentaBDE produced was used in North America, where 
concentrations in people are significantly higher than in European and Asian populations 
(Meironyte et al. 1999). Due to its persistence, ability to bioaccumulate, and potential 
adverse health effects, the chemical manufacturers voluntarily withdrew PentaBDE from 
production in 2004 (USEPA 2006). However, older products containing PentaBDE (e.g. 
furniture) remain in use and continue to contribute to exposure m indoor 
microenvironments (e.g. homes, offices, and vehicles) (Watkins et al. 2012). 
Additionally, PentaBDEs are still commonly found in food products (Schecter et al. 
201 0) such that diet continues to be an important source of human exposure in the US 
(Fraser et al. 2009). 
Animal studies have shown that the PentaBDEs are endocrine disrupting 
chemicals and adversely affect neurodevelopment (Stoker et al. 2004). Structurally 
similar to polychlorinated biphenyls (PCBs), it is possible that PBDEs or their hydroxyl 
metabolites also activate or antagonize the estrogen and/or androgen receptor, which is 
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associated with reproductive effects (Stoker et al. 2005; van der Ven et al. 2008). 
However, animal studies to date have been inconsistent regarding the effects of PBDEs 
on reproductive endpoints. There is some evidence that PBDE exposure decreases 
circulating sex steroids (Lilienthal et al. 2006; Stoker et al. 2005) or leads to adverse 
effects on reproductive endpoints (van der Ven et al. 2008; Wang et al. 2013), while two 
studies report no effects on reproductive endpoints (Ernest et al. 2012; He et al. 2011). 
Few human studies have examined the association between PentaBDEs and 
reproductive function in men (Table 1.5). Meeker et al. found that BDE-99 in house dust 
was negatively associated with LH, and FSH, and positively associated with inhibin-B 
and estradiol in men (Meeker et al. 2009). In a follow-up, Johnson et al. found that 
PentaBDEs in house dust were associated with a 20% decrease in FSH and were 
positively associated with estradiol and sex hormone binding globulin (SHGB) (Johnson 
et al. 2013). Meijer et al., reported positive associations between maternal BDE-154 
exposure and testosterone, SHBG, inhibin B and estradiol measured in male infants 
(Meijer et al. 2008). Turyk et al., found that serum BDE-47 was positively associated 
with testosterone in adult sports fishermen (Turyk et al. 2008). Studies have also found 
associations between PentaBDEs and decreased sperm concentration, (Ak:utsu et al. 
2008) decreased sperm motility (Abdelouahab et al. 2011), and cryptorchidism (Main et 
al. 2007). Furthermore, a few studies have linked PBDE exposure in females with 
potentially adverse effects on reproductive health endpoints (Chen et al. 2011; Harley et 
al. 2010; Johnson et al. 2012). 
Our study uses repeated serum measures to assess the association between 
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PentaBDE exposure and reproductive function tests (RFTs) in a longitudinal cohort of 
healthy, adult men. Our primary aim is to examine the association between the 
PentaBDEs and the RFTs: total testosterone, free testosterone, inhibin-B, luteinizing 
hormone (LH), follicle stimulating hormone (FSH), prolactin, sex hormone binding 
globulin, inhibin-B/FSH ratio, and the free androgen index (FAI). Our secondary aims 
are to assess the stability of RFT measures in serum, and the effects of effect modifiers in 
our cohort. 
Methods 
Study Design and Population. Characteristics and descriptions of the entire FlaRE 
(Flame Retardant Exposure Study) study population are presented elsewhere (Makey et 
al. 2014). Briefly, participants had to be healthy, non-smoking men over the age of 18, 
working in an office environment at least 20 hours a week, and planning to reside in the 
greater Boston metropolitan area for the study duration. The recruited population 
included 52 men and women, but the current analysis is restricted to the subset of 27 
men. 
We collected three rounds of blood samples (total of 76 samples) at 
approximately six-month intervals from 2010 to 2011. Twenty-six males participated in 
Round 1 and one additional male participant was recruited in Round 2. Participation rate 
by sampling round was: 92% (24/26) in Round 1, 100% (27/27) in Round 2, and 93% 
(25/27) in Round 3. The four serum samples were missing for the following reasons: too 
little serum collected (n=1), unable to conduct venipuncture (n=2), and loss to follow-up 
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(n=1). We used questionnaires to collect information about demographics, general health, 
prior diagnosis of reproductive disease and use of medications that can affect testosterone 
levels: Testosterone, Methadone, Megestrol, Ketoconazole, Spironalactone, and DHEA-
sulfate. We obtained informed consent prior to participation and the Boston University 
Medical Center Institutional Review Board approved the study protocol. 
Blood Samples. A trained phlebotomist collected 30 rnL of blood from participants 
during each sampling round. The samples were processed on the day of collection and 
serum samples were stored at -80°C in amber glass vials until analysis. To eliminate 
potential issues with inter-assay variability, we analyzed all samples at one time 
following round 3. Serum samples were analyzed for lipids (total triglycerides, total 
cholesterol) and 11 PBDE congeners (BDE-17, BDE-28, BDE-47, BDE-66, BDE-85, 
BDE-99, BDE-100, BDE-153, BDE-154, BDE-183, BDE-209) at the Centers for Disease 
Control and Prevention (CDC) using established methods (Sjodin et al. 2004). Samples 
were randomized and analyzed with quality control (QC) (n=3) and blank samples (n=3) 
in each batch of 24 unknowns. The coefficient of variation (CV) of included QC samples 
was less than 10%. 
Hormone Analysis. RFTs were analyzed at the Steroid Hormone Research Laboratory at 
Boston Medical Center, Boston, MA. We analyzed Testosterone by LC-MS (AB Sciex 
QTRAP® 55000 System) and had sensitivity of 1 ng/dL and intra-assay CV of 2% and 
inter-assay CV 7%. We calculated IT using Vermeulen's formula (Vermeulen et al. 
1999). SHBG and LH levels were measured using a two-site immunofluorometric assay 
(DELFIA-Wallac, Inc. , Turku, Finland). The inter-assay CVs for SHBG were 8.3%, 
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7.9%, and 10.9%, and intra-assay CVs 7.3%, 7.1% and 8.7%, respectively, in the low, 
medium, and high pools and the analytical sensitivity of the assays was 0.5 nmol/L. We 
measured FSH and prolactin using time-resolved fluoroimmunoassay (DELFIA-Wallac, 
Inc. Turku, Finland) performed on a Wallac-Victor 1420 Multilabel Counter (Perkin 
Elmer, Waltham, MA.). We measured Inhibin-B using the Inhibin B Gen II ELISA kit 
(Beckman-Coulter, Brea, CA). 
Statistical Analysis. Continuous population characteristic variables, PBDEs, and RFis 
are presented with measures of central tendency and the minimum and maximum values 
by each sampling round. In summary statistics, PBDEs were presented standardized to 
serum lipids (ng/g lipids) for comparability with previous studies. For PBDE 
measurements below the LOD, we substituted Y2 LOD. :EPBDE was the sum of the five 
most prevalent PentaBDE congeners, BDE-28, -47, -99, -100, and -153. For each subject 
an inhibin B/FSH ratio was calculated as inhibin B (pg/rnL)/FSH (lUlL). We also 
calculated the free androgen index (FAI) for each participant using the formula: [(total 
T/SHBG) * 100]. We assessed normality of continuous variables using histograms and 
Shapiro-Wilks tests. The dependent variables: FSH, LH, prolactin, SHBG, lnhibin-
B/FSH ratio, and FAI were transformed for regression analysis because they were log-
normally distributed and appeared more normally distributed after transformation. 
Geometric means (GMs and geometric standard deviations (GSD) were presented, 
instead of mean and standard deviation (SD), if the continuous variable was log-normally 
distributed. We used Spearman correlation coefficients to determine the amount of 
correlation between PBDE congeners. Influential points were identified in a scatterplot of 
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RFfs x PBDE. All statistical analyses were conducted using SAS statistical software 
version 9.3 (SAS Institute, Cary, NC, USA) and statistical significance is reported at the 
0.05level. 
We used a general linear model for repeated measures with a random intercept to 
assess the association between the PBDE congeners (BDE-47, BDE-99, BDE-100, BDE-
153) and RFTs, which in its simplest form is: 
(1) 
where Yij represents the reproductive function test level of the ith participant on the jth 
day. f3o is the fixed effect intercept, /31 is our effect measure, PBDE is the PBDE level of 
the ith participant on the jth day, bi is the random intercept of the i1h individual, and eij is 
the random error of the ith participant on the jth day. We refer to ni as the number of 
individuals, nii as the number of samples at time j, and n as the total number of samples. 
The following covariates were added to equation (1) to form our primary model: 
Sampling Round (Categorical, Round 1, 2, or 3), total lipids (mg/dL), age (years), BMI 
(mg/kg2), As a sensitivity analysis, we also included time of day of blood sampling as a 
covariate. We ran additional analysis for the relationship between each congener of 
interest and RFT: a) adjusted for round only b) adjusted for round and lipids, c) adjusted 
for round, and using a lipid-standardized (ng/g lipid) PBDE exposure metric. We 
presented scatterplots of the crude associations between PBDE and RFf from Round 2 
because this was the sampling period where we had a participation rate of 100%. For 
interpretation in the results section, we used percent change for equations with a log-
transformed dependent variable. The percent change in hormone per unH change of 
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PBDE can be computed by exponentiation of the regression coefficients presented in the 
tables, subtracting one and multiplying by 100. 
Based on a priori expectation, age and BMI, were assessed as potential 
confounders. Confounding was assessed using a change of > 10% or greater in the beta 
estimate as a guide. To determine whether there was effect measure modification for the 
relationship between PBDEs and RFT by a demographic covariate, we included a cross 
product of PBDE concentrations and covariate (treating age and BMI as continuous 
variables). Additionally, we examined stratified analysis of age and BMI. For age, we 
dichotomized our cohort above and below 40 years old. For BMI, we dichotomized our 
cohort by the following: normal (BMI<25), overweight/obese (~25). Male fertility 
gradually decreases with age, unlike female fertility that begins to precipitously decline 
around age 35. However research indicates male fertility becomes clinically reduced 
around 40 years of age (Zitzmann 2013). 
We estimated intraclass correlation coefficients (ICCs) to assess the stability of 
semm RFTs in men (de Vet et al. 2006). We used an intercept-only general linear model 
for repeated measures with the RFTs as the dependent variable. We also used a general 
linear model for repeated measures with blood collection time as a predictor in a second 
model. Stability was classified as "poor" (ICC=O to 0.39), "moderate" (ICC=0.4 to 0.59), 
"good" (ICC= 0.6 to 0.79), or "excellent" (ICC~0.80). 
We had non-fasting blood samples and used lipid as a covariate in our primary 
regression models, instead of standardizing PBDE measurements to lipids. As it is 
currently unclear which method of accounting for semm lipids produces the least bias 
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when describing the relationship between lipophilic compounds and health effects 
(Schisterman et al. 2005), we also performed regression analysis using a PentaBDE 
predictor standardized to lipids (PBDE ng/g lipid). 
Results 
We collected 76 serum samples from 27 male participants from 2010 to 2011. 
Twenty-three men were white, two were Hispanic/Latina, and two were Asian. All men 
reported to be in good to excellent health, 100% had a college degree, and 56% had a 
BMI < 25. The mean age by sampling round was 41 years old. Characteristics of the 
entire cohort (men and women) are presented elsewhere (Mak:ey et al. 2014). Twenty-
four men participated in all three rounds and three men participated in two sampling 
rounds. Two participants reported to be taking a medication that may affect testosterone 
levels during the study period and one participant reported to have previously had 
prostate cancer. However, regression analyses were not affected when these men were 
excluded (Table 4.4). 
Eleven PBDEs congeners and nme RFTs were measured in serum samples. 
Detection rates for BDE-17, BDE-66, BDE-85, BDE-154, BDE-183, and BDE-209 
ranged from 1% to 22% and were not further analyzed (Table 4.5). Table 4.1 presents the 
round-specific GMs, GSDs, and range for the major PentaBDE congeners as well as 
other information by sampling round. GM concentrations of LPBDEs by sampling round 
(Round 1, Round 2, Round 3) were 25.5 ng/g, 25.5 ng/g, and 21.1 ng/g lipid, 
respectively. BDE-47, BDE-99, and BDE-100 were highly correlated, r spearman> 0.94, 
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p<O.OOl. BDE-153 was not as strongly correlated (rspearman between 0.40 and 0.56, p-
values between 0.048 and 0.004) with BDE-47, BDE-99, and BDE-100. 
Levels of BDE-28, BDE-47, BDE-99, and BDE-100 were lower in our cohort 
than levels reported for, the 2003-4 National Health and Nutrition Examination Survey 
(NHANES), a large representative sample of the US population (Figure 4.2). For 
example, the geometric mean of BDE-47 in Round 1 of our cohort was 9.4 ng/g lipid 
compared to 21.4 ng/g lipid in NHANES (Sjodin et al. 2008). However, the GM of BDE-
153 in our study, 8.6 ng/g lipid, was similar to NHANES, 6.9 ng/g lipid. Similar results 
were found for our entire cohort (Makey et al. 2014). 
As shown in Table 4.1, RFTs were predominantly within normal ranges. The 
normal range for free (bio-available) testosterone for healthy, adult (18-65 years old) 
males is 50 to 200 pg/mL. The IT range for rounds 1, 2, and 3 were (59.7 to 167.1), (50.4 
to 197.5), and (34.6 to 149.1) pg/mL, respectively. The geometric means of inhibin-
B/FSH ratios by round were 63.0, 64.1, and 65.8, respectively. Our cohort GM inhibin-
B/FSH ratios by round were higher than those reported in a normal population (median = 
48) and comparable to a proven fertile male population (median = 70) (Andersson et al. 
2004). 
Table 4.2 shows the results from our primary linear mixed-effects models using 
serum PBDEs (pg/g serum) to predict the RFTs, adjusted for serum lipids, age, BMI, and 
sampling round. BDE-47 was significantly and inversely associated with inhibin-B, after 
adjustment for lipids, age, BMI, and sampling round. BDE-99, BDE-100, BDE-153 were 
inversely related to inhibin-B, but the association did not reach statistical significance in 
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the fully adjusted models. These inverse relationships persisted in the crude models, 
models adjusted for lipids only, and in models using a lipid standardized exposure metric 
(Table 4.6). We also conducted cross-sectional analysis by sampling round using a 
general linear regression model with RFTs as the dependent variable, and results were 
consistent over time. Figure 4.2 shows scatterplots from Round 2; however relationships 
between PBDEs and RFTs were similar at all time points (not shown). The beta 
coefficients and confidence limits from the lipid-only regression models and models 
adjusted for lipids, age, and BMI were similar, indicating age and BMI are not 
confounding the association we report between PBDEs and inhibin-B (Table 4.2 and 
Table 4.6). This was true for all congeners in relation to inhibin-B and is an expected 
result because we previously reported that age and BMI are not predictors of PentaBDEs 
in our cohort (Makey et al. 2014 ). Furthermore, age and BMI have not been shown to be 
a risk factor for decreased inhibin-B levels (Andersson et al. 2004). The negative 
association was present in analysis of the entire cohort, however stratified analysis 
revealed the inverse relationship was likely attributed to men over 40 in our cohort (Table 
2, Figure 4.1). 
We did not observe any important associations between PentaBDEs and total or 
free testosterone (Table 4.2, Figure 4.3). We found a small, imprecise, positive 
association between PBDEs and SHBG, particularly for BDE-47 and BDE-100 in men 
over 40 years old. There was a positive association between BDE-47 and BDE-99 and 
LH; however, after removal of a single potentially influential data point, the positive 
relationship was almost completely absent (Table 2, Figure 4.4). Relationships between 
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PBDEs and prolactin were small and imprecise. 
We found evidence of effect measure modification by age in the relationship 
between PBDEs and FSH, (8BoE-47*AoE=0.000047, p=0.004). Among older men (~40 
years old), for every one-unit increase in BDE-100 we had a 0.43% (95% Cl= 0.0012 to 
0.0074) IUIL increase in FSH, while among younger men(< 40 years old) for every one-
unit increase there was a 0.23% (95% CI = -0.0048 to 000020) IUIL decrease in FSH 
(Table 2, Figure 1). BDE-47 presented a similar pattern to BDE-100, and BDE-153 had a 
significant and positive relationship with FSH among older men, but the relationship in 
younger men was imprecise and appeared null. Among younger men, BDE-99 was 
inversely associated with FSH, and among older men, this inverse association was 
attenuated and appeared null. 
We also observed different effects of PBDE exposure by age group for the 
inhibin-B/FSH ratio, which is a diagnostic tool used in idiopathic male infertility. We 
found that BDE-47 and BDE-100 exposure was associated with a decrease in the inhibin-
B/FSH ratio among older men but an increase in the inhibin-B/FSH ratio among younger 
men. However, the strength of this pattern differed by congener and some associations 
were weak and imprecise. The relationship between BDE-153 and the inhibin-B/FSH 
ratio was imprecise. The pattern with the lower brominated congeners, excluding BDE-
153, was consistent, but did not reach statistical significance, possibly as the result of 
decreased power after stratification into age groups (e.g. younger (< 40, 14 men, 40 
serum samples), older (~40, 13 men, 36 serum samples), (Table 4.2, Figure 4.1). We also 
found a negative relationship between BDE-47, BDE-99, and BDE-100, and FAI. Among 
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older men, for every one-unit increase in BDE-47 we observed a 0.049% (95% CI= -0.15 
to -0.003) decrease in FAI, while among younger men for every one-unit increase there 
was a 0.045% (95% CI = -0.13 to 0.22) increase in FAI. For associations between PBDEs 
and the other reproductive function tests (testosterone, free testosterone, LH, and 
prolactin), we found no evidence of effect modification by age. We did not find any 
evidence for effect measure modification between PentaBDEs and any of the RFfs by 
BMI (Table 4.7). 
Inhibin-B, FSH, SHBG, and the inhibin-B/FSH ratio were highly stable at 
assessing an individual's status over the one-year study period based on ICCs of 0.85, 
0.98, 0.91, 0.93, respectively (Table 4.3). LH and FAI had good stability. Total 
testosterone and prolactin had moderate stability. Free testosterone had poor stability (e.g. 
a high degree of intra-individual variability). The results for testosterone and free 
testosterone are expected, as these hormones exhibit diurnal variability, where levels 
taken in morning are typically higher than those in the afternoon (Brambilla et al. 2009). 
Our non-fasting serum samples were collected at various times during the day based on 
the convenience of the participant. Blood collection time of day was an inverse predictor 
of total and free testosterone (not shown), i.e., as daily time increased, levels of these 
hormones decreased. Inclusion of time of time of day slightly increased ICCs for 
testosterone and free testosterone (Table 4.3). However, inclusion of blood collection 
time of day did not affect our effect estimates for associations of PBDEs with total or free 
testosterone (not shown). The associations between PBDEs and RFTs comparing results 
from the lipid adjusted to lipid standardized regression models are presented in Table 4.6. 
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Discussion 
We found that exposure to PentaBDEs was associated with decreased inhibin-B in 
healthy adult men living in the Boston area, particularly for men forty years and older. In 
adult men, inhibin-B is produced by the Sertoli cells and serum levels of the hormone are 
strongly, positively correlated with testicular volume and sperm counts (Meachem et al. 
2001). A recent European study of 299 men also reported inverse associations between 
BDE-47 and inhibin-B, estradiol, testosterone, free androgen index and one marker of 
sperm DNA damage (Toft et al. 2014). Our finding of decreased inhibin-B is consistent 
with one study reporting PBDE exposure was associated with decreased sperm 
concentration (Akutsu et al. 2008). Our results are inconsistent with three other previous 
human studies that reported a positive association between PBDEs and inhibin-B 
(Johnson et al. 2013; Meeker et al. 2009; Meijer et al. 2008). Meeker et al. and Johnson et 
al. found a positive association between summed PentaBDEs (BDE-47, BDE-99, BDE-
100) in house dust and inhibin-B, SHBG, and estradiol in adult men seeking infertility 
treatment (Table 1.5). 
FSH and inhibin-B are tightly regulated v1a negative feedback in the 
hypothalamic-pituitary-testicular axis. Sub-fertile or infertile adult men typically have 
low inhibin-B, in combination with high FSH levels, oftentimes indicated by a low 
inhibin-B/FSH ratio (Andersson et al. 2004). Furthermore, the inhibin-B/FSH ratio is a 
serum marker for seminiferous tubule health and Sertoli cell viability, such that men after 
undergoing chemotherapy will have decreased inhibin-B levels, decreased inhibin-B/FSH 
ratio and decreased sperm concentrations (van Beek et al. 2007). Among older men in our 
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cohort, we found that increased exposure to BDE-47 and BDE-100 was linked to a 
significant decrease in inhibin-B, significant increase in FSH, and non-significant 
decrease in the inhibin-B/FSH ratio. A recent toxicological study in mice reported 
exposure to BDE-47 impaired spermatogenesis, possibly driven by an increase apoptosis 
of germ cells in the seminiferous tubules (Wang et al. 2013). Interestingly, within the 
younger men of our cohort, we found exposure to BDE-47, BDE-99, and BDE-100 was 
associated with non-significant decreases in FSH and increases in the inhibin-B/FSH 
ratio. While the inhibin-B/FSH ratio would be used in combination with other RFfs, 
clinical evaluations, and semen analysis in the determination of fertility status (Han and 
Bouloux 2010), we have evidence that PBDEs may be affecting male fertility by 
disrupting the hypothalamic-pituitary-testicular axis and this relationship may differ 
dependent upon age. The effect measure modification by age in the relationship between 
PentaBDE/reproductive hormones in men has not been reported in previous studies. 
We failed to find an association between PBDEs and testosterone, similar to 
several other studies that evaluated this relationship (Hagmar et al. 2001) (Ernest et al. 
2012) (Kuriyama et al. 2005; Stoker et al. 2005). However, human studies have found 
associations between PBDEs and testosterone (Johnson et al. 2013; Meijer et al. 2008; 
Toft et al. 2014; Turyk et al. 2008). In our cohort, testosterone had a low ICC, indicating 
there is a high degree of intra-individual variability in the serum measurement. We 
hypothesized that part of this variability arises from normal diurnal variations and 
variable sampling times, and is independent of exposure. As expected, we found that 
testosterone and free testosterone decreased as blood was sampled later in the day. 
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However addition of blood sampling time into regression models did not have impmtant 
impacts on our effect estimates. Our small sample size may have limited our ability to 
detect an association between PBDEs and testosterone. We did find a small imprecise 
inverse association between the BDE-47 and BDE-99 and FAI. While our results of a 
decrease in F AI are consistent with some previous studies, it is unclear how valid F AI is 
as a marker for reproductive function in men (Kapoor et al. 1993). FAI was historically 
used as a measure for free testosterone, but has since been determined to be a poor 
predictor of bioavailable testosterone, particularly for men (Rosner et al. 2007). Using 
other reproductive endpoints, studies have shown PBDEs possibly have adverse effects 
on fecundity in animals (Kuriyama et al. 2005; Lilienthal et al. 2006; Stoker et al. 2005; 
Talsness et al. 2008; Wang et al. 2013) and humans (Harley et al. 2010), however we do 
not have evidence that the PentaBDE congeners affected circulating testosterone in the 
men of our cohort. 
Our study is the first prospective study to use repeated serum measures to assess 
the association between PBDE exposure and male reproductive function tests. Our study 
design allowed us to assess the stability of PBDE and RFTs measures in serum, and we 
report that serum PBDEs (Makey et al., 2014) and some RFTs (Inhibin-B, FSH, SHBG, 
FAI) are highly stable in our cohort. Following our participants through time, in 
combination with having a very stable exposure metric, reduces, but does not eliminate, 
the possibility that we are observing an association due to reverse causation, which is 
much more likely in cross-sectional studies. Additionally, we used multiple methods to 
account for serum lipids (crude, adjustment, standardization), which has been a source of 
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debate when studying the health effects of lipophilic compounds in non-fasting serum 
samples (Schisterman et al. 2005). As expected, serum lipids were positively correlated 
with serum PBDE levels in our cohort (Makey et al. 2014). Research has also shown 
serum lipid levels are correlated with hormone levels in men (Monroe and Dobs 2013). 
While the causal structure between PBDEs, reproductive function tests, and serum lipids 
is unknown, we adjusted for serum lipids as a covariate, instead of using a standardized 
PBDE exposure metric. This allowed us to assess the independent effects of serum lipids 
and PBDE concentration, as well as theoretically remove the possibility of reverse 
causation through serum lipids by controlling for the covariate and removing a potential 
backdoor pathway (Figure 4.4). 
Based on simulations constructed by Gaskins et al. , it is possible we are observing 
a situation of positive confounding by serum lipids, where serum lipids affect serum 
PBDE levels and serum lipids affect the reproductive function test, leading to a crude 
association that is biased away from the null, and a standardized model that is biased 
toward the null, which is precisely what we report (Gaskins and Schisterman 2009). In 
these simulations, the lipid-adjusted model correctly accounts for serum lipids effect on 
RFTs and presents limited bias for the relationship between the lipophilic exposures and 
health outcome (Gaskins and Schisterman 2009). 
Our sample size was relatively small, limiting our ability to detect relationships 
between PBDEs and RFTs while adjusting for multiple covariates. There may be other 
exposures that could confound the relationships we report or contribute to a mixtures 
effect. There is also the possibility of chance associations based on the number of 
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congeners and RFTs tested. However our main conclusions, regarding the lower 
brominated PentaBDEs and the RFTs (inhibin-B, FSH, and inhibin-B/FSH ratio) had a 
consistency in direction of effect. Our cohort was 85% white, highly educated men, living 
in Boston (USA), and is not representative of the US general population. However, 
having a fairly homogenous population in which to study health effects should increase 
internal study validity (Rothman 2008). 
In conclusion, our results suggest that environmental exposure to PBDEs 
decreases inhibin-B levels, a marker of spermatogenesis, in older men. Additionally, 
among older men we found PBDE exposure was associated with increases in FSH, and a 
decrease in the inhibin-B/FSH ratio, which is a diagnostic tool used in idiopathic male 
infertility. Future prospective studies are needed to further understand how PBDEs and 
their metabolites may affect reproductive hormone levels and possibly testicular function 
in healthy adult men. 
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Table 4.1 Summary Statistics for demographic characteristics, and repeated serum 
samples of selected PBDEs, and reproductive function tests in adult men, by sampling 
round (27 men, 76 samples). 
Round 1 (24 samples) 
Characteristic GM(GSD) Range 
Demographics 
Age (yearsl 41.0 (13.8) 25-66 
BMI (mg/kg2)A 25.3 (3.6) 20-38 
Total LipidsA 644.8 (118) 448- 864 
PBDE Exposures 
BDE - 28 (ng/g lipid)8 0.51 (2.5) 0.15-2.8 
BDE- 47 (ng/g lipid) 9.4 (3.0) 1.7- 151 
BDE - 99 (ng/g lipid)8 1.9 (3.0) 0.25-43.5 
BDE- 100 (ng/g lipid)8 1.8 (4.0) 0.20-42.4 
BDE- 153 (ng/g lipid) 8.6 (3.1) 1.6- 96.7 
LPBDE (ng/g lipid) 25.5 (2.8) 5.8- 294.0 
Reproductive Function Testsc 
Total Testosterone (ng/dl)A 627.6 (254) 310- 1182 
Free Testosterone (pg/ml)A 109.1 (34.2) 59.7- 167.1 
Inhibin-B (pg/rnLl 189.8 (67.2) 16.6- 320.9 
FSH (lUlL) 3.12 (1.73) 1.40- 17.6 
LH (U/L) 4.5 (1.58) 2.12- 12.57 
Prolactin (ng/mL) 4.25 (1.45) 2.05 -7.28 
SHBG (nmol/L) 42.7 (1.60) 14.0- 83.8 
Inhibin-B (pg/rnL)/FSH (IU/L) 63.0 (52.6) 0.94- 188 
Free Androgen Index 1360 (104) 738- 3850 
A Means and standard deviations presented. 
8 LOD = 0.025 ng/g lipid for BDE-28, 99, and 100. 
c Normal Reference Range for adult males in good health: testosterone= 300- 1000 
ng/dL, free testosterone = 50 - 200 pg/rnL 
inhibin-B =elevated if above 399 pg/rnL, FSH=0.60- 9.98 lUlL, LH = 1.0- 8.4 U/L, 
SHBG =12.9- 61.7 nmol/L . 
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Table 4.1 (continued). Summary Statistics for demographic characteristics, and repeated 
serum samples of selected PBDEs, and reproductive function tests in adult men, by 
sampling round (27 men, 76 samples). 
Characteristic 
Demographics 
Age (years )A 
BMI (mg/kg2)A 
Total LipidsA 
PBDE Exposures 
BDE - 28 (ng/g lipid)8 
BDE - 47 (ng/g lipid) 
BDE - 99 (ng/g lipid)8 
BDE - 100 (ng/g lipid)B 
BDE- 153 (ng/g lipid) 
:LPBDE (ng/g lipid) 
Reproductive Function Testsc 
Total Testosterone (ng/dl)A 
Free Testosterone (pg/mlt 
Inhibin-B (pglmLt 
FSH (lUlL) 
LH (UIL) 
Prolactin (ng/mL) 
SHBG (nmol/L) 
Inhibin-B (pg/mL)/FSH (lUlL) 
Free Androgen Index 
A Means and standard deviations presented. 
B LOD = 0.025 ng/g lipid for BDE-28, 99, and 100. 
Round 2 (27 samples) 
GM (GSD) Range 
41.3 (13.3) 
25.3 (3.5) 
630.4 (123) 
0.62 (2.5) 
9.9 (2.8) 
1.9 (3.0) 
2 (3.5) 
8.6 (3.1) 
25.5 (2.6) 
633.2 (200) 
109.6 (36.8) 
183.7 (75.8) 
3.21 (1.76) 
3.93 (1.53) 
4.97 (1.49) 
45.3 (1.59) 
64.1 (56.8) 
1330 (149) 
25-66 
20-38 
396- 912 
0.15-5.1 
1.4- 149.0 
0.25- 34.1 
0.25-44.1 
1.7- 94.7 
6.55-293.5 
285.4-1031 
50.4- 197.5 
18.5-423.3 
1.32- 19.6 
1.97- 13.9 
2.39- 9.34 
12.7-92.7 
0.95-258 
685-3180 
c Normal Reference Range for adult males in good health: testosterone= 300- 1000 
ng/dL, free testosterone = 50 - 200 pg/mL 
inhibin-B =elevated if above 399 pg/mL , FSH=0.60- 9.98 IU/L, LH = 1.0- 8.4 U/L, 
SHBG =12.9- 61.7 nmol/L 
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Table 4.1 (continued) Summary Statistics for demographic characteristics, and repeated 
serum samples of selected PBDEs, and reproductive function tests in adult men, by 
sampling round (27 men, 76 samples). 
Round 3 (25 samples) 
Characteristic GM (GSD) Range 
Demographics 
Age (years)A 41.8 (12.6) 26-67 
BMI (mg/kg2l 25.1 (3.6) 20-38 
Total LipidsA 632.2 (124) 328- 843 
PBDE Exposures 
BDE - 28 (ng/g lipid)B 0.5 (2.3) 0.15-3.6 
BDE - 47 (ng/g lipid) 8.2 (2.5) 1.8- 98.9 
BDE - 99 (ng/g lipid)B 1.6 (2.5) 0.30-20.1 
BDE - 100 (ng/g lipid)B 1.5 (3.0) 0.30- 35.2 
BDE - 153 (ng/g lipid) 6.8 (2.8) 1.5- 55.2 
LPBDE (ng/g lipid) 21.1 (2.3) 5.85-211.1 
Reproductive Function Testsc 
Total Testosterone (ng/dl)A 470.1 (159) 199.4- 795.4 
Free Testosterone (pg/rnl)A 83.8 (29.5) 34.6- 149.1 
Inhibin-B (pg/mLl 190.1 (83.6) 17.2-441.1 
FSH (lUlL) 3.29 (1.81) 1.41- 19.6 
LH (UIL) 4.39 (1.60) 1.82- 13.7 
Prolactin (ng/mL) 5.15 (1.43) 2.40-9.82 
SHBG (nmol/L) 40.5 (1.56) 12.2- 76.4 
Inhibin-B (pg/mL)/FSH (lUlL) 65.8 (57.1) 0.88-238 
Free Androgen Index 1090 (151) 520- 2100 
A Means and standard deviations presented. 
B LOD = 0.025 ng/g lipid for BDE-28, 99, and 100. 
c Normal Reference Range for adult males in good health: testosterone = 300 - 1000 
ng/dL, free testosterone = 50 - 200 pg/mL 
inhibin-B =elevated if above 399 pg/mL , FSH=0.60 - 9.98 IU/L, LH = 1.0- 8.4 UIL, 
SHBG =12.9- 61.7 nmol/L 
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Table 4.2. Adjusted beta-coefficients, 95% Cis and p-values from general linear 
regression models for repeated measures examining the relationship between serum 
PBDEs (pg/g serum) and reproductive function tests in all men (27 men, 76 serum 
samples) and stratified by age: <40 (14 men, 40 serum samples), 2:::40 (13 men, 36 serum 
sam les) . 
BDE-47 (pg/g serum) 
~ (95% Cl) 
Total Testosterone (ng/dlt 0.063 (-0.28 to 0.41) 
<40 yo8 0.11 (-0.78 to 1.0) 
2:::40 yo8 0.069 ( -0.36 to 0.50) 
Free Testosterone (pg/ml)A -0.022 ( -0.080 to 0.036) 
<40 yo8 0.031 (-0.14 to 0.21) 
2:::40 yo8 -0.032 ( -0.085 to 0.022) 
Luteinizing Hormone (U/L)A* 0.00082 (0.00071 tO 0.0016) 
<40 yo8 -0.00067 (-0.0026 to 0.0012) 
2:::40 yo8 0.0012 (0.00032 to 0.0021) 
FSH (IU/L)A* -0.00012 (-0.00071 to 0.00047) 
<40 yo8 -0.0015 (-0.0027 to -0.00021) 
2:::40 yo8 0.00036 (-0.00035 to 0.0011) 
Inhibin-B (pg/mL)A -0.14 (-0.27 to -0.020) 
<40 yo8 -0.0029 ( -0.30 to 0.30) 
2:::40 yo8 -0.17 ( -0.31 to -0.030) 
Prolactin (ng/mL)A* -0.00050 (-0.00071 to 0.00061) 
<40 yo8 -0.00059 (-0.0023 to 0.0011) 
2:::40 yo8 0.000029 (-0.00081 to 0.00087) 
SHBG (nmol!Lt* 0.00050 (-0.00015 to 0.0011) 
<40 yo8 0.00041 (-0.0013 to 0.0022) 
2:::40 yo8 0.00059 ( -0.00003 to 0.0012) 
lnhibin-B/FSHA* -0.00033 (-0.0014 to 0.00070) 
<40 yo8 0.0016 (0.0000057 to 0.0032) 
2:::40 yo8 -0.0013 (-0.0028 to 0.00028) 
Free Androgen IndexA* -0.00049 (-0.0012 to 0.00018) 
<40 yoB 0.00045 (-0.0013 to 0.0022) 
>40 yo8 -0.00077 (-0.0015 to -0.00003) 
A Yii =Po + P 1PBDEii + PzRound + P3LIPIDii + P4AGEi + PsBMii + bi + l>ij 
8 Yii =Po + P1PBDEii + PzRound + P3LIPIDii + P&Mii + bi + cii 
* Dependent variable was transformed by the natural log. 
p-value 
0.715 
0.789 
0.739 
0.3 18 
0.714 
0.233 
0.046 
0.472 
0.011 
0.681 
0.025 
0.030 
0.024 
0.984 
0.020 
0.875 
0.471 
0.944 
0.135 
0.633 
0.061 
0.524 
0.043 
0.102 
0.149 
0.590 
0.042 
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Table 4.2 (continued) Adjusted beta-coefficients, 95% Cis and p-values from general 
linear regression models for repeated measures examining the relationship between serum 
PBDEs (pg/g serum) and reproductive function tests in all men (27 men, 76 serum 
samples) and stratified by age: <40 (14 men, 40 serum samples), ;:::40 (13 men, 36 serum 
sam les) . 
BDE-99 (pg/g serum) 
~ (95% CI) 
Total Testosterone (ng/dl)A 0.022 ( -1.34 to 1.38) 
<40 yo8 1.2 (-5.3 to 7.6) 
;:::40 yo8 -0.26 ( -1.8 to 1.2) 
Free Testosterone (pg/ml)A -0.12 (-0.35 to 0.11) 
<40 yo8 0.15 (-1.1 to 1.4) 
;:::40 yo8 -0.15 (-0.34 to 0.050) 
Luteinizing Hormone (UIL)A* 0.0028 (-0.00015 to 0.0058) 
<40 yo8 -0.0025 (-0.016 to 0.011) 
;:::40 yo8 0.0029 ( -0.00034 to 0.0060) 
FSH (IUIL)A* -0.00061 ( -0.0022 to 0.00099) 
<40 yo8 -0.0080 (-0.015 to -0.00084) 
;:::40 yo8 -0.00028 (-0.0019 to 0.0013) 
Inhibin-B (pg/mL)A -0.39 (-0.82 to 0.034) 
<40 yo8 0.024 (-1.9 to 1.9) 
;:::40 yo8 -0.38 ( -0.82 to 0.067) 
Prolactin (ng/mL)A* 0.0007 (-0.0019 to 0.0032) 
<40 yo8 -0.0041 (-0.016 to 0.0079) 
;:::40 yo8 0.0013 (-0.0014 to 0.0041) 
SHBG (nmol/L)A* 0.00069 (-0.0014 to 0.0027) 
<40 yo8 0.0036 (-0.0069 to 0.014) 
;:::40 yo8 0.00046 ((-0.0015 to 0.00024) 
Inhibin-B/FSHA* -0.00056 (-0.0033 to 0.0022) 
<40 yo8 0.0088 (0.000008 to 0.018) 
;:::40 yo8 -0.0014(-0.0051 to 0.0023) 
Free Androgen lndexA* -0.0019 (-0.0044 to 0.00063) 
<40 yo8 0.0022 (-0.010 to 0.015) 
>40 yo8 -0.0027 (-0.0052 to -0.0001) 
A Yii = f3o + fJ1PBDEij + fJ2Round + /33LIPIDii + /34AGEi + f3sBMii + bi + C:ij 
B Yii = f3o + fJ1PBDEii + fJ2Round + /33LIPIDii + /34BMii + bi + C:ij 
* Dependent variable was transformed by the natural log. 
p-value 
0.974 
0.713 
0.721 
0.162 
0.814 
0.135 
0.062 
0.702 
0.077 
0.447 
0.030 
0.719 
0.071 
0.979 
0.092 
0.608 
0.487 
0.328 
0.501 
0.486 
0.624 
0.685 
0.049 
0.445 
0.138 
0.712 
0.042 
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Table 4.2 (continued) Adjusted beta-coefficients, 95% Cis and p-values from general 
linear regression models for repeated measures examining the relationship between serum 
PBDEs (pg/g serum) and reproductive function tests in all men (27 men, 76 serum 
samples) and stratified by age: <40 (14 men, 40 serum samples), ~40 (13 men, 36 serum 
sam les). 
BDE-100 (pg/g serum) 
~ (95% Cl) 
Total Testosterone (ng/dl)A 0.19 (-0.72 to 1.1) 
<40 yoB 0.089 ( -1.4 to 1.5) 
~40 yoB 0.38 ( -1.03 to 1.8) 
Free Testosterone (pglml)A -0.032 (-019 to 0.12) 
<40 yoB 0.063 (-0.21 to 0.34) 
~40 yoB -0.094 ( -0.26 to 0.076) 
Luteinizing Hormone (U!Ll* 0.0017 (-0.00054 to 0.0039) 
<40 yoB -0.0017 (-0.0047 to 0.0014) 
~40 yoB 0.0048 (0.0019 to 0.0077) 
FSH (IUIL)A* -0.00070 (-0.0026 to 0.0012) 
<40 yoB -0.0023 ( -0.0048 to 0.00020) 
~40 yoB 0.0043 (0.0012 to 0.0074) 
Inhibin-B (pglmL)A -0.31 ( -0.67 to 0.055) 
<40 yoB 0.043 (-0.47 to 0.56) 
~40 yoB -0.60 ( -1.1 to -0.088) 
Prolactin (ng/mL)A* -0.00019 (-0.0020 to 0.0016) 
<40 yoB -0.00087 (-0.0036 to 0.0018) 
~40 yoB -0.00028 ( -0.0032 to 0.0026) 
SHBG (nmol/L)A* 0.0007 (-0.0017 to 0.0027) 
<40 yoB 0.00042 ( -0.0028 to 0.0036) 
~40 yoB 0.0027 (0.00055 to 0.0049) 
lnhibin-B/FSHA* -0.00027 (-0.0037 to 0.0032) 
<40 yoB 0.0034 (0.00038 to 0.0065) 
~40 yoB -0.011 (-0.017 to -0.0046) 
Free Androgen IndexA* -0.0011 (-0.0029 to 0.00075) 
<40 yoB 0.00073 ( -0.0020 to 0.0035) 
>40 yoB -0.0024 (-0.0049 to 0.00016) 
A Yij = f3o + fJ1PBDEij + fJ2Round + /33LIPIDii + /34AGEi + fJsBMii + bi + G'ij 
B Yij = f3o + fJ1PBDEij + fJ2Round + /33LIPIDii + fJ~Mii + bi + G'ii 
* Dependent variable was transformed by the natural log. 
p-value 
0.673 
0.90 
0.58 
0.623 
0.641 
0.263 
0.132 
0.266 
0.003 
0.469 
0.069 
0.008 
0.094 
0.863 
0.024 
0.828 
0.512 
0.838 
0.142 
0.785 
0.017 
0.874 
0.020 
0.002 
0.238 
0.580 
0.065 
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Table 4.2 (continued) Adjusted beta-coefficients, 95% Cis and p-values from general 
linear regression models for repeated measures examining the relationship between serum 
PBDEs (pg/g serum) and reproductive function tests in all men (27 men, 76 serum 
samples) and stratified by age: <40 (14 men, 40 serum samples), ~40 (13 men, 36 serum 
sam les). 
BDE-153 (pg/g serum) 
~ (95% CI) 
Total Testosterone (ng/dl)A 0.25 (-0.15 to 0.66) 
<40 yo8 0.27 (-0.22 to 0.75) 
~40 yo8 0.31 ( -0.63 to 1.2) 
Free Testosterone (pg/ml)A 0.040 (-0.028 to 0.11) 
<40 yo8 0.067 (-0.026 to 0.16) 
~40 yo8 -0.043 (-0.16 to 0.069) 
Luteinizing Hormone (UIL)A* 0.00028 (-0.0008 to 0.0014) 
<40 yo8 -0.00035 (-0.0014 to 0.00072) 
~40 yo8 0.0020 ( -0.00037 to 0.0045) 
FSH (IUIL)A* -0.00001 (-0.0010 to 0.00098) 
<40 yo8 -0.00039 (-0.0015 to 0.00070) 
~40 yo8 0.0023 (0.00011 to 0.0044) 
Inhibin-B (pg/mL)A -0.094 ( -0.27 to 0.079) 
<40 yo8 -0.043 ( -0.23 to 0.15) 
~40 yo8 -0.24 ( -0.62 to 0.13) 
Prolactin (ng/mL)A* -0.0005 (-0.0013 to 0.0003) 
<40 yo8 -0.00066 (-0.0016 to 0.00025) 
~40 yo8 -0.00065 (-0.0026 to 0.0013) 
SHBG (nmol/L)A* 0.00047 (-0.00043 to 0.0014) 
<40 yo8 0.00014 (-0.0013 to 0.0014) 
~40 yo8 0.0015 (-0.00014 to 0.0030) 
Inhibin-B/FSHA* -0.00032 (-0.0021 to 0.0015) 
<40 yo8 0.00041 (-0.0010 to 0.0018) 
~40 yo8 -0.0039 ( -0.0088 to 0.00092) 
A* Free Androgen Index 0.00008 ( -0.00076 to 0.00092) 
<40 yo8 0.00067 (-0.00025 to 0.0016) 
~40 yo8 -0.0011 (-0.0028 to 0.00065) 
A Yii =Po + P1PBDEii + P2Round + P3LIPIDii + P4AGEi + PsBMii + bi + C:ii 
8 Yii =Po + P1PBDEii + P2Round + P3LIPIDii + P4BMii + hi + C:ij 
* Dependent variable was transformed by the natural log. 
p-value 
0.207 
0.260 
0.504 
0.246 
0.148 
0.431 
0.602 
0.499 
0.093 
0.980 
0.463 
0.040 
0.281 
0.638 
0.194 
0.219 
0.147 
0.483 
0.301 
0.823 
0.072 
0.721 
0.561 
0.106 
0.849 
0.146 
0.209 
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Table 4.3 Intraclass correlation coefficients (ICCs) and stability category of repeated 
serum measures ofreproductive function tests in men (27 men, 76 serum samples). 
RFT ICCA ICCB 
Total Testosterone (ng/dl) 0.47 0.50 
Free Testosterone (pg/ml) 0.38 0.41 
Inhibin-B (pg/mL) 0.85 0.89 
FSH (IU/L) 0.98 0.98 
LH (U/L) 0.71 0.71 
Prolactin (ng/mL) 0.54 0.49 
SHBG (nmol/L) 0.91 0.92 
Inhibin-B/FSH ratio 0.93 0.93 
Free Androgen Index 0.65 0.66 
A intercept only model. 
8 model with blood -
collection time as a predictor 
Table 4.4 Adjusted beta-coefficients, 95% Cis and p-values from general linear regression models for repeated measures 
examining the relationship between serum PBDEs (ng/g serum) and reproductive function tests (24 men, 68 serum samples) 
without men on medication (two men) or a history of prostate cancer (one man) 
Total Testosterone (ng/dl)A 
Free Testosterone (pg/ml)A 
Luteinizing Hormone (U/L)A* 
FSH (IU/L) A* 
Inhibin-B (pg/mL) A 
Prolactin (ng/mL)A* 
SHBG (nmol/L)A* 
BDE-47 (pg/g serum) 
~ (95% CI) 
-0.11 ( -0.50 to 0.28) 
-0.047 (0.11 to 0.015) 
0 .00082 (0.000047 to 0.0016) 
0.00012 (-0.00049 to0.00073) 
-0.17 ( -0.29 to -0.049) 
-0.00038 (-0.0010 to 0.00024) 
0.00041 (-0.00026 to 0.0011) 
A Yii = /Jo + /J1PBDEii + /J2Round +hi+ G"ij 
* Dependent variable was transformed by the natural log. 
p-Value 
0.568 
0.132 
0.038 
0.705 
0.007 
0.224 
0.226 
BDE-153 (pg/g serum) 
~ (95% CI) 
0.13 ( -0.38 to 0.62) 
0.025 (-0.056 to 0.11) 
0.000056 (-0.0011 to 0.0012) 
0.00029 (-0.00069 to 0.0013) 
-0.15 (-0.33 to 0.032) 
-0.00064 (-0.0015 to 0.00017) 
0.00046 (-0.00054 to 0.0015) 
p-Value 
0.612 
0.531 
0.921 
0.553 
0.105 
0.119 
0.355 
....... 
....... 
0\ 
Table 4.5 Polybrominated diphenyl ethers analyzed and detection rates in men of the FlaRE study. 
total 
total serum % 
Analyte Abbr. men samples Detect Range 
Polybrominated Diphenyl Ethers (PBDEs) 
2,2',4-tribromodiphenyl ether BDE-17 
2,4,4'-tribromodiphenyl ether BDE-28 
2,2'4,4'-hexabromodiphenyl ether 
2,3',4,4'-tetrabromodiphenyl ether 
2,2',3,4,4'-pentabromodiphenyl ether 
2,2',4,4,5-pentabromodiphenyl ether 
2,2',4,4',6-pentabromodiphenyl ether 
2,2',4,4',5,5'-hexabromodiphenyl ether 
2,2',4,4',5,6'-hexabromodiphenyl ether 
2,2',3,4,4',5',6-heptabromodiphenyl ether 
2,2',3,3',4,4',5,5',6,6'-decabromodiphenyl ether BDE-209 
BDE-47 
BDE-66 
BDE-85 
BDE-99 
BDE-100 
BDE-153 
BDE-154 
BDE-183 
27 
27 
27 
27 
27 
27 
27 
27 
27 
27 
27 
76 
76 
76 
76 
76 
76 
76 
76 
76 
76 
76 
1 
68 
100 
1 
22 
92 
89 
100 
19 
12 
16 
<LOD- 0.8 
<LOD- 5.1 
0.6- 151 
<LOD- 0.7 
<LOD- 4.0 
< LOD- 43.5 
< LOD- 44.1 
0.06- 96.7 
<LOD- 4.5 
<LOD- 3.3 
< LOD- 18.3 
-
--....) 
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Table 4.6 Estimates from regression models analyzing the relationship between PBDEs and 
reproductive function tests (27 men, 76 serum samples). 
BDE-47 fJ (95% CD p-value 
Total Testosterone (ng/dl) 
crude A 
-0.12 (-0.49 to 0.25) 0.514 
lipid covariate8 0.047 ( -0.28 to 0.37) 0.771 
lipid standardizedc 0.15 (-2.4 to 2.7) 0.907 
Free Testosterone (pg/rnl)A 
crude A 
-0.046 (-0.10 to 0.011) 0.112 
lipid covariate8 -0.28 ( -0.084 to 0.028) 0.318 
lipid standardizedc -0.18 (-0.58 to 0.22) 0.363 
Luteinizing Hormone (UIL/* 
crude A 0.00074 (0.00018 to 0.0057) 0.055 
lipid covariate8 0.00093 (0.00018 to 0.0017) 0.016 
lipid standardizedc 0.0054 (0.00036 to 0.010) 0.036 
FSH (IU/L)A* 
crude A 0.000066 (-0.000052 to 0.00065) 0.820 
lipid covariate8 -0.000060 ( -0.000064 to 0.00053) 0.850 
lipid standardizedc 0.000047 (-0.0035 to 0.0036) 0.979 
lnhibin-B (pg/mL)A 
crude A -0.18 (-0.30 to -0.068) 0.002 
lipid covariate8 -0.15 ( -0.27 to -0.0037) 0.011 
lipid standardizedc -1.1 ( -1.9 to -0.35) 0.005 
Prolactin (ng/mL)A* 
crude A -0.00038 (-0.0010 to 0.00027) 0.248 
lipid covariate8 -0.00033 (-0.00099 to 0.00034) 0.328 
lipid standardizedc -0.0030 (-0.0074 to 0.0013) 0.169 
SHBG (nmol/L)A* 
crude A 0.00036 (-0.00030 to 0.0010) 0.275 
lipid covariate8 0.00038 (-0.00030 to 0.0011) 0.266 
lipid standardizedc 0.0030 (-0.0014 to 0.0074) 0.175 
Inhibin-B (pg/mL)/FSH 
(IU/L)A* 
crude A -0.00086 ( -0.0020 to 0.00020) 0.109 
lipid covariate8 -0.00045 (-0.0015 to 0.00056) 0.374 
lipid standardizedc -0.0037 (-0.010 to 0.0027) 0.245 
Free Androgen Index A* 
crude A -0.00060 (-0.0013 to 0.000084) 0.084 
lipid covariate8 -0.00053 (-0.0012 to 0.00019) 0.143 
lipid standardizedc -0.0036 (-0.0083 to 0.0010) 0.217 
A Y;i =flo+ fl1PBDE;i + fl2Round + b; + £;i 
8 Y;i =flo+ fl1PBDE;i + fl2Round + fl3LIPID;i + b; + £;i 
c Y;i =flo+ fl 1 [PBDE/Lipid]ii + fl2Round + b; + £;j 
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Table 4.6 (continued) Estimates from regression models analyzing the relationship between 
PBDEs and reproductive function tests (27 men, 76 semm samples). 
BDE-99 j3 (95% CI) p-value 
Total Testosterone (ng/dl) 
cmdeA -0.46 (-1.9 to 0.96) 0.514 
lipid covariate8 0.030 ( -1.23 to 1.29) 0.963 
lipid standardizedc 0.64 (-9.1 to 10) 0.896 
Free Testosterone (pg/mll 
cmdeA -0.20 (-0.42 to 0.021) 0.075 
lipid covariate8 -0.15 (-0.37 to 0.063) 0.162 
lipid standardizedc -0.86 (-2.4 to 0.67) 0.263 
Luteinizing Hormone (U/L)A* 
cmdeA 0.0029 (0.00018 to 0.0057) 0.038 
lipid covariate8 0.0034 (0.00064 to 0.0061) 0.017 
lipid standardizedc 0.019 (0.00 13 to 0.037) 0.036 
FSH (IU!Ll* 
cmdeA -0.00040 (-0.0021 to 0.0012) 0.615 
lipid covariate8 -0.00046 (-0.0021 to 0.0011) 0.564 
lipid standardizedc -0.0029 (-0.012 to 0.0067) 0.547 
Inhibin-B (pg/mLl 
cmdeA -0.49 (-0.90 to -0.077) 0.021 
lipid covariate8 -0.43 ( -0.83 to -0.030) 0.036 
lipid standardizedc -2.7 (-5.2 to -0.064) 0.045 
Prolactin (ng/mL)A* 
cmdeA -0.00072 (-0.0032 to 0.0018) 0.569 
lipid covariate8 -0.00066 ( -0.0025 to 0.0013) 0.628 
lipid standardizedc -0.0072 ( -0.024 to 0.0093) 0.384 
SHBG (nmol/L)A* 
cmdeA 0.00044 (-0.0016 to 0.0025) 0.670 
lipid covariate8 0.00045 (-0.0016 to 0.0025) 0.667 
lipid standardizedc 0.0058 (-0.0076 t o0.019) 0.387 
Inhibin-B (pg/mL)/FSH 
(IU!Ll* 
cmdeA -0.0011 (-0.0040 to 0.0018) 0.446 
lipid covariate8 -0.00082 (-0.0036 to 0.0029) 0.553 
lipid standardizedc -0.0040 (-0.021 to 0.013) 0.639 
Free Androgen IndexA* 
cmdeA -0.0023 (-0.0048 to 0.00019) 0.070 
lipid covariate8 -0.0021 (-0.0047 to 0.00045) 0.103 
lipid standardizedc -0.014 (-0.030 to 0.0024) 0.093 
A Y;i = f3o + j31PBDE;i + j32Round + b; + C:;j 
8 Y;i = f3o + j31PBDE;j + j32Round + j33LIPID;j + b; + C:;j 
c Yii = {30 + {31(PBDE/Lipid];j + fJ2Round + b; + C:;j 
* Dependent variable was transformed by the natural log. 
120 
Table 4.6 (continued) Estimates from regression models analyzing the relationship between 
PBDEs and reproductive function tests (27 men, 76 serum samples). 
BDE-100 p (95% CI) p-value 
Total Testosterone (ng/dl) 
crude A 
lipid covariateB 
lipid standardizedc 
Free Testosterone (pg/mll 
crude A 
lipid covariateB 
lipid standardizedc 
Luteinizing Hormone (U/Ll* 
crude A 
lipid covariateB 
lipid standardizedc 
FSH (IU/L)A* 
crude A 
lipid covariateB 
lipid standardizedc 
Inhibin-B (pg/mL)A 
crude A 
lipid covariateB 
lipid standardizedc 
Prolactin (ng/mL)A* 
crude A 
lipid covariateB 
lipid standardizedc 
SHBG (nmol!Ll* 
-0.30 (-1.34 to 0.74) 
0.16 (-0.75 to 1.06) 
0.49 (-6.9 to 7.8) 
-0.092 ( -0.25 to 0.070) 
-0.042 (-0.20 to 0.11) 
-0.25 ( -1.4 to 0.90) 
0.0015 (-0.00074 to 0.0037) 
0.0019 (-0.00030 to 0.0042) 
0.012 (-0.0031 to 0.027) 
0.000016 (-0.0019 to 0.0019) 
-0.00062 ( -0.0026 to 0.0013) 
0.0014 (-0.013 to 0.016) 
-0.43 ( -0.78 to -0.086) 
-0.33 ( -0.68 to 0.013) 
-3.0 (-5.5 to -0.61) 
-0.00077 ( -0.0026 to 0.0011) 
-0.00063 (-0.0025 to 0.0013) 
-0.0072 ( -0.020 to 0.0055) 
0.561 
0.732 
0.894 
0.259 
0.591 
0.658 
0.187 
0.088 
0.117 
0.986 
0.524 
0.843 
0.016 
0.059 
0.015 
0.403 
0.504 
0.258 
crudeA 0.0011 (-0.00091 to 0.0031) 0.273 
lipid covariateB 0.0012 (-0.00092 to 0.0033) 0.264 
lipid standardizedc 0.0095 (-0.0055 to 0.024) 0.210 
Inhibin-B (pg/mL)/FSH 
(WILl* 
crudeA -0.0022 (-0.0057 to 0.0012) 0.195 
lipid covariateB -0.00047 (-0.0039 to 0.0029) 0.782 
lipid standardizedc -0.019 ( -0.044 to 0.0068) 0.146 
Free Androgen lndexA* 
crudeA -0.0014 (-0.0034 to 0.00056) 0.157 
lipid covariateB -0.0012 (-0.0032 to 0.00086) 0.248 
lipid standardizedc -0.0080 ( -0.022 to 0.0058) 0.250 
A Yii = f3o + P 1PBDEij + PzRound +hi+ C:ij 
B Yii =Po+ P1PBDEii + PzRound + P3LIPIDii + hi + C:ij 
c Yij =Po+ P 1[PBDE!Lipid]ij + PzRound +hi+ C:ij 
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Table 4.6 (continued) Estimates from regression models analyzing the relationship between 
PEDEs and reproductive function tests (27 men, 76 serum samples). 
BDE-153 fJ (95% Cl) p-value 
Total Testosterone (ng/dl) 
crude A 
lipid covariate8 
lipid standardizedc 
Free Testosterone (pg/rnit 
crudeA 
lipid covariate8 
lipid standardizedc 
Luteinizing Hormone (U/L)A* 
crude A 
lipid covariate8 
lipid standardizedc 
FSH (IUIL)A* 
crude A 
lipid covariate8 
lipid standardizedc 
Inhibin-B (pg/mLt 
crude A 
lipid covariate8 
lipid standardizedc 
Prolactin (ng/mLt* 
crude A 
lipid covariate8 
lipid standardizedc 
SHBG (nmoi/L)A* 
crude A 
lipid covariate8 
lipid standardizedc 
Inhibin-B (pg/mL)/FSH 
(IU/L)A* 
0.13 (-0.35 to 0.61) 0.589 
0.27 (-0.14 to 0.67) 0.192 
2.1 (-1.2to5.4) 0.202 
0.022 (-0.053 to 0.097) 0.557 
0.039 (-0.031 to 0.11) 0.263 
0.34 (-0.17 to 0.86) 0.187 
0.00012 (-0.00095 to 0.0012) 0.821 
0.00026 (-0.00083 to 0.0014) 0.630 
0.00087 ( -0.0065 to 0.0082) 0.812 
0.000027 (-0.00068 to 0.0012) 0.574 
-0.000050 (-0.0011 to 0.00096) 0.928 
0.0024 ( -0.0051 to 0.0099) 0.518 
-0.15 (-0.32 to 0.031) 0.105 
-0.092 ( -0.26 to 0.078) 0.283 
-0 .91 (-2.1 to 0.31) 0.140 
-0.00051 (-0.00014 to 0.00034) 0.231 
-0.00046 (-0.0013 to 0.00040) 0.287 
-0.0040 (-0.0098 to 0.0018) 0.170 
0.00048 (-0.00050 to 0.0015) 0.328 
0.00051 (-0.00052 to 0.0015) 0.322 
0.0043 (-0.0030 to 0.012) 0.241 
crudeA -0.0012 (-0.0029 to 0.00056) 0.181 
lipid covariate8 -0.00026 (-0.0021 to 0.0015) 0.768 
lipid standardizedc -0.094 ( -0.023 to 0.0043) 0 .174 
Free Androgen IndexA* 
crudeA -0.00005 (-0.00098 to 0.00089) 0.914 
lipid covariate8 0.000064 (-0.00089 to 0.0010) 0.892 
lipid standardizedc 0.00092 (-0.0054 to 0.0073) 0.772 
A Yii = f3o + /]1PBDEii + fJ2Round + bi + C:ii 
8 Yii = f3o + /]1PBDEii + fJ2Round + {J3LIPIDii + bi + C:i i 
c Yii = /]0 + /] 1[PBDE/Lipidh + fJ2Round + bi + G'ii 
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Table 4.7. Adjusted beta-coefficients, 95% Cis and p-values from general linear 
regression models for repeated measures examining the relationship between serum 
PBDEs (pg/g serum) and reproductive function tests (27 men, 76 serum samples) and 
stratified by BMI category: <25 (14 men, 40 serum samples), 2::25, 13 men, 36 serum 
sam les). 
BDE-47 (pg/g serum) p-Value ~ (95% CI) 
Total Testosterone (ng/dl)A 
BMI <25 -1.8 (-3.7 to 0.14) 0.068 
BMI >25 0.11 (-0.19 to 0.41) 0.449 
Free Testosterone (pg/rnl)A 
BMI <25 -0.28 ( -0.57 to 0.0032) 0.052 
BMI >25 -0.038 (-0.094 to 0.018) 0.175 
Luteinizing Hormone (U/L)A* 
BMI <25 -0.0011 (-0.0046 to 0.0025) 0.540 
BMI >25 0.0011 (0.00032 to 0.0019) 0.009 
FSH (IU/L)A* 
BMI <25 0.0018 (-0.0012 to 0.0047) 0.234 
BMI >25 -0.00002 ( -0.00071 to 0.00062) 0.945 
lnhibin-B (pg/mL)A 
BMI <25 -0.83 (-1.5 to -0.15) 0.019 
BMI >25 -0.14 (-0.22 to 0.066) 0.001 
A* Prolactin (ng/mL) · 
BMI <25 -0.00058 (-0.0042 to 0.0030) 0.744 
BMI >25 -0.00039 (-0.0010 to 0.00024) 0.209 
SHBG (nmol/L)A* 
BMI <25 -0.00029 ( -0.0031 to 0.0025) 0.829 
BMI >25 0.00074 (-0.000014 to 0.0015) 0.046 
lnhibin-B (pg/mL)/FSH (IUIL)A* 
BMI <25 -0.0055 (-0.011 to 0.00014) 0.055 
BMI >25 -0.00025 (-0.0013 to 0.00081) 0.625 
A Yij = f3o + fJ1PBDEii + fJzRound +hi+ C:ij 
* Dependent variable was transformed by the natural log. 
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Table 4.7 (continued). Adjusted beta-coefficients, 95% Cis and p-values from general 
linear regression models for repeated measures examining the relationship between serum 
PBDEs (pg/g serum) and reproductive function tests (27 men, 76 serum samples) and 
stratified by BMI category: <25 (14 men, 40 serum samples), ~25, 13 men, 36 serum 
sam les). 
BDE-153 (pg/g serum) p-Value ~ (95% Cl) 
Total Testosterone (ng/dl)A 
BMI <25 0.072 ( -1.1 to 1.2) 0.900 
BMI >25 0.26 (-0.14 to 0.66) 0.190 
Free Testosterone (pg/ml)A 
BMI <25 0.058 (-0.12 to 0.23) 0.501 
BMI >25 0.011 (-0.074 to 0.095) 0.798 
Luteinizing Hormone (U/L)A* 
BMI <25 -0.00046 (-0.0024 to 0.0015) 0.634 
BMI >25 0.00038 ( -0.0011 to 0.0019) 0.609 
FSH (IU/L)A* 
BMI <25 0.00025 (-0.0013 to 0.0018) 0.745 
BMI >25 0.00023 (-0.0012 to 0.0016) 0.738 
lnhibin-B (pg/mL)A 
BMI <25 -0.21 ( -0.63 to 0.313) 0.240 
BMI >25 -0.097 ( -0.25 to 0.059) 0.313 
A"' Prolactin (ng/mL) · 
BMI <25 -0.00070 (-0.0027 to 0.0013) 0.471 
BMI >25 -0.00039 (-0.0013 to 0.00054) 0.391 
SHBG (nmol/L) A* 
BMI <25 -0.00043 (-0.0019 to 0.0011 ) 0.562 
BMI >25 0.00098 ( -0.00029 to 0.0023) 0.122 
lnhibin-B (pg/mL)/FSH (IU/L)A* 
BMI <25 -0.0014 (-0.0045 to 0.0017) 0.361 
BMI >25 -0.00066 ( -0.0029 to 0.0016) 0.559 
A Yii = f3o + fJ1PBDEii + fJ2Round + bi + G'ij 
* Dependent variable was transformed by the natural log. 
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Figure 4.1. Cross-sectional relationship, stratified by age group, showing relationship 
between BDE-47 and RFTs in Round 2 (27 men, 27 serum samples). 
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Figure 4.2. Comparison of serum concentrations of PBDEs in men from 
NHANES* (2003-04) and the FlaRE study (2010-11). 
Geometric Means and 95% Cis of PentaBDEs: 
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Figure 4.4. Cross-sectional scatterplot with prediction line showing relationship between 
BDE-47 and luteinizing hormone in Round 2 with (27 men) and without influential point 
(26 men). 
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Figure 4.5 Directed acyclic graph of the relationship 
between PBDEs, serum lipids, and reproductive function tests. 
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CHAPTER 5: CONCLUSIONS 
The aim of this research was to characterize Polybrominated diphenyl ether 
(PBDEs) serum concentrations and to assess the association between PBDEs and 
endocrine disruption. This was achieved by measuring serum concentrations of PBDEs in 
a well-defined cohort during a study period of one-year from 20 10-2011. This 
longitudinal study included the collection of three equally spaced (six months) rounds of 
biological samples (serum, urine) from each participant and the administration of a 
questionnaire. Serum samples were analyzed for PBDEs, lipids (cholesterol, 
triglycerides), thyroid function tests (TSH, TT4, ff4, TT3,), and reproductive function 
tests (testosterone, free testosterone, FSH, inhibin-B, LH, prolactin, SHBG). We analyzed 
urine samples for perchlorate, thiocyanate, iodide, and specific gravity. In addition to the 
collection of biomarkers, questionnaires were designed to obtain information relevant to 
health status and possible confounders or effect modifiers. Using general linear models 
for repeated measures, we characterized the stability of serum PBDE measures as well as 
each endocrine function test. For PBDEs, we evaluated temporal trends over the study 
period. Finally, we investigated the association between PBDE exposure and endocrine 
function tests while controlling for important covariates. 
Chapter 2. Time trends and stability of PentaBDE congeners 
To satisfy fire safety regulations, PBDEs were the additive flame retardants used 
in many consumer products in the US. The common commercial formulations of PBDEs 
are Pentabromodiphenyl ethers (PentaBDE), Octabromodiphenyl ethers (OctaBDE) and 
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Decabromodiphenyl ether (DecaBDE). High PBDE serum concentrations m US 
populations in combination with the health concerns linked to these compounds led to a 
phase out of PentaBDE and OctaBDE by US chemical manufacturers in 2004 (USEP A 
2008). Despite the current US restrictions, human exposure is likely still occurring from 
the release of PBDEs from existing products and through foods contaminated with 
PBDEs (Frederiksen et al. 2009). In our cohort BDE-28, BDE-47, BDE-99, BDE-100, 
and BDE-153 were detected in greater than two-thirds of serum samples. These are the 
congeners that are present in PentaBDE formulations and are found to a lesser extent (e.g. 
1-8%) in the OctaBDE commercial formulation (La Guardia et al. 2006). We analyzed 
six other PBDE congeners but they were not frequently detected in serum samples. 
It is unknown how serum concentrations of the PentaBDE congeners have 
changed since the 2004 US phase-out. Calculating these concentrations is further 
complicated by the fact that the various congeners have different half-life values in 
humans (Sjodin et al. 2004; Thuresson et al. 2006; Trudel et al. 2011). The half-life of 
these congeners has not been laboratory tested in humans. Due to ongoing environmental 
exposures, the half-live of these congeners can only be estimated. The following are the 
PentaBDE congeners and their half-life values reported in days as estimated by Trudel et 
al.: BDE-28 = 1100, BDE-47 = 510, BDE-99 = 280, BDE-100 = 670, BDE-153 = 2700 
(Trudel et al. 2011). We observed significant temporal declines of serum concentrations 
of BDE-47 and BDE-100 over the one-year study period, suggesting a downward trend 
for some PentaBDE congeners. We did not find temporal declines from sampling Round 
1 to Round 3 for BDE-28, BDE-99, and BDE-153. In a pilot study to this investigation, 
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Watkins et al. reported measurable PentaBDE serum concentrations from a cohort of 
Boston, USA office workers collected in 2009 (Watkins et al. 2011). The reported 
geometric mean serum concentrations ofBDE-28, BDE-47, BDE-99, and BDE-100 were 
approximately 1.5 to 2 times greater (p<0.001) than our Round 1 values, which were 
collected in 2010. The populations from each study were demographically and 
geographically similar. This provides corroborating evidence that these congeners with 
shorter estimated half-lives are having an appreciable decline in the Boston population. 
In contrast, we did not find a temporal decline in BDE-153 in the FlaRE cohort. Levels of 
BDE-153 in our study were similar to those reported for NHANES 2003-04 (5.7 ng/g 
lipid) and for Watkins et al. (5.0 ng/g lipid) (Sjodin et al. 2008; Watkins et al. 2011). This 
suggests that BDE-153 is not declining in the populations that were studied. This 
corroborates the work by Trudel et al. They estimated the half-life of BDE-153 to be 
2700 days, much longer than BDE-47, BDE-99, and BDE-100 (Trudel et al. 2011). One 
of our results conflicted with the estimates by Trudel. BDE-99 is estimated to have a 
shorter half-live than BDE-47 and BDE-100, however we did not observe a temporal 
decline in this congener over our study period. 
An important conclusion we draw from our data is that a single serum 
measurement is a stable estimate of exposure over a one-year period. We calculated 
intraclass correlation coefficients (ICCs) using repeated serum measures in individuals. 
The ICC expresses the proportion of variance attributable to differences between subjects 
compared to variability within subjects over the study period. For a reproducible 
exposure classification, and ICC close to one is optimal (Fleiss 1986). The ICC estimates 
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were very high, particularly for LPBDE, BDE-47 and BDE-153, ranging from 0.96 to 
0.99. Epidemiological studies conducted in the US have linked PBDE exposure to 
adverse health effects. Most of these studies have used a single biological sample to 
measure exposure. Therefore our study lends credence to other PentaBDE 
epidemiological studies that use or have used a single serum sample. 
Chapter 2. Limitations 
One general limitation of our study was that our sample size was relatively small. 
This limited our ability to detect trends in serum samples and possible relationships 
between PBDEs and endocrine function tests. This became especially true when we did 
sub-group analysis such as in men only. Another was the homogeneity of our cohort. 
Our cohort was 85% white, highly educated, healthy, non-smoking adults, living in 
Boston (USA), and is not representative of the US general population. However, having a 
fairly homogenous population in which to study health effects should increase internal 
study validity (Rothman 2008). A third was that we were not able to directly measure 
half-lives in our cohort, because our elimination rate estimates would be upward biased 
as a result of ongoing background exposures to PBDEs (Bartell 2012). A final weakness 
is that we did not have completely balanced data. Some participants contributed only one 
or two samples instead of three, however our retention rate was > 80%. Moreover, our 
study dropout was classified as missing completely at random (MCAR). We used general 
linear models for repeated measures to analyze these data which are robust to MCAR 
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data (Fitzmaurice 2008). We feel . our high retention rate and data analysis technique 
guarded against missing data bias. 
Chapter 2. Future Research 
Future research on human exposure to PBDEs should include repeated measures 
in populations geographically different from the FlaRE cohort to determine if congeners 
(BDE-47 and BDE-100) are declining throughout North America. Future research should 
focus on understanding how specific PBDE congeners are metabolized and eliminated 
from humans. A quasi-experimental population may exist where background exposures 
abruptly cease, allowing investigators to more accurately estimate elimination rates. We 
observed a non-significant increase in mean serum measures collected from June to 
August 2010, compared to the two winter sampling time points. Thus research is needed 
to identify any possible trends that can be attributed to seasonal variability of PBDE 
serum measures. Additionally, there is some evidence that PBDEs body burdens may be 
higher in certain sub-populations (e.g. lower-income, collegiate gymnasts) (Carignan et 
al. 2013; Quiros-Alcala et al. 2011). Future studies should identify and assess serum 
PBDE concentrations in highly exposed sub-populations. 
Chapter 3. Disruption of thyroid function 
The primary aim of Chapter 3 was to use the FlaRE cohort to explore the 
association between PBDE exposure and thyroid function. While the toxicological 
experiments consistently report PentaBDE exposure is associated with a decrease in T4, 
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results from human studies have been inconsistent. The inconsistent direction of these 
and other reported associations was discussed by Chevrier. The following hypotheses 
were offered to explain the inconsistency: reverse causation effect (e.g. thyroid hormone 
levels are affecting PBDE levels in serum), presence of iodine deficiency, different 
measurement techniques of free hormone concentrations (e.g. equilibrium dialysis vs. 
immunoassays), varying effect of hydroxylated PBDE metabolites, varying adjustment 
methods of serum lipids in regression analysis (Chevrier 2013). 
In the FlaRE cohort, we found that the PentaBDE congeners were associated with 
a decrease in Total T 4, similar to what is found in animal experiments. Strong 
associations did not exist for the other thyroid function tests except for BDE-153 and IT 4. 
Because strong associations did not exist between PentaBDEs and TSH, it is unlikely that 
PBDE exposure was causing clinical thyroid disease in our cohort. The most likely 
mechanisms of action based on toxicological studies are a decrease in serum T4 binding 
leading to a decrease in total T4or an increase in liver detoxification enzymes leading to 
increased clearance of total T4. 
Chapter 3. Strengths and Limitations 
We addressed three of the potential explanations for the current inconsistencies in 
the PBDEffH literature put forth by Chevrier, namely reverse causation, different 
methods of lipid adjustment, and varying iodine status. Reverse causation is much more 
likely in cross-sectional studies. The longitudinal nature of our study and the consistency 
of our results make reverse causation an unlikely explanation for the inverse association 
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found between both BDE-47 and BDE-100 and IT4. In regards to lipid adjustment, we 
compared multiple methods for lipid adjustment (Chevrier 2013; Schisterman et al. 
2005). The results from the crude and lipid-adjusted models were negatively associated 
between PentaBDEs and IT4. The lipid-standardized model also resulted in a negative 
association between PBDEs and IT4. In other words, the method used for correction of 
blood lipid levels in non-fasting serum samples did not remove the inverse association 
between PentaBDEs and IT4. In regards to Iodide (I), we did not find any evidence of 
effect measure modification in the PBDEff4 relationship in our cohort possibly because 
our cohort was likely iodine sufficient. Median urinary iodide concentrations in each 
sampling round were all above the WHO recommended level of 100 J..lg/L for non-
pregnant adults (WHO 2013). 
The other proposed mechanisms for inconsistent results between PBDEs and TH 
in the literature that we did not address are hydroxylated PBDE metabolites and different 
measurement methods for ff4. We did not measure the hydroxylated PBDE metabolites. 
If the OH-PBDE metabolites are the more potent TH disruptors, and they affect TH 
homeostasis via disrupting hormone-binding patterns, we would expect to observe a 
stronger inverse association between OH-PBDEs and TT4 than the parent PBDEs. To 
measure IT4, we only used an immunoassay. We did not use equilibrium dialysis, which 
is the gold standard, because it is expensive. There are reports that an increase in protein-
bound T4 may positively bias immunoassay ff4 measurements (Wang et al. 2000). 
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Chapter 3. Future Research 
Future research on human exposure to PBDEs and thyroid disruption should 
include a larger study population and other PentaBDE (e.g. OH-PBDEs) and thyroid 
function measures (e.g. serum binding proteins, liver detoxification enzymes, deiodinase 
activity). There may also be other exposures that confound the relationships we report, 
contribute to a mixtures effect, or be effect measure modifiers. An example of a possible 
effect modifier not discussed in this dissertation is vitamin A. Some animal studies 
report that PBDE exposure can lower circulating levels of vitamin A (Ellis-Hutchings et 
al. 2006; Hallgren et al. 2001). In vitro studies reveal vitamin A is a regulator of thyroid 
hormone induced gene expression (Tagami et al. 2009). One toxicological study reports 
that rodents with vitamin A deficiency were more susceptible to a decrease in T 4 after 
exposure to PentaBDEs (Ellis-Hutchings et al. 2009). Thus future studies should 
investigate the potential effects of the most well known effect modifiers on PBDEs and 
THs. 
Thyroid hormone diseases are more common in women than men. Furthermore, 
maternal thyroid function . is critical for in utero development. Future research should 
continue to focus on women of childbearing age and in birth cohorts. Interpreting TH 
measurements in pregnant women is different than in the general adult population 
because of the large estrogen-induced elevations of serum TBG (Stagnaro-Green et al. 
2011). Thus birth cohorts may be a good population to study the possible implications of 
methodological issues regarding IT 4 measurements. 
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The adjustment of lipids when studying the health effects of lipophilic compounds 
in non-fasting serum samples will continue to be a source of debate. We agree with 
Chevrier, Gaskins and Schisterman who recommend using multiple methods (Chevrier 
2013; Gaskins and Schisterman 2009; Schisterman et al. 2005). 
Chapter 4. Disruption of male reproductive hormones 
The primary aim of Chapter 4 was to use repeated measures in serum to assess 
the association between PBDE exposure and reproductive function in men of the FlaRE 
cohort. Animal experiments have reported decreases in male reproductive organ weights 
(e.g. seminal vesicle, prostate, testis, epididymis) and changes in some reproductive 
hormone levels in male rodents (Kuriyama et al. 2005; Stoker et al. 2005). Additionally, 
there appears to be some evidence that PBDEs may affect sperm quality in toxicological 
studies (van der Ven et al. 2008). PBDE exposure and male reproductive function has 
been less studied than thyroid hormone disruption. While results are inconsistent, PBDEs 
have been associated with changes in male reproductive hormone levels, and decreased 
semen quality and mobility (Abdelouahab et al. 2011; Meeker et al. 2009). 
In the FlaRE cohort, we discovered associations between PentaBDEs and 
reproductive hormone levels among men 40 years and older. We report that increased 
exposure to PentaBDEs was associated with a decrease in inhibin-B, an increase in 
follicular stimulating hormone (FSH), and decreases in the inhibin-B/FSH ratio and the 
free androgen index. These associations were not found in the younger men of our cohort. 
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Chapter 4. Strengths and Limitations 
Our study is the first prospective study to use repeated serum measures to assess 
the association between PBDE exposure and male reproductive function tests in the US. 
Similar to the strengths of our research on PBDEs and THs discussed in Chapter 3, we 
were less likely be observing an association due to reverse causation because of our study 
design. Serum lipids can be correlated with hormone levels in men, so we used multiple 
methods to account for lipids in our non-fasting serum samples (Monroe and Dabs 2013). 
Sometimes more than a single reproductive hormone measurement is needed to 
determine an individual's reproductive function level (Paduch et al. 2014). In our study 
population we were able to assess the within- and between- variability of our hormone 
measurements using repeated serum measures. 
There are other limitations in Chapter 4, in addition to the general study 
limitations stated in Chapter 3 for the PentaBDE/TH epidemiology. We did not find any 
associations between PentaBDEs and testosterone or free testosterone. Toxicological and 
epidemiological reports have been inconsistent on results pertaining to PentaBDEs effects 
on testosterone. It is possible that PentaBDEs do not affect testosterone levels in men. 
Another explanation is that we had insufficient power to detect an association. We did 
not examine sperm counts and testicular volume. These outcomes are typically positively 
correlated with inhibin-B serum levels and would be indicative of potentially clinically 
relevant adverse effects of PentaBDEs on male fertility (Meachem et al. 2001). 
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Chapter 4. Future Research 
PBDE is but one family of hormonally active chemicals found in the 
environment. Finding a direct mechanism between one chemical and one adverse health 
effect is difficult. It is like finding the one carcinogen in cigarettes that causes lung 
cancer. It is the combination of multiple chemicals that causes the most harm. 
Epidemiological studies have indicated that there has been a possible increase in the 
incidence of male reproductive dysfunction (Acerini et al. 2009; Richiardi et al. 2007; 
Toppari et al. 2010). Exposure to hormone disrupting chemicals in the environment is a 
likely factor, but studying only a single agent, while ignoring the possibility of joint 
action, will likely lead to underestimation of effects (Silva et al. 2002). Future studies 
should not only focus on PBDE exposure, but to the environmentally relevant toxic 
exposures of multiple agents. 
The effect of PBDEs in women should be studied more. Currently there are very 
few studies exploring PBDE exposure and reproductive hormones in women. A possible 
reason for this is that it is more difficult. Adult female hormone levels are more variable 
than male levels. Menstrual cycling, pregnancy, birth control use, and menopause cause 
large hormonal variations (Widmaier et al. 2008). Therefore studying the effect of 
exogenous chemicals on female reproductive hormone levels is much more complex. 
However studies have shown exposure to xenobiotic compounds can have as much if not 
more change in female reproductive health than in male health. Studies have shown a 
decrease in the age of menarche (Denham et al. 2005; Selevan et al. 2003), a change in 
menstrual cycle length (Eskenazi et al. 2002; Farr et al. 2004), and an increased time to 
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pregnancy (Harley et al. 2010). Examining the effect of PBDEs and other xenobiotic 
compounds on female reproductive health is critically important. 
PBDEs and other flame retardant chemicals were added to consumer products to 
meet fire safety standards such as California Technical Bulletin TB-117. These 
regulations were intended to reduce the risk of fire. Unfortunately, the chemical 
properties that make PBDEs effective flame-retardants are also what make them toxic 
and persist in the environment. We now know that these compounds are linked to 
adverse health effects. Effective January 1, 2014, California adopted a new law to exempt 
certain low-risk products from the flammability standard (CA TB-117-2013). This law 
also made changes to the flame test. The new standard is to "conduct smolder resistance 
testing of products [instead of open flame tests] for the purpose of protecting consumers 
from fires ignited by smoking material [cigarettes] which are the leading ignition source 
of fires today" (CA TB-117-2013). This regulation was designed to decrease the amount 
of flame retardant chemicals needed in consumer products without compromising fire 
safety. The risk/benefit debate over flame-retardants will hopefully shift towards more 
judicious use of these chemicals, as their environmental and health effects are more 
thoroughly investigated. 
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